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Chapter 1
General introduction and outline of this thesis
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The present thesis focuses on breast surgery in BRCA1/2 gene mutation carriers. The top-
ics that are studied vary broadly, representing the multiple disciplines that are involved 
in the diagnostic work-up and treatment of BRCA1/2-associated breast cancer. The first 
part contains studies on molecular and prognostic tumor characteristics in breast cancer. 
The thesis continues with an anatomical study on safety of prophylactic mastectomy, 
and finishes with studies on aesthetics and patient reported outcomes of prophylactic 
breast surgery and breast reconstruction. The title of this thesis ‘Genaesthics’ is a merger 
of the two extremities of this spectrum: ‘genetics’ and ‘aesthetics’.
HISTORy And EPIdEMIOlOGy Of GERM lInE BRCA1/2 GEnE MuTATIOnS
Already in 1866 the French physician and surgeon Paul Broca suspected the heredity of 
cancer. A family with an extraordinary high breast cancer incidence, which was suppos-
edly his wife’s family, prompted Broca to draw a four-generation pedigree. The pedigree 
showed an incidence of fifteen out of twenty-six family members with cancer who were 
thirty years or older at the time of the pedigree drawing. Fourteen of them were women; 
nine of them had breast cancer whereas the other four had ‘abdominal’ or ‘liver’ cancer1-3. 
Finally, in 1990 the evidence for Broca’s suspicions was provided by the discovery of the 
BReast CAncer 1 (BRCA1) gene and, in 1994, the BRCA2 gene4, 5. BRCA1 and BRCA2 germ 
line mutations, as we now estimate, are accountable for about 5% of all breast cancers 
and for about 16% of hereditary breast cancers4, 6-8. Furthermore, about 12% of all ovar-
ian cancers are likely due to a germ line mutation in the BRCA1/2 genes9.
As reflected by the composition of many study populations, the incidence of BRCA1-
associated breast cancers seems to be much higher as compared to BRCA2-associated 
breast cancers in most populations. This is of interest, because the incidence of BRCA1 
and BRCA2 gene mutations in the entire population is estimated to be equally high, 
as is the penetrance of both genes8, 10-14. An explanation for this finding may be that in 
some BRCA2-associated breast cancers, because of their more sporadic-like phenotype, 
an underlying BRCA2 gene mutation remains unrecognized10. Further, variations in the 
pathogenic mutation spectrum in BRCA1 or BRCA2 may explain regional differences in 
penetrance and age of first breast cancer15. Generally, cumulative lifetime risks (CLTR) 
for women who carry a germ line BRCA1/2 gene mutation are estimated 55-85% to 
develop breast cancer by the age of 70 10-14. The estimated CLTRs of developing ovarian 
cancer vary between 15-60% for BRCA1 and 10-35% for BRCA2 mutation carriers10-14. The 
large variation in estimated CLTRs is partly attributable to differences in study designs16. 
Population-based studies have prospective designs but relatively small sample sizes and 
low event rates, while family-based studies frequently are of (partly) retrospective de-
sign with concurrent recall- and ascertainment biases. A priori, women who present to 
genetic clinics and who are therefore included in studies have moderate to high cancer 
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risks that meet criteria to participate in breast cancer screening programs. Moreover, it is 
very likely that variations in estimated CLTRs are attributable to genetic, environmental 
and lifestyle factors that modify cancer risks in BRCA1/2 gene mutation carriers16.
In the Netherlands, women with high breast cancer risks due to a BRCA1/2 gene muta-
tion may choose whether they opt for frequent breast cancer screening by biannual 
alternating mammography and breast MRI, or whether they want to undergo prophy-
lactic surgery.
PATHOlOGIC CHARACTERISTICS Of BRCA1/2-ASSOCIATEd bREAST CAnCER
Compared to the general population, women with a BRCA1/2 gene mutation are 
younger, often younger than 40 years, when they develop breast cancer14 and the breast 
cancers they develop more frequently have aggressive tumor characteristics17. Biannual 
breast cancer screening consists of alternating mammography and MRI. Due to intensive 
screening, typically, screen-detected BRCA1/2-associated breast cancers are early stage 
(i.e. small and node-negative) breast cancers18, but the majority is poorly differentiated 
(Bloom Richardson grade 3)17, 19, 20. BRCA1-associated breast cancers are typically basal-
like with a triple-negative receptor status (negative for estrogen receptor; ER, proges-
terone receptor; PR, and HER2 receptor) in up to 70%, whereas BRCA2-associated breast 
cancers resemble more the sporadic breast cancer phenotype and more frequently 
are ER positive17, 19, 20. The relative uniformity of BRCA1/2-associated breast cancers in 
stage and tumor characteristics limits the use of established prognostic markers such as 
nodal status, grade, and hormone receptor status in the work-up and risk-assessment of 
BRCA1/2 gene mutation carriers with breast cancer. Moreover, effective targeted therapy 
is applicable only in selected cases due to the lack of hormonereceptor and HER2 posi-
tivity, especially in BRCA1-associated cancers.
THE RISk Of OvARIAn CAnCER And RISk-REduCInG bIlATERAl SAlPInGO-
OOPHORECTOMy
As mentioned before, beside a very high breast cancer risk, BRCA1/2 gene mutation car-
riers have up to 60% CLTR of developing ovarian cancer. Despite of numerous attempts 
to develop efficient screening programs to detect BRCA1/2-associated ovarian cancer in 
an early stage, the safest and most efficient measure to prevent morbidity and especially 
mortality from ovarian cancer remains to undergo a risk-reducing bilateral salpingo-
oophorectomy (RRSO)21-23. It is therefore recommended to women with a BRCA1/2-gene 
mutation, especially when they have a family history for ovarian cancer, to undergo 
RRSO as soon as they have completed childbearing, but preferably around 35-40 years 
for BRCA1 gene mutation carriers and 40-45 years for BRCA2 gene mutation carriers24, 25. 
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The biological downside of RRSO includes that the patient enters menopause at young 
age, with possible adverse physical and psychological effects26. A potential benefit 
of RRSO is that it may have a preventive effect on the development of breast cancer. 
However, controversies remain around the true extent of risk-reduction as achieved by 
RRSO and on the mechanism of risk-reduction by estrogen depletion on the develop-
ment of ER negative breast cancer (as typically associated with BRCA1)27. Hypothesizing 
that post-RRSO breast cancers may lack the prognostic adverse characteristics typical for 
BRCA1/2-associated tumors, we study tumor characteristics of breast cancers in BRCA1/2 
gene mutation carriers before and after RRSO in Chapter 3.
POTEnTIAl PROGnOSTIC MARkERS In BRCA1/2-ASSOCIATEd bREAST 
CAnCERS
There are several tumor characteristics reported to be of possible prognostic value in 
other types of solid cancer and/or in sporadic breast cancer, which may be of prognostic 
value in BRCA1/2-associated breast cancers as well.
Tumor-associated stroma
In sporadic breast cancers, the amount of tumor-associated stroma has been reported to 
be a prognostic marker, with stroma-rich breast cancer being an independent predictor 
of poor prognosis as compared with stroma-poor breast cancer28, 29. Stroma surround-
ing cancer cells is thought to have various functions concerning the genesis and the 
behavior of tumors. The prognostic role of tumor stroma in BRCA1/2-associated tumors, 
specifically, has not been investigated so far.
Tumor-associated inflammation
A lymphocytic infiltrate surrounding a tumor consists of numerous different inflammato-
ry agents (i.e. B-lymphocytes, T-lymphocytes, macrophages, dendritic cells, plasma cells, 
mast cells) that display different – possibly anti-tumor as well as pro-tumor – effects30. 
Effects of tumor infiltrate therefore may vary depending on the subset of infiltration and 
possibly even on the tumor subtype30. Infiltration of lymphocytes is especially marked 
in medullary breast cancers and therefore in BRCA1-associated breast cancers17. The role 
of various prognostic markers such as density of tumor-associated inflammation and of 
tumor-stroma ratio is discussed in Chapter 4.
β-Catenin expression
In colon cancer, activity of the Wnt-pathway plays an important role in tumorigenesis31. 
Mutations in the APC gene cause the hereditary cancer syndrome familial adenomatous 
polyposis (FAP). A concurrent second hit leads to a dysfunctioning APC protein, there-
16
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fore to inappropriate stabilization of cytoplasmic β-catenin and eventually to signaling 
of the nuclear Wnt target genes31. Also in other solid tumors, such as breast cancer, 
activity of the Wnt pathway may play a role in tumorigenesis31. However, the role of Wnt 
in breast cancer is much less established than in colon cancer32-36. In Chapter 6, we assess 
the presence and prognostic significance of β-catenin expression in BRCA1/2-associated 
breast cancers.
PREvAlEnCE Of MulTIPlE TuMORS In BRCA1/2 GEnE MuTATIOn CARRIERS
Beside high CLTRs of breast and ovarian cancer, BRCA1/2 gene mutation carriers possibly 
have a higher susceptibility for other cancer types, as well. This frequently results in the 
prevalence of multiple tumors that may occur and/or metastasize either synchronously 
of metachronously. In all forms, it is of utmost importance to differentiate between 
primary tumor origins, and between primary versus recurrent or metastasized disease, 
since this strongly determines prognosis and guides surgical and systemic treatment 
options37, 38. On top of diagnostic modalities to determine tumor origins such as tumor 
morphology and immunohistochemical tests, DNA next generation sequencing (NGS) is 
an upcoming diagnostic modality that may be helpful in differentiating between tumors 
and their origins. In Chapter 5, we analyze the additional value of NGS in the diagnostic 
workup of BRCA1/2 gene mutation carriers with multiple tumors.
RISk-REduCInG SuRGERy: bIlATERAl MASTECTOMy
As an alternative to intensive breast cancer screening, BRCA1/2 gene mutation carriers 
and other women with high breast cancer risks may choose to undergo risk-reducing 
bilateral mastectomy mostly followed by direct breast reconstruction. Common pro-
cedures are the skin-sparing mastectomy and nipple- (and skin-) sparing mastectomy. 
In skin-sparing mastectomy, all breast tissue is removed including the nipple-areola 
complex, leaving a skin envelope that is used to cover a direct breast reconstruction. In 
nipple-sparing mastectomy, the nipple-areola complex is spared together with the skin 
envelope. However, since the nipple-areola complex is the center of the breast gland, 
this may leave more glandular tissue in situ. Although it is imperative to remove as 
much breast glandular tissue as possible to minimize any residual breast cancer risk, the 
impact of microscopic amounts of residual breast tissue on breast cancer risk is difficult 
to estimate. In Chapter 2, we review the literature on oncologic safety of risk-reducing 
nipple-sparing mastectomy versus skin-sparing mastectomy. In Chapter 7 a patho-
logical study on breast specimens is described, in which we assessed and compared the 
amount of breast glandular tissue left behind the NAC to the amount of breast glandular 
Introduction
17
tissue behind the skin flap (left in situ in skin-sparing mastectomy and nipple-sparing 
mastectomy).
AESTHETIC OuTCOME AfTER PROPHylACTIC MASTECTOMy
When choosing a prophylactic mastectomy technique, it is necessary to balance any 
remaining oncological risk versus the expected aesthetic outcome. Nipple-sparing 
mastectomy may lead to a more natural and thus more desirable aesthetic outcome 
and possibly increases patient satisfaction39-41. In skin-sparing mastectomy the nipple-
areola complex needs to be reconstructed. Current techniques of nipple-areola 
complex reconstruction consist of a small skin flap and specialized tattoo techniques. 
When performed well, this frequently leads to aesthetic outcomes that can hardly be 
distinguished from a native nipple-areola complex. Nipple-areola complex reconstruc-
tion may even have a superior aesthetic outcome since it can be delayed until the final 
breast shape is achieved and shape and place on the breast therefore can be adjusted 
to it. Patient satisfaction with nipple-sparing mastectomy and skin-sparing mastectomy 
and the function of the nipple-areola complex (either spared or reconstructed) after 
risk-reducing bilateral mastectomy were assessed and compared in Chapter 9. Another 
point of interest is the reconstruction modality used after prophylactic mastectomy. Au-
tologous reconstruction techniques yield natural aesthetic outcomes but require more 
extensive surgery with concurrent morbidity42. Implant reconstruction may be preceded 
by tissue expansion using an inflatable tissue expander placed beneath the pectoral 
muscle. Direct-to-implant breast reconstruction is performed immediately after mas-
tectomy without previous tissue expansion. The definitive prosthesis is placed partly 
subpectoral and sometimes partly covered with a pedicled latissimus dorsi muscle. In 
Chapter 10, the long-term results of quality of life and aesthetic outcome after risk-
reducing mastectomy and direct-to-implant breast reconstruction are described. An 
expert panel assessed photographs of postoperative breast reconstruction results and 
patients were asked to complete the Breast Q reconstruction questionnaire. Chapter 
8 describes a validation study of the Hopwood Body Image Scale (BIS) for the Dutch 
Language. The BIS is a 10-item scale suitable for daily practice to better assess patient 
satisfaction and body image as a quality of life parameter after cancer surgery. The BIS 
was concurrently used in Chapter 9.
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AbSTRACT
Women with a BRCA1/2 gene mutation and others with a high breast cancer risk may opt 
for bilateral prophylactic mastectomy. To allow for immediate breast reconstruction the 
skin envelope is left in situ with or without the nipple-areola complex (NAC). Although 
possibly leading to a more natural aesthetic outcome than the conventional total mas-
tectomy, so-called skin-sparing mastectomies (SSM) and nipple-sparing mastectomies 
(NSM) may leave some breast glandular tissue in situ. The oncological risk associated 
with remaining breast glandular tissue is unclear. We present a case of primary breast 
cancer after prophylactic mastectomy followed by a review of the literature on remain-
ing breast glandular tissue after various mastectomy techniques and oncological safety 
of prophylactic mastectomies.
Oncological safety of prophylactic mastectomy
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InTROduCTIOn
BRCA1/2 mutation carriers have a cumulative lifetime breast cancer risk of 55-85% by the 
age of 701-5. As an alternative to surveillance, BRCA1 and BRCA2 mutation carriers and 
other women with a high breast cancer risk may choose to undergo bilateral prophylac-
tic mastectomy, reducing breast cancer risks by 90-100% after 3-13 years of follow-up6-10. 
The prophylactic character of the bilateral mastectomy emphasizes the importance of 
a natural aesthetic outcome11, which can be achieved by various immediate autolo-
gous and implant breast reconstruction techniques. Instead of the conventional total 
mastectomy, to allow for an immediate breast reconstruction and to achieve a natural 
aesthetic outcome so-called conservative mastectomies are increasingly performed 
for risk reduction. In conservative mastectomies, all breast glandular tissue is removed 
while leaving the skin envelope and, if spared, the nipple-areola complex (NAC) in situ 
(respectively, skin-sparing mastectomy; SSM and nipple-sparing mastectomy; NSM).
Safety of conservative mastectomies in women at high breast cancer risk is subject to 
an ongoing debate. The presumed oncological risk of the conservative technique lies 
in potential remaining breast glandular tissue with the skin flap and, if spared, with the 
NAC. Smaller incisions that are tailored to individual reconstruction wishes, however, 
may result in a technically difficult surgical approach. Therefore, the oncological safety 
of the conservative mastectomy remains a challenge for the surgeon. We present a 
case of primary breast cancer developed after prophylactic conservative mastectomy. 
Further, we provide a review of the literature on the oncological safety of prophylactic 
conservative mastectomies.
CASE: A 43-yEAR Old wOMAn wITH PRIMARy bREAST CAnCER In THE 
PROPHylACTIC MASTECTOMy SCAR
In 2011 a 43-year old woman presented a lesion clinically suspicious of breast cancer. In 
1982 at the age of 15, she had been successfully treated for stage IIa Hodgkin’s disease 
in her neck and mediastinum with 40 Gy mantle field radiation. After 10 years there were 
no signs of recurrence and she was discharged from follow-up.
In 1998, a mammography - performed because of a wish for breast reduction - re-
vealed suspect microcalcifications in the left breast. The suspect lesion was excised by 
upper outer quadrantectomy. Pathological examination of the lumpectomy specimen 
showed grade 2 ductal carcinoma in situ. No adjuvant radiotherapy was administered 
due to the history of mantle field radiation. Initially, physicians and patient agreed to 
frequent radiological screening instead of a completing mastectomy. However, after 
several additional diagnostic procedures due to suspect lesions of the left breast, in 
2001, the patient chose to undergo a SSM and immediate implant reconstruction. In 
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figure 1. 43-year old woman presented with a primary, ulcerous breast cancer in the right prophylactic 
mastectomy scar. Eight years before presentation she had undergone prophylactic mastectomy and imme-
diate breast implant reconstruction because of a history of Mantle fi eld radiation at the age of 15. Histology 
of the mastectomy specimens showed no (in situ) malignancy.
A Computer-assisted Tomography (CT) scan of the thorax shows the tumor of 2.1 x 2.7 cm that invades the 
skin and causes dimpling of the subpectoral implant.
b Microscopic examination showed a grade 3 invasive ductal carcinoma with skin involvement, indicated 
by the arrowhead. Haematoxylin and eosin stained (H&E); 4x objective.
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2003, this was followed by a prophylactic SSM of the right breast and bilateral implant 
reconstruction. In both cases, histologic investigation showed no (in situ) malignancy.
In 2011, she returned with an ulcerous lesion in the right mastectomy scar. On CT-scan 
a superficial tumor of 21 x 27 mm was seen (Figure 1A). Ultrasonography of the axilla 
did not show pathological lymph nodes. A wide local excision with axillary lymph node 
dissection was performed and the implants were removed. Histological examination 
of the excised specimen showed an invasive ductal carcinoma with a diameter of 2.4 
cm, Bloom Richardson grade 3, estrogen receptor (ER) positive, progesterone receptor 
(PR) and human epithelial growth factor-2 receptor (HER2 receptor) negative (Figure 
1B). Adjacent to the tumor, normal glandular breast tissue was found. One out of eight 
dissected axillary nodes showed a metastasis. According to our national protocol, she 
received adjuvant chemotherapy, hormonal therapy and re-irradiation with hyperther-
mia of the chest wall. At the time of writing the patient is alive without breast cancer 
recurrence.
SuRGICAl TECHnIquES Of COnSERvATIvE MASTECTOMIES: SkIn-SPARInG 
MASTECTOMy (SSM) And nIPPlE-SPARInG MASTECTOMy (nSM)
Examples of conservative mastectomies include skin-sparing mastectomy (SSM) and 
nipple-sparing mastectomy (NSM). In SSM, a periareolar incision is used with caudal or 
lateral extension if necessary (‘racquet’ incision). The skin envelope is created by sub-
cutaneously excising the breast glandular tissue while preserving a thin subcutaneous 
layer to support skin vascularization. Nipple-papilla and surrounding pigmented areola 
(nipple-areola complex; NAC) are removed. In NSM, the skin envelope is created through 
a semicircular periareolar or an inframammary incision. The NAC is dissected as thin 
as possible by macroscopically removing all breast glandular tissue while preserving 
vascularization. The nipple-papilla is ‘cored’ by inverting it and excising residual breast 
glandular tissue. The NAC is then left in situ adherent to the skin envelope. A breast 
reconstruction is performed during the same procedure. The oncological safety of SSM 
in the prophylactic setting is generally acknowledged, whereas safety of NSM is still 
subject to debate.
In the last two decades of the past century it was common to perform a so-called sub-
cutaneous mastectomy. Although subcutaneous mastectomy encompassed a skin- and 
nipple-sparing technique as well, it is likely that this was not comparable to current NSM 
and SSM techniques. A description of the ‘state of the art’ subcutaneous mastectomy in 
1983 mentions that a plaque of one centimeter of breast glandular tissue should be left 
in situ with the areola12. In contrast, current NSM and SSM techniques aim for skin flaps 
<5 mm and NACs of 2-3 mm thickness13.
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bREAST GlAndulAR TISSuE OR TERMInAl duCT lObulAR unITS (TdluS): 
RESIduAlS AfTER MASTECTOMy
The hazard of remaining breast glandular tissue after mastectomy for development or 
recurrence of breast cancer has been a recurring subject to debate since more than half 
of a century. Anatomically the NAC is a continuation of the mammary gland and there-
fore should be removed when pursuing a complete mastectomy. Therefore, especially 
sparing of nipple and areola in NSM has been a controversial topic. However, the grow-
ing ability of more specifically identifying women at high breast cancer risk and the con-
sequently increasing interest in prophylactic mastectomies has revived the discussion. 
Breast cancer is thought to originate in terminal duct lobular units (TDLUs), defined as a 
terminal duct combined with an associated lobule14-16. Consequently, theoretically any 
remaining TDLUs may represent a lifelong potential breast cancer hazard. To estimate 
the remaining risk after prophylactic mastectomy, some authors have studied whether 
TDLUs are left in situ. Several others have simply examined the presence of remaining 
ductal or lobular structures or more non-specifically the presence of glandular tissue.
Residual breast glandular tissue after total mastectomies
The first study to investigate the amount of glandular tissue left in situ after a conven-
tional total mastectomy was already in 1940 by Hicken et al.17 The authors had been 
triggered by two cases of women who developed breast cancer and mastitis of residual 
axillary breast tissue 15 and 10 years, respectively, after an ipsilateral mastectomy for a 
benign indication. Mammographies of 385 breasts using intraductal contrast showed 
that mammary ducts frequently extend beyond regular mastectomy resection planes. 
In 95%, mammary ducts extended into the axillary fossa, in 15% downward into the 
epigastric region, in 2% beyond the lateral limits of the latissimus dorsi muscle and 
in two cases even past the midsternal line to the contralateral side17. A histological 
analysis of17 total mastectomies was performed in the same study by preoperatively 
injecting methylene blue dye into the ducts of the nipple-papilla. Any resection plane 
that colored blue during surgery meant that ducts had been cut and the resection site 
was defined as ‘irradical’17. Results showed that breast glandular tissue had been excised 
irradically underneath the skin flap in 94% of cases, in 12% the axillary tail had been 
removed irradically, in 23% the ducts had been cut in the sternal region and in 11% in 
the epigastric region17. The authors therefore concluded that, even when it is intended 
to perform a total mastectomy, it is seldom accomplished17.
In 1991, a small study was performed in 10 total mastectomies in five women18. Frozen 
sections of skin flaps, pectoral muscle and axillary tail were examined. Similar to the 
results of Hicken, residual breast glandular tissue was found in caudal skin flaps, the 
axillary tail and even in the pectoral fascia18. Another small study separately resected 
specimens specifically of the inframammary fold (IMF) and encountered small amounts 
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of residual breast tissue in 13/24 IMF specimens (with breast glandular tissue volume / 
IMF specimen volume rates of 0.04%)19.
In 2013, Griepsma et al. studied the superficial dissection planes of 206 – mostly total – 
mastectomy specimens20. Per mastectomy 36 biopsies were obtained from standardized 
locations of the subcutaneously dissected part of the total mastectomy specimens. In 
76% of mastectomies, one or more biopsies contained breast glandular tissue at the 
resection plane. Areas of predilection were the lower outer quadrant (15% positive bi-
opsies) and halfway the subcutaneous dissection plane between the peripheral pectoral 
muscle margin and central skin margin (12% positive biopsies)20.
Residual breast glandular tissue after conservative mastectomy: SSM and nSM
Three decades after the first report on total mastectomies by Hicken et al, Goldman and 
Goldwyn picked up on the issue of conservative prophylactic mastectomy by perform-
ing 12 subcutaneous (skin- and nipple-sparing) mastectomies in six cadavers through 
an inframammary incision21. Biopsies of post-mastectomy skin flaps, resection planes 
and any fibrous or adipose tissue remaining elsewhere showed residual breast glandular 
tissue after 83% of mastectomies21. In all cases even, residual breast glandular tissue was 
found behind the spared NAC. However, the authors do not describe which biopsy sites 
were positive for breast glandular tissue, nor the surgical technique used for dissection 
of the NAC21.
Aiming to investigate the potential value of NSM in the treatment of lobular carci-
noma in situ (LCIS), Rosen and Tench22 vertically sectioned 101 nipples in conventional 
mastectomies performed for breast cancer. In 17% of the nipples lobules were found 
and in 13% (in situ) carcinoma was encountered. The authors propose that ‘coring’ of 
the nipple-papilla in NSM, which had been described before23, is necessary to remove as 
much glandular tissue as possible. The NAC was further examined in 199324. By inverting 
the projected center of the NAC - the nipple-papilla - and grossly removing all glandular 
tissue inside the papilla, the nipple was cored. Despite nipple-coring the authors did 
encounter mammary ducts in the areolar dermis24.
In 1991, Barton et al. compared 27 conservative mastectomies with 28 modified radical 
mastectomies25. Post-mastectomy biopsies were taken at the inframammary fold, para-
sternal region, infraclavicular chest wall, latissimus dorsi muscle border, anterior lower 
axilla and skin flaps. The NAC was not examined. No differences were found between the 
number of biopsies containing residual breast glandular tissue after conservative mas-
tectomy (22%) and after total mastectomy (21%)25. After conservative mastectomy, most 
positive biopsies (50%) originated in the skin flap. In contrary, after total mastectomy, 
most positive biopsies (38%) originated at the latissimus dorsi border25.
The skin flap after conservative mastectomy was further examined in 199826. The 
authors removed 114 small (0.5 x 2.0 cm) strips of skin from the remaining skin flap in 32 
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patients for complete histological examination. In none of the strips ductal breast tissue 
was encountered26, however, regarding the size of the strips, this negative finding may 
be due to a sampling error. Somewhat larger skin flaps have been examined in a more 
recent study27. In 66 SSMs, skin specimens that had been removed additionally to the 
SSM specimen to facilitate reconstruction were examined for residual glandular tissue. 
Skin specimens had a mean volume of 93.9 cm3 and in specimens of only four patients 
(6%) residual breast tissue was found27. However, since only a minimum of 3 sites per 
skin specimen was analyzed, again in this study a sampling error cannot be ruled out. 
A study of 168 SSMs for therapeutic indication analyzed the superficial margin to the 
dermis just above the tumor that would have been left in situ otherwise. In contrast 
with the two studies described above, in 89 (53%) of the cases benign breast ducts were 
present in the superficial margin specimen28.
Residual terminal duct lobular units (Tdlus) after conservative mastectomy: 
SSM and nSM
Several studies have more specifically studied whether TDLUs remain after SSM or NSM 
22, 29-31. The only study on SSM was by Torresan et al in 200532. In 42 total mastectomies, 
they resected the skin flap that would have been left in situ if it were a SSM and submitted 
80 slides per skin specimen for examination. In contrary to the two studies mentioned 
earlier, they found TDLUs in 60% of the skin flaps32. The risk of finding TDLUs strongly 
increased for skin flaps thicker than 5 mm32.
The other five studies focus on NSM. Stolier et al. examined the nipple-papilla for 
presence of TDLUs in 200829. During mastectomies, 32 nipple-papilla’s were transected 
at the junction of papilla and areola. Nipple-papilla’s were sectioned, entirely embedded 
and examined microscopically for presence of TDLUs. Only in three out of 32 nipple-
papilla TDLUs were found. Therefore, it was concluded that TDLUs are scarce in the 
nipple-papilla29. Reynolds et al. collected 62 mastectomy specimens from 33 BRCA1/2 
mutation carriers and excised the NAC for histologic evaluation30. In 24% of the NACs, 
TDLUs were found; only 8% was located in the papilla30. Similarly, Kryvenko et al. studied 
105 NACs from mastectomy specimens31. Sixty-five NACs were entirely embedded for 
examination of presence of TDLUs; of 40 NACs only one vertical section was examined. 
TDLUs were found in 26% of NACs but most frequently were located in the papilla31 - in 
contrast to the results of Reynolds and Stolier29, 30. It has been suggested that an areola-
sparing mastectomy rather than a NAC-sparing mastectomy should be performed for 
risk reduction. Removing the nipple-papilla might reduce any remaining breast cancer 
risk. However, this is not supported by the abovementioned studies since two of the 
three show a higher incidence of TDLUs in the areola versus the nipple-papilla. Recently, 
our own group compared presence and numbers of TDLUs between skin flap and NAC 
33. In 105 total mastectomies, the NAC and an adjacent skin-island were dissected as if an 
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NSM was performed, and the papilla was cored. TDLUs were found in 61% of the NACs 
vs. 24% of the skin islands33. Also after adjustment for volume of the excised specimens, 
density of TDLUs was significantly higher in the NACs as compared with the skin. Further, 
risk factors for presence of TDLUs were younger age and parity (vs. nulliparity)33. We 
concluded that NACs, as well as skin flaps might harbor a risk for developing breast 
cancer, albeit very small.
OnCOlOGICAl SAfETy Of PROPHylACTIC MASTECTOMy: ClInICAl STudIES
In addition to the histopathological studies, we assessed whether there are any oncologi-
cal consequences of the residual glandular tissue. We performed a systematic PubMed 
search using the term ‘prophylactic mastectomy [Title/Abstract] OR skin-sparing 
mastectomy [Title/Abstract] OR nipple-sparing mastectomy [Title/Abstract] OR subcu-
taneous mastectomy [Title/Abstract] OR conservative mastectomy [Title/Abstract] OR 
risk-reducing mastectomy [Title/Abstract] AND breast cancer [Title/Abstract], yielding 
680 titles. Titles and abstracts were checked for relevance. Reviews and case reports 
were excluded, as were articles that were not in English. Also excluded were: studies 
that focused (1) on merely therapeutic mastectomy and/or comprised <20 prophylactic 
mastectomies and/or did not report clinical follow-up outcome of prophylactic mastec-
tomies; (2) on survival benefits of contralateral prophylactic mastectomy or oophorec-
tomy and (3) on uptake, counseling and decision-making of prophylactic surgery.
Twenty-four studies from 1976-2014 met our criteria and are summarized in Table 
1. All are observational studies describing prospective or retrospective cohorts or a 
case-control series. In 24 studies, 7,173 mastectomies are described of which 1,392 were 
for therapeutic indications and which were not considered in further analysis. Most 
prophylactic mastectomies were performed in BRCA1/2 gene mutation carriers and 
other women at high breast cancer risk. Average follow-up periods range from 10.4-
168 months. Most recent studies focus on NSM rather than SSM, while in older studies 
conservative mastectomies are defined as ‘subcutaneous mastectomy’, suggesting that 
the NAC is – partly – spared. However, as described above, it is likely that in subcutane-
ous mastectomy the NAC and skin are not dissected as thin as modern NSM or SSM 
techniques dictate.
As reported by the 24 studies in Table 1, grossly, 21 primary breast cancers occurred 
after 6,044 prophylactic mastectomies. Of these, three occurred after a total mastectomy 
(0.6% of all total mastectomies), 17 occurred after a conservative mastectomy (0.3% of 
all subcutaneous mastectomies, NSM or SSM) and for one breast cancer the prophylactic 
mastectomy technique was not specified. Besides, four patients presented with distant 
metastases with unknown primary site. Most prophylactic mastectomies included in 
these studies, as well as the ones in which a primary breast cancer developed, were 
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Table 1. Primary breast cancers after prophylactic total mastectomy, nipple-sparing and skin-sparing mastectomies: 
an overview of studies
1st author Year Study population Mastec-
tomies
Therapeutic 
mastectomy 
Not taken into 
account
Prophylactic 
mastectomy (PM)
Follow-up after 
PM
Primary BC after PM Distant metastases 
after PM
Location primary breast cancer after PM
Conservative PM Total 
PM
SSM NSM
n n n n n Months (range) n (% of all PM)
de Alcantara Filho 2011 125 unknown
36 BRCA1/2+ 
39 non-BRCA1/2
353 157 - 196 - 10.4 
(0–109)
0 - 0
Arver 2011 129 BRCA1/2+
94 non-BRCA1/2 or unknown
446 - 100 3381 8 79.2 
(25.2-168.0)
0 1 metastatic disease 9 
yrs after PM
(0.2%)
Distant metastases 
Colwell 2014 285 patients 482 222 - 260 - 26.0 
(10.8-71.0)
0 - N/A
Contant 2002 63 BRCA1+
13 BRCA2+
36 non-BRCA1/2 or unknown
207 - 193 - 14 30.0 
(12.0-70.8)
0 - N/A
Evans 2009 202 BRCA1/2+
348 non-BRCA1/2 >25% BC risk
864 - 3462 2002 73.2
(range NR)
0 - N/A
Garcia-Etienne 2009 25 patients 42 7 - 34 - 10.5 
(0.4-56.4)
0 - N/A
Hagen 2014 267 BRCA1/2+
(104 history of BC)
449 - 1662 492 52 35 
(3-336)
1 primary BC 6.6 yrs after 
subcutaneous PM 
(0.2%)
- NR
Harness 2011 6 BRCA1/2+
37 non-BRCA1/2 or unknown
60 40 - 20 - 18.5 
(6-62)
0 - N/A
Hartmann 1999 and 2001 26 BRCA1/2+
150 non-BRCA1/2 high risk
38 not tested
425 moderate risk
1278 - 11463 132 168
(range NR)
6 primary BC: 2, 3, 5, 
6, 15 and 25 yrs after 
subcutaneous PM
(0.5%)
1 metastatic disease 12 
yrs after subcutaneous 
PM
2 yrs: chest wall
3 yrs: lateral side chest wall
5 yrs: left breast ‘above areola’
6 yrs: left nipple
15 yrs: left breast 
25 yrs: chest wall
Heemskerk-Gerritsen 2013 156 BRCA1+
56 BRCA2+
424 - 384 40 - 75.6 
(1.2-208.8)
0 1 metastatic disease 3.5 
yrs after prophylactic 
SSM
(0.1%)
N/A
Jensen 2010 99 patients 149 99 - 50 - 60.2 
(12–144)
0 - N/A
Kaas 2010 179 BRCA1+
75 BRCA2+
401 - NR
(Majority)
NR NR Bilateral: 63.5 
Unilateral: 65.0 
(ranges NR)
1 primary BC 2 yrs after PM 
(history of contralateral BC)
(0.2%)
- Axillary tail which was incompletely 
removed
Meijers-Heijboer 2001 64 BRCA1+
12 BRCA2+
152 - 148 - 4 33.6 
(1.2-68.4)
0 - N/A
Munhoz 2013 158 patients, genetic status 
unknown
233 114 - 119 - 65.6 
(6-130)
0 - N/A
Peled 2014 53 BRCA1/2+
53 non-BRCA1/2
212 108 - 104 - 51 
(8.3-132.8)
0 - N/A
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Table 1. Primary breast cancers after prophylactic total mastectomy, nipple-sparing and skin-sparing mastectomies: 
an overview of studies
1st author Year Study population Mastec-
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mastectomy (PM)
Follow-up after 
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Primary BC after PM Distant metastases 
after PM
Location primary breast cancer after PM
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SSM NSM
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Table 1. Primary breast cancers after prophylactic total mastectomy, nipple-sparing and skin-sparing mastectomies: 
an overview of studies (continued)
1st author
 
Year Study population Mastec-
tomies
Therapeutic 
mastectomy 
Not taken into 
account
Prophylactic 
mastectomy (PM)
Follow-up after 
PM
Primary BC after PM Distant metastases 
after PM
Location primary breast cancer after PM
Conservative PM Total 
PM
SSM NSM
n n n n n Months (range) n (% of all PM)
de la Peña-Salcedo 2011 52 patients 64 - - 42 22 144 
(range NR)
0 - N/A
Pennisi 1976 1244 patients NR 642 11802,3 - 84
(range NR)
6 primary BC after 
subcutaneous mastectomy 
- NR
Rebbeck 2004 105 BRCA1/2+ 210 - 583,4 1005 66
(0-373)
2 BC 2 and 9 yrs after 
subcutaneous mastectomy 
in BRCA2+ and BRCA1+, 
respectively 
(1.0%)
- 1 in axillary lymph node, 1 in residual right 
breast tissue (exact location NR)
Sacchini 2006 3 BRCA1/2+
1 non-BRCA1/2
119 unknown
219 68 - 151 - 24.6 
(2.1-570.4)
2 BC 2 and 5 yrs after 
prophylactic NSM
(1.3%)
- 1 in the axillary tail 
1 in the upper-outer quadrant
Skytte 2011 67 BRCA1+
29 BRCA2+
192 - NR NR NR 47.3
(range NR)
3 BC in BRCA1+; 2, 5 and 7 
yrs after total mastectomy
(1.6%)
- 2 at the thoracic wall, 
1 in the axilla (lymph node metastasis or 
ectopic breast tissue)
Spear 2011 22 BRCA1/2+
79 non-BRCA1/2 or unknown
162 49 - 113 - 43 (5-246) 0 1 metastatic disease of 
unknown primary after 
9 yrs 
(0.9%)
N/A
Wagner 2012 7 BRCA1/2+
3 BRCA1/2-
23 unknown
33 patients
54 17 - 37 - 15.0 (1–29) 0 - N/A
Warren Peled 2012 19 BRCA1/2+
411 non-BRCA1/2 or unknown
657 412 - 245 - 28 0 - N/A
Wijayanayagam 2008 43 patients; partly BRCA1/2+ 75 35 - 29 11 NR 0 - N/A
Total numbers of primary BC after conservative and total PM: 5,548 conservative PM
496 total PM
17 BC after conservative PM (0.3%)
3 BC after total PM (0.6%)
1 BC after unknown PM technique
(6-9, 13, 34-52)
BC, breast cancer; PM, prophylactic mastectomy; SSM, skin-sparing mastectomy; NSM, nipple-sparing 
mastectomy; NR, not reported; N/A, not applicable; 
BRCA1/2+, female BRCA1/2 gene mutation carrier; BCT, breast conserving therapy
1 202 of 338 NSM concerned SSM with retransplantation of the nipple but removal of the areola
2 Women with unilateral and bilateral mastectomies; exact numbers of mastectomies 
not reported and are analyzed as one mastectomy per woman
3 Conservative mastectomy = subcutaneous mastectomy 
4 Of 26 patients (52 mastectomies) mastectomy techniques were unknown
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Conservative PM Total 
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SSM NSM
n n n n n Months (range) n (% of all PM)
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Total numbers of primary BC after conservative and total PM: 5,548 conservative PM
496 total PM
17 BC after conservative PM (0.3%)
3 BC after total PM (0.6%)
1 BC after unknown PM technique
(6-9, 13, 34-52)
BC, breast cancer; PM, prophylactic mastectomy; SSM, skin-sparing mastectomy; NSM, nipple-sparing 
mastectomy; NR, not reported; N/A, not applicable; 
BRCA1/2+, female BRCA1/2 gene mutation carrier; BCT, breast conserving therapy
1 202 of 338 NSM concerned SSM with retransplantation of the nipple but removal of the areola
2 Women with unilateral and bilateral mastectomies; exact numbers of mastectomies 
not reported and are analyzed as one mastectomy per woman
3 Conservative mastectomy = subcutaneous mastectomy 
4 Of 26 patients (52 mastectomies) mastectomy techniques were unknown
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subcutaneous mastectomies, NSM or SSM. Nonetheless, the majority of primary breast 
cancers did not originate near the NAC or skin flap. Of the 21 breast cancers that de-
veloped after prophylactic mastectomy, five were encountered at the chest wall, four 
in the axilla, (two in the axillary tail, one in an axillary lymph node, one in an unknown 
location), one in the outer quadrant, one in the nipple and one ‘above the areola’ (not 
further specified). In nine cases the location was unclear or not reported.
The 21 loco-regional primary breast cancers correspond with an incidence of 0.7% 
per woman who undergoes bilateral prophylactic mastectomy (0.35% per mastectomy). 
Most breast cancers that developed after conservative mastectomy were found at the 
chest wall or in the axilla. Although the chest wall and the axilla may be at risk in total 
mastectomy as well, two things should be considered: First, the origin of the breast 
cancer may have been the skin flap, even though it was described as ‘chest wall’. Most 
breast implants in immediate breast reconstruction are placed underneath the pectoral 
muscle. Consequently, skin-flap and chest wall are in direct contact. Therefore, although 
we have no information on the reconstruction techniques used in these studies, it is 
possible that the breast cancers developing at the chest wall actually did originate in the 
skin flap. Second, as mentioned before, the surgical technique of SSM and NSM using 
small peri-areolar or inframammary incisions can be challenging. A suboptimal exposure 
may impede thorough removal of remaining breast glandular tissue in all quadrants and 
in the axillary tail.
In four cases, breast cancer presented as metastatic disease and the primary tumor 
site was never found. Pathological findings specific for breast cancers, the high a priori 
breast cancer risk of the patient and elimination of other potential first sites because 
of negative radiological examinations may all have led to the conclusion that the 
metastatic disease most probably originated from breast cancer. The possibility that 
the primary tumor already may have been present in the prophylactic mastectomy 
specimen emphasizes the importance of standardized pathological examination of the 
excised specimen, and – even more – thorough radiological screening by MRI before 
prophylactic mastectomy.
In conclusion, the incidence of primary breast cancers after prophylactic mastectomy 
is very low after total as well as after conservative mastectomies. However, theoretically, 
according to these data, approximately one out of 140 women undergoing bilateral 
prophylactic mastectomy for breast cancer prevention will develop a primary breast 
cancer over time. Oncological surgeons should be aware of this risk and may minimize it 
by putting extra care in dissecting all glandular tissue, especially in the axillary tail and 
chest wall, and by dissecting skin flaps and NAC as thin as possible. More studies are 
warranted that further assess long-term oncological safety. Further, it is important to 
more specifically study patient satisfaction after NSM and SSM and potential differences 
Oncological safety of prophylactic mastectomy
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in patient expectations. Ultimately, surgeons and patients may be able to balance any 
remaining oncological risk against expected benefits of NSM or SSM.
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AbSTRACT
Risk-reducing salpingo-oophorectomy (RRSO) is associated with 50% reduction of 
BRCA1/2-associated breast cancer (BC) risk, possibly through decreased growth activity. 
In this pilot study, tumor characteristics and growth rates of BRCA1/2-associated primary 
BCs (PBCs) detected after RRSO were compared with those of PBCs originating without 
RRSO. From a cohort of 271 women with BRCA1/2-associated screen detected BC, we 
selected 20 patients with PBC detected ≥12 months after RRSO (RRSO group). Controls 
were 36 BRCA1/2 mutation carriers with PBC detected without RRSO (non-RRSO group) 
matched for age at diagnosis (±2.5 years) and for BRCA1 or BRCA2 mutation. Pathol-
ogy samples were revised for histological subtype, tumor differentiation grade, mitotic 
activity index (MAI), estrogen receptor (ER), progesterone receptor (PR) and HER2 status. 
Tumor growth rates, expressed as tumor volume doubling times (DT), were calculated 
from revised magnetic resonance and mammographic images. Median age at PBC diag-
nosis was 52 years (range 35-67). PBCs after RRSO had lower MAIs (12 versus 22 mitotic 
counts/2mm, P=0.02), were smaller (11 versus 17 mm, P=0.01), and tend to be PR-positive 
more often than PBCs without RRSO (38% versus 13%, P=0.07). Differentiation grade, 
ER and HER2 status were not different. Median DT was 124 days (range 89-193) in the 
RRSO group and 93 days (range 54-253) in the non-RRSO group (P=0.47). BC occurring 
after RRSO in BRCA mutation carriers features a lower MAI, suggesting a less aggressive 
biological phenotype. When confirmed in larger series, this may have consequences for 
BC screening protocols after RRSO.
Tumor characteristics after risk-reducing salpingo-oophorectomy
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BRCA1/2 mutation carriers face increased lifetime risks by the age of 70 years of develop-
ing breast cancer (BC; 55-85%), contralateral breast cancer (CBC; 20-60%) and ovarian 
cancer (18-54% for BRCA1 and 3-23% for BRCA2 mutation carriers)1-5. In view of the 
increased ovarian cancer risk, and the unavailability of an adequate screening tool, the 
majority of BRCA1/2 mutation carriers opt for risk-reducing salpingo-oophorectomy 
(RRSO), mostly before 50 years of age6, 7. RRSO significantly reduces the risk of ovarian/
fallopian tube cancer by more than 95%6, 8, 9, while it is also associated with a primary 
BC (PBC) risk-reduction of about 50%, being most pronounced when performed at 
premenopausal age7, 10.
BRCA1/2-associated BCs are often diagnosed at young age and are more often poorly 
differentiated than sporadic BCs (grade 3 in 50-75% versus 35%, respectively)11, 12. The 
BRCA1 BC phenotype is mainly estrogen receptor (ER) and progesterone receptor (PR) 
negative, and does not express HER2, resulting in approximately 60% of the BCs being 
triple negative.12 The BRCA2 BC phenotype is quite similar to sporadic BCs regarding ER, 
PR and HER2 status.12 Furthermore, shorter tumor volume doubling times (DT), express-
ing faster tumor growth, have been described for both BRCA1- and BRCA2-associated 
tumors as compared to non-BRCA1/2-associated tumors in patients of similar age.13 
At increasing age, BRCA1/2-associated tumors have longer DTs,13 a more favorable dif-
ferentiation grade and are more often ER positive possibly due to changes in ovarian 
hormone production12, 14, 15. In view of the mentioned observations and the reduced BC 
risk after RRSO, we hypothesized that PBCs developing after RRSO-induced menopause 
might show altered characteristics and decreased tumor growth. The latter is also an 
observation at our institute, although an earlier study on tumor growth did not find a 
correlation of menopausal status with tumor growth.13 To our knowledge, no detailed 
data are available on this topic. The finding of a lowered growth rate of BCs occurring 
after RRSO might have consequences for BC screening protocols for the subgroup of 
BRCA1/2 mutation carriers who underwent RRSO.
We performed a pilot study in a matched cohort of BRCA mutation carriers, and com-
pared tumor characteristics and tumor growth rates of PBCs developing after RRSO with 
PBCs originating without RRSO.
METHOdS
Patients
Since the start of the Rotterdam Family Cancer Clinic (FCC, approximately 1991), women 
at increased risk of hereditary breast and/or ovarian cancer are prospectively followed. 
From this cohort, we identified BRCA1/2 mutation carriers with a PBC detected at least 
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12 months after RRSO (RRSO group, cases). Patients were matched for age at PBC (+/- 2.5 
years) and type of mutation (BRCA1 or BRCA2), with an intended ratio of 1:2, to obligate 
or proven BRCA1/2 mutation carriers with a PBC developing without RRSO (non-RRSO 
group, controls) (Figure 1).
Family Cancer Clinic Registry
BRCA1/2-associated screen detected PBCa
n=271
• < 12 months RRSO - PBC
n=4
• No available match
n=1
PBC after RRSOb
n=25
PBC without/before RRSO
n=246
RRSO group
n=20
non-RRSO group
n=36
• No (optimal) match
• Tumour material not 
available
n=210
Ratio RRSO/non-RRSO 1:2
figure 1. Patient inclusion from the Rotterdam Family Cancer Clinic
A PBC: primary breast cancer
b RRSO: risk-reducing salpingo-oophorectomy
Further eligibility criteria included (a) PBC detected at screening or presenting as interval 
carcinoma between two screening examinations (previous examination within 2 years 
before diagnosis), and (b) availability of tumor material for pathology revision. Exclusion 
criteria were risk-reducing mastectomy prior to PBC, neoadjuvant chemotherapy and/or 
a history of ovarian cancer. Detailed data on hormonal status and reproductive factors 
including menarche, number of pregnancies and childbearing, breast feeding, use of 
oral contraceptives and age at RRSO and/or menopause were collected from medical 
records.
Written informed consent was obtained according to research protocols approved by 
the Medical Ethical Committee.
Radiological tumor measurements and growth rate assessment
Radiological images of serial screening examinations (magnetic resonance imaging 
(MRI) or mammography; previous and at PBC diagnosis) of selected patients were col-
lected. Eligibility criteria for this research question included (a) invasive carcinoma and 
(b) the availability of at least two well interpretable imaging examinations of the same 
Tumor characteristics after risk-reducing salpingo-oophorectomy
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screening modality (MRI, preferably, or mammography), one made at diagnosis and one 
within two years prior to PBC diagnosis.
Images were revised by a breast radiologist (I.O.) being unaware of RRSO status of 
the patients, regarding visibility of the lesion and perpendicular tumor diameters. If the 
tumor was visible on ≥ 2 comparable, consecutive examinations, the first and the last 
examination were used for tumor volume calculations. If the tumor was clearly visible 
on MRI, three perpendicular tumor diameters were measured. On mammography, three 
perpendicular diameters were measured if possible, but if only two diameters could be 
measured, the smaller of the two diameters was used as third diameter. Tumor volumes 
were calculated by using a formula for obloid spheroids: c21b21a21π34V  
13, 16. Because 
of the assumed exponential growth pattern of small tumors,17 an exponential formula 
was used to calculate tumor volume doubling time: E
2ln DT  with β being the slope of 
the straight line between the logarithms of the tumor volumes versus time13, 16. If the 
tumor was only visible on MRI or mammography at diagnosis, the tumor volume of the 
preceding examination was set corresponding with the assumed lower detection limit 
of that imaging examination, being 2 mm for MRI, corresponding with a volume of 0.004 
cm3, and 4 mm for mammography, corresponding with a volume of 0.033 cm3 13.
Histological tumor characteristics
Pathology slides were revised by a breast pathologist (C.v.D.) unaware of the RRSO sta-
tus of patients. Items scored concerned: tumor subtype according to the World Health 
Organization classification, grade according to the modified Bloom & Richardson score 
(based on tubule formation, nuclear pleomorphism and Mitotic Activity Index (MAI)),18 
and ER, PR and HER2 status. For categorization of MAI, thresholds of the modified Bloom 
& Richardson grade were used resulting in three categories (low 0-7 mitoses/2 mm2, 
moderate 8-12 mitoses/2 mm2 and high ≥13 mitoses/2 mm2)19. For ER and PR, histoscores 
(H-scores) were calculated as the sum of the percentages of immunoreactive staining of 
tumor cells, multiplied by ordinal values corresponding to the intensity levels of the 
staining: H-score (0-300) = % weakly immunoreactive cells x 1 + % moderately immunoreac-
tive cells x 2 + % intensely immunoreactive cells x 3. An H-score of ≥10 was considered 
positive, since 10% of immunoreactive staining of tumor cells, independent of intensity, 
is the cut-off point for ER/PR positivity according to Dutch national guidelines19. Patients 
with carcinoma in situ without an invasive component were also included. Data on 
tumor size and nodal status were obtained from the database and/or pathology reports.
Statistical analysis
Differences between the RRSO and non-RRSO groups were tested by using Chi-square 
and Fisher’s exact tests for categorical variables, and by using Mann-Whitney U tests for 
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continuous variables. The SPSS computer package (version 20.0) was used for statistical 
analyses.
RESulTS
From a cohort of 271 patients with screen detected BRCA1/2-associated BC retrieved 
from the FCC database 21 female BRCA1/2 mutation carriers were identified with a PBC 
detected at least 12 months after RRSO. One woman with BC after RRSO was excluded 
from further analysis because no match was available (Figure 1). Of 246 proven or ob-
ligate mutation carriers with BC without RRSO, 36 appropriate matches (including two 
obligate mutation carriers) were found for the non-RRSO group (Figure 1). For four RRSO 
women only one appropriate match was found.
Patient characteristics and demographics are listed in Table 1. As year of diagnosis 
was not a matching criterion, median year of PBC diagnosis in the RRSO group was 2009 
vs. 2001 in the non-RRSO group (P=0.001). RRSO was performed at a median age of 50 
years, and four women (20%) were postmenopausal at RRSO. Nine women (45%) of this 
group had used hormone replacement therapy (HRT) between RRSO and PBC diagnosis. 
In the non-RRSO group, 18 women (50%) were postmenopausal at PBC diagnosis, none 
of them having used HRT. More PBCs were detected by MRI in the RRSO group (14 out 
of 20, 70% by MRI) than in the non-RRSO-group (8 out of 36, 22% by MRI, P=0.001) as 
compared to mammography (Table 1). Both groups were comparable regarding age at 
PBC (due to matching), parity and other hormonal factors.
Radiological tumor measurements and growth analysis of invasive carcinomas
Tumor volume doubling times (DTs) of invasive BCs, as an expression of tumor growth 
rate, could be calculated for 12 of 17 tumors (71%) in the RRSO group and for 18 of 34 
tumors (53%) in the non-RRSO group (Table 2). In total, 13 tumors (43%) were only visible 
on the imaging examination at diagnosis (5 on MRI, 8 on mammography), concerning 
10 patients of the non-RRSO group. Twelve tumors (40%) were on revision visible on two 
consecutive examinations, and 5 tumors (17%) were visible on three or more consecu-
tive examinations performed over a time period of 0.5-3.5 years (4 in the RRSO group, 1 
in the non-RRSO group). Median DT of the PBCs was 124 days (IQR 89-193) in the RRSO 
group and 93 days (IQR 54-253) in the non-RRSO group (P=0.47) (Figure 2 and Table 2).
Tumor characteristics after risk-reducing salpingo-oophorectomy
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Table 1. Patient characteristics
RRSO a group Non-RRSO group P value
N 20   36    
BRCA1 17 85% 31 86%  
BRCA2 3 15% 5 14% 1.0
Age PBCb (median, IQR c), years 52.0 46.0-62.5 50.0 46.0-57.0 0.44
Year PBC diagnosis (median, IQR) 2009 2005-2011 2001 1996-2006 0.001
Screening method that detected PBC  
 MRI 14 70% 8 22%  
  Mammography 6 30% 28 78% 0.001
Menopausal status at PBC  
  Pre- 0 0% 17 49%  
  Post- 20 100% 18 51%  
  Unknown 0   1    
Age RRSO (median, IQR), years 50.0 41.0-55.0 -    
Menopausal status at RRSO          
  Pre- 14 78% -    
  Post 4 22% -    
  Unknown 2   -    
Months RRSO-PBC (median, IQR) 19.0 14.5-118.0 -    
Hormone replacement therapy (HRT)          
  Yes 8 45% 0 0 0.003
  No 12 55% 18 100%  
Age menarche (median, IQR), years 14.0 12.5-15.5 14.0 12.0-14.0 0.93
Oral contraceptive use          
  Yes 15 88% 29 97% 0.54
  No 2 12% 1 3%  
  Unknown 3   6    
Years of oral contraceptive use (median, IQR) 18.0 9.5-22.0 9.0 4.0-18.0 0.42
Parity (mean, standard deviation) 1.9 1.0 1.6 1.1 0.43
Nulliparity  
  Yes 3 15% 8 26% 0.49
  No 17 85% 23 74%  
  Unknown 0   5    
Age at 1st child (median, IQR), years 26.0 21.5-28.0 25.5 24.0-30.0 0.61
Breastfeeding  
  Yes 6 40% 17 57% 0.35
  No 9 60% 13 43%  
  Unknown 5   6    
Months breastfeeding (median, IQR) 4.0 0.5-9.5 6.0 3.0-8.0 0.51
a RRSO: risk-reducing salpingo-oophorectomy
b PBC: primary breast cancer
c IQR: interquartile range
Hormone replacement therapy, after RRSO (RRSO group) or menopause (non-RRSO group)
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figure 2. A Tumor volumes over time and b tumor volume doubling times (DTs) for primary breast cancers 
occurring after risk-reducing salpingo-oophorectomy (RRSO) and without RRSO (non-RRSO)
ln: natural logarithm
Tumor volumes: V= 4/3π*1/2a*1/2b*1/2c; a, b and c are perpendicular tumor diameters on MRI or mam-
mography
Tumor volume doubling time (DT): DT= (ln2)/β; β= slope between natural logarithms of tumor volumes
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Table 2. Radiological tumor growth analysis of invasive carcinomas
RRSOa group Non-RRSO group P value
Invasive carcinomas (n) 17   34    
Eligible for growth rate analysis 12 71% 18 53%  
BRCA1 11   17    
 MRI screening 9 82% 7 41% 0.05†
  Mammography screening 2 18% 10 59%  
BRCA2 1   1    
  MRI screening 1 100% 0 -  
  Mammography screening 0 - 1 100%  
Tumor on revision visible on          
  1 examinationb 3 25% 10 56% 0.164†
  2 examinations 5 42% 7 39%  
  ≥3 examinations 4 33% 1 5%  
Time between two screening examinations (median, IQRc), days 344 243-433 397 286-676 0.212¶
Time between examinations used for tumor growth calculation 
(median, IQR), days
427 201-586 400 341-676 0.719¶
Tumor volume doubling time (DT) (median, IQR), days 124 89-193 93 54-253 0.472¶
All percentages are of invasive carcinomas
aRRSO: risk-reducing salpingo-oophorectomy
bTumor growth rate is calculated combined with one baseline examination with no visible tumor (baseline 
tumor volume 0.004cm (MRI) or 0.033 cm3 (mammography))
cIQR: interquartile range
†Fisher’s Exact Test
¶Mann-Whitney U Test
Histological tumor characteristics
Tumor characteristics are presented in Table 3. The RRSO group comprised three cases of 
DCIS (two BRCA1, one BRCA2) and 17 invasive PBCs (15 BRCA1, two BRCA2), concerning 
15 ductal carcinomas, one lobular and one metaplastic carcinoma. The non-RRSO group 
comprised two cases of DCIS (one BRCA1, one BRCA2) and 34 invasive ductal carcinomas 
(30 BRCA1, four BRCA2), including one with metaplastic characteristics. Median tumor 
size of the invasive PBCs was 10.0 mm (interquartile range (IQR) 6.5-16.0) in the RRSO 
group, versus 17.0 mm (IQR 10.0-25.0) in the non-RRSO group (P=0.01). The majority of 
invasive PBCs in both groups was node negative (15/17 in the RRSO group and 25/34 in 
the non-RRSO group, P=0.30).
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Table 3. Histological tumor characteristics
  RRSOa group Non-RRSO group P-value
N 20   36    
DCISb 3 15% 2 6% 0.34†
Invasive carcinoma 17 85% 34 94%  
T status*          
 T1a/b 9 53% 10 30% 0.16‡
  T1c 6 35% 13 38%  
  T2 2 12% 11 32%  
Size, mm (median, IQRc)* 11.0 6.0-17.0 17.0 10.0-25.0 0.01¶
N status*          
  Negative 15 88% 27 74% 0.29†
  Positive 2 12% 9 26%  
Tubule formation*          
  > 75% 0   1 3% 0.74‡
  10-75% 2 12% 3 9%  
  < 10% 14 88% 28 88%  
  Unknown 1   2    
Nuclear pleomorphism*          
  Minimal 0   0    
  Moderate 6 38% 8 25% 0.50†
  Extensive 10 62% 24 75%  
  Unknown 1   2    
Mitotic count /2mm2 (median, IQR)* 12 1-20 22 14-29 0.02¶
Mitotic Activity Index* (mitoses/2mm2)          
  0-7 6 38% 6 19% 0.008‡
  8-12 3 19% 0    
  ≥13 7 43% 26 81%  
  Unknown 1   2    
Bloom & Richardson grade*          
  1 1 6% 0   0.16‡
  2 6 38% 7 22%  
  3 9 56% 25 78%  
  Unknown 1   2    
Lymphovascular invasion*          
  Yes 1 7% 6 19% 0.40‡
  No 14 93% 26 81%  
  Unknown 2   2    
ERd H-scoree (median, IQR)* 0 0-270 1 0-41 0.63¶
  Positive (H-score ≥10) 7 47% 9 29% 0.33†
  Negative (H-score <10) 8 53% 22 71%  
  Unknown 2   3    
PRf H-score (median, IQR)* 3 0-150 0.0 0-1 0.05¶
  Positive (H-score ≥10) 6 38% 4 13% 0.07‡
  Negative (H-score <10) 10 62% 27 87%  
  Unknown 1   3    
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MAI of the PBCs was significantly lower in the RRSO group than in the non-RRSO group, 
with a median of 12 mitoses/2mm2 (IQR 1-20) and 22 mitoses/2mm2 (IQR 14-28.5), 
respectively (P=0.02). No differences were found in the amount of tubule formations, 
nuclear pleomorphism, overall Bloom & Richardson grade, ER status or HER2 status. The 
proportion of PR positive PBCs (PR H-score ≥10) was higher in the RRSO group than in 
the non-RRSO group (38% vs. 13%) without reaching statistical significance (P=0.07), 
while median PR H-score was significantly higher in the RRSO than in the non-RRSO 
group (3 vs. 0, P=0.05). As a consequence, the percentage of triple negative PBCs was 
lower in the RRSO group than in the non-RRSO group (47% vs. 68%) without reaching 
statistical significance (P=0.21).
dISCuSSIOn
In this pilot study in an age-matched cohort consisting of BRCA1/2-associated BC pa-
tients, PBCs occurring after RRSO were featured by significantly lower mitotic counts, 
a trend for more PR positivity, and (non-significantly) more often ER positivity as com-
pared to PBCs without RRSO. Tumor volume doubling time (DT) was non-significantly 
longer in the RRSO group. To our knowledge, this is the first report comparing tumor 
characteristics and growth patterns of PBCs occurring after RRSO to those without RRSO.
Table 3. Histological tumor characteristics (continued)
  RRSOa group Non-RRSO group P-value
HER2 status*          
  Positive 1 6% 0   0.36†
  Negative 15 94% 28 100%  
  Unknown 1   6    
Triple-negativeg *          
  Yes 7 47% 19 68% 0.21†
  No 8 53% 9 32%  
  Unknown 2   6    
a RRSO: risk-reducing salpingo-oophorectomy
b DCIS: ductal carcinoma in situ
c IQR: interquartile range
d ER: estrogen receptor
e H-score: histoscore (0-300) = % weakly immunoreactive cells x 1 + % moderately immunoreactive cells x 2 
+ % intensely immunoreactive cells x 3
f PR: progesterone receptor
g Triple-negative: negative status for ER, PR and HER2
*Invasive carcinomas only
†Fisher’s Exact Test
‡Chi-square Test
¶Mann-Whitney U Test
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The significantly lower mitotic count in PBCs occurring after RRSO as compared to 
PBCs without RRSO suggests that estrogen depletion induced by RRSO decreases cell 
proliferation. As the majority of PBCs in this study was ER negative, the mechanism be-
hind this observation remains unclear. Various authors confirm that the development of 
BRCA1-associated triple negative BCs is susceptible to estrogen depletion or inhibition 
as achieved by RRSO or tamoxifen20-22. It has been hypothesized that the explanation 
lies in high ER expression of early stages of triple negative BC genesis23, 24. Estrogens 
may facilitate BRCA1-mutant cell proliferation and tumor development in premalignant 
mammary tissue until ER expression extinguishes in later stages, possibly after the 
loss of transcriptional ER-activation by the second BRCA1 allele25. By this mechanism, 
estrogen depletion by RRSO may inhibit tumor development of triple negative BC in a 
very early stage. Furthermore, there is some evidence suggesting that in a later stage of 
tumor development estrogen may induce changes even in ER-negative BCs by affecting 
the microenvironment of the tumor26.
Interestingly, a recent study found that also RRSO performed after natural menopause 
was associated with BC risk-reduction. The authors suggest that androgens, being 
produced by the ovaries after menopause, may affect cell proliferation either directly 
or indirectly through the aromatization to estrogens27, and possibly play a role in the 
risk-reduction of hormone receptor negative breast cancer.
As 85% of the study patients were BRCA1 mutation carriers, our findings are majorly 
driven by BRCA1. BRCA1-associated BCs are known to have higher mitotic counts than 
BRCA2-associated and sporadic BCs28, possibly because proteins associated with nor-
mally functioning BRCA1 genes inhibit cell proliferation29, 30. Separate analyses of BRCA1 
carriers alone revealed comparable results as for the overall group (data not shown). 
To our knowledge, reduced cell proliferation in BRCA1-associated BCs after RRSO or 
menopause has not been described so far. Although tubule formation and nuclear pleo-
morphism, two other components of the Bloom & Richardson grade scoring system, and 
overall differentiation grade were not significantly different in PBCs after versus without 
RRSO, there is evidence that MAI is the most important prognostic factor in early stage 
BCs31, 32. The finding of lower MAI in PBCs after RRSO therefore suggests a less aggressive 
biological growth pattern of this subgroup.
Still, 43% of the tumors in the RRSO group had high mitotic counts (≥13 mitoses/2 
mm2). An explanation may be that the time period of 12 months between RRSO and BC 
diagnosis considered in this study was relatively short, and that some tumors already 
had developed before RRSO. Of interest, PBCs with a high MAI were detected at a me-
dian of 24 months after RRSO, while this was 69 months for tumors with a lower MAI 
(0-12 mitoses/2 mm2; data not shown). This supports previous data suggesting that the 
maximum level of risk reduction by RRSO is effective more than 12 months post-RRSO, 
although some risk reducing effect is already present one year after RRSO.7
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We observed a trend for more PR positivity in the RRSO group, but without significant 
difference in ER status (Table 3). Consequently, fewer tumors in the RRSO group (47%) 
were triple negative, as compared to 68% in the non-RRSO group. The latter percentage 
is in accordance with data from the literature for BRCA1-associated BC12, and mirrors the 
fact that the majority of our patients were BRCA1 mutation carriers. Earlier studies found 
that the proportion of ER and PR positive tumors in BRCA1-associated BC increases 
with increasing age at diagnosis, but is still lower than the percentage of ER-positivity 
in sporadic tumors irrespective of age12, 14, 15. In these studies however, menopausal 
status and history of RRSO were not taken into account. As patients in the current study 
were matched for age, the increased expression of PR in PBCs in the RRSO group, in 
our opinion, suggests transcriptional activation by ER and therefore can be a sign of 
increasing ER-functionality33-35. Therefore, in a larger series we expect not only increase 
of PR positivity, but also of ER positivity in PBCs after RRSO. To our knowledge, only one 
study reported on BC characteristics after RRSO36, but due to a different study design 
and patient cohort, the outcomes of both studies are not comparable.
Tumor size at surgery as reported in pathology reports was significantly smaller in 
the RRSO group than in the non-RRSO group. This is most likely a reflection of the dif-
ferences in screening regimens between the two groups. In the RRSO group all women 
knew their BRCA mutation status prior to RRSO and consequently were screened by 
means of annual MRI and mammography, according to Dutch guidelines. The non-RRSO 
group was more heterogeneous with respect to radiological screening, since 19 of the 
36 women had not been genetically tested until PBC diagnosis. First, time intervals be-
tween screening examinations were longer in the non-RRSO group. Second, due to our 
matching criteria and evolving approaches over time regarding RRSO, year of diagnosis 
ranged from 1999-2012 in the RRSO group as compared to 1987-2011 in the non-RRSO 
group with consequently varying quality of radiological screening examinations. These 
differences between the two groups probably resulted in earlier detection and in smaller 
tumor sizes at diagnosis in the RRSO group (Table 2). In smaller tumors, mitotic counts 
may be lower, as has been reported for screen-detected sporadic BCs37. Therefore, the 
reduced mitotic activity we found in BCs developing after RRSO may partly have been a 
consequence of the smaller tumor size in this group.
Median tumor volume DT was longer in the RRSO group than in the non-RRSO group, 
but this difference was not statistically significant. As pointed out before, in the RRSO 
group women were more often screened with MRI, resulting in more precise tumor vol-
ume assessment. Because of the better imaging quality of MRI over mammography and 
of digital mammography in recent years as compared to previous analogue mammog-
raphy, tumors in the RRSO-group may have been longer visible in retrospect, resulting in 
lower DTs, suggesting slower growth. Further, in both groups large (interquartile) ranges 
for DTs were found (Figure 2), suggesting that the formula used for DT was imprecise. 
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Possibly the assumptions of presumed obloid tumor shape and the exponential growth 
are a too simplified approach of real tumor volume and growth. In combination with 
small groups, this might be the reason no statistical significant DT difference was found.
Unfortunately, due to the small numbers it was not possible to take menopausal 
status and HRT use into account regarding differences in histological characteristics 
and tumor volume DT. Of the non-RRSO group, 51% was naturally postmenopausal at 
PBC diagnosis and growth in these tumors may already have been restrained due to 
declined or absent production of ovarian hormones. Moreover, 45% of women in the 
RRSO group used HRT before PBC. Based on our hypothesis of tumor growth stimulation 
by estrogens, we expect that the differences between the groups in MAI, ER and PR 
status and DT will increase when comparing HRT-naïve patients in the RRSO group with 
premenopausal PBC patients in the non-RRSO group.
Strikingly, in five patients the tumor was visible on three or more screening examina-
tions over a time period of 0.5-3.5 years before BC diagnosis. All women were BRCA1 
mutation carriers and screened by MRI, while four of them had undergone RRSO. In all 
five cases the lesion was noticed earlier, but classified as “probably benign”, while ad-
ditional ultrasonography showed no signs of malignancy. Our observations support the 
fact that radiologists must be aware that in BRCA1 mutation carriers, and especially after 
RRSO, BC can present during screening as small benign looking lesions.
An important strength of our pilot study concerns the matched design, chosen to 
adjust for age at PBC and type of mutation (BRCA1 or BRCA2). Furthermore, pathology 
samples were revised by a breast pathologist, and all imaging examinations were revised 
by a breast radiologist, both unaware of RRSO status and therefore not biased regarding 
results.
However, we are aware of some relevant limitations. First, only 20 patients were eli-
gible for the RRSO group due to the relatively low number of PBCs detected after RRSO. 
Women who consult our cancer center nowadays are encouraged to undergo RRSO as of 
40 years of age, and some women already have suffered from BC by that time. Strict in-
clusion criteria and the matched design restricted further enlargement of the non-RRSO 
group. While some women in the RRSO group were relatively old at the time of PBC 
diagnosis (> 60 years), only few BRCA mutation carriers were identified with a first BC 
occurring at older age without prior RRSO. Groups were too small to perform multivari-
able analysis to correct for other variables possibly of influence on tumor biology, such 
as HRT use, menopausal status and tumor size at detection. Second, the group consisted 
mostly of BRCA1 mutation carriers, as this is most frequently seen in the Netherlands. 
The number of BRCA2 mutation carriers was too small to perform a subgroup analysis.
In conclusion, the lower MAI and the increased proportion of PR positive BRCA1/2-
associated BCs developing after RRSO suggest a less aggressive biological phenotype 
compared with PBCs occurring without RRSO. This was not confirmed by significantly 
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longer DTs, probably due to small numbers. Our findings in BRCA1/2-associated PBCs 
occurring after RRSO are the first of this kind, but confirmation is warranted in larger 
sample sizes, since these findings may have consequences for less intensive breast 
cancer screening protocols after RRSO in mutation carriers, with possibly less outpatient 
clinic visits, less distress for the patient, and lower costs.
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AbSTRACT
The prognosis of BRCA1/2-associated breast cancer partly depends on histologic 
characteristics. The majority of these breast cancers, however, is poorly differentiated. 
BRCA1-associated cancers are mainly negative for estrogen (ER), progesterone (PR) and 
HER2 receptor. Consequently, the use of these histologic features for risk stratification in 
BRCA1/2-breast cancer is limited. We assessed the prognostic value of additional histo-
logic features, including tumor-associated inflammation and tumor-associated stroma 
in BRCA1/2-breast cancer patients. From the Rotterdam Family Cancer Clinic database 
we collected demographics, tumor characteristics and follow-up data from female 
BRCA1/2-breast cancer patients. Tumor samples were centrally reviewed including his-
tologic subtype, differentiation grade, tumor-associated inflammation density, amount 
of tumor-associated stroma and intra-tumor necrosis. The impact of these factors on 
recurrence-free survival (RFS) was evaluated using uni- and multivariable Cox regres-
sion, adjusted for established prognostic features and year of diagnosis. We included 
138 BRCA1- and 37 BRCA2-breast cancer patients. Median follow-up after diagnosis was 
9.7 years. Independent prognostic factors for RFS were tumor size (HR 2.47 for >2 cm 
vs. ≤2 cm; 95%CI 1.10-5.57), tumor-associated inflammation (HR 0.18 for moderate/
marked vs. absent/mild; 95%CI 0.05-0.61) and intra-tumor necrosis (HR 2.60 for pres-
ence vs. absence; 95%CI 1.12-6.05). Established prognostic factors as nodal status and 
differentiation grade were not significantly related to RFS. Subgroup analyses of 138 
BRCA1- and 118 triple-negative breast cancer cases showed similar results. Tumor-
associated inflammation density was the strongest predictor for RFS in this series of 
BRCA1/2-breast cancer patients. This provides a potential risk stratification tool that can 
easily be implemented in routine histological examination.
Prognostic features of BRCA1/2-associated breast cancer
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InTROduCTIOn
The presence of a BRCA1/2 gene mutation in women is associated with a primary breast 
cancer risk of 55-85% by the age of 70 and a contralateral breast cancer (CBC) risk of 
20-60%1-5. Generally, the prognostic value of established histologic characteristics such 
as differentiation grade and hormone receptor status seems comparable for BRCA1/2-
associated and sporadic early breast cancers6. However, the majority of both BRCA1- and 
BRCA2-associated breast cancers are poorly differentiated7-9. Besides, the BRCA1 breast 
cancer phenotype is mostly triple-negative (negative for estrogen (ER), progesterone 
(PR) and HER2 receptor), limiting the role of receptor status for risk stratification7-9, 
although BRCA2-associated breast cancers are more similar to sporadic breast can-
cers and frequently express ER7-9. Moreover, due to frequent breast cancer screening 
of BRCA1/2 mutation carriers and addition of magnetic resonance imaging (MRI) to 
screening programs, BRCA1/2-associated breast cancer can be detected early resulting 
in a low incidence of axillary lymph node positive disease10. These findings limit the 
opportunity for using established histologic prognostic factors for risk stratification in 
BRCA1/2-associated breast cancer. Therefore, the identification of additional prognostic 
parameters is warranted.
In sporadic breast cancers, additional histologic features including tumor-associated 
inflammation density and the amount of tumor-associated stroma have recently been 
described as prognostic factors11-13. Stroma-rich breast cancer has been reported to be 
related to poor prognosis as compared to stroma-poor breast cancer, especially in the 
triple-negative subgroup11. So far, these characteristics have not been investigated yet 
in relation to prognosis of BRCA1/2-associated breast cancers. However, these features 
could especially be of prognostic relevance in the subgroup of BRCA1/2-associated 
breast cancer since these cancers have a higher frequency of dense tumor-associated 
inflammatory infiltrate and specifically BRCA1 has a higher proportion of triple-negative 
tumors as compared to the sporadic breast cancer cohort7, 14.
In this study, we assessed the value of several histologic parameters, including 
tumor-associated inflammation density, intra-tumor necrosis and the amount of tumor-
associated stroma, taking into account established prognostic factors in relation to 
recurrence-free survival (RFS) of BRCA1- and BRCA2-associated breast cancer patients.
METHOdS
Patients
Patients at increased breast cancer risk visiting the Family Cancer Clinic (FCC) of the Eras-
mus MC Cancer Institute for counseling and surveillance programs are registered in an 
institutional ongoing database after written informed consent. From this database, we 
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selected female breast cancer patients diagnosed between 1982 and 2008 with a proven 
BRCA1/2 gene mutation and for whom breast cancer tumor slides were available. Breast 
cancer was mainly diagnosed by fine needle aspiration or core needle biopsy (using a 14 
Gauge needle for ultrasonography-guided procedures of solid lesions and a 10 Gauge 
needle for MRI-guided biopsies).
Exclusion criteria were: a history of a malignancy other than BC at the time of breast 
cancer diagnosis except for basal cell carcinoma, neoadjuvant chemotherapy or 
radiotherapy given for the primary breast cancer or distant metastasis at the time of 
diagnosis (M1 disease). Women with CBC were included in the analysis since low stage 
CBCs, as typically detected during screening in BRCA1/2 gene mutation carriers, do not 
influence primary breast cancer prognosis15. In case of synchronous CBC, the tumor with 
the highest stage was included. Data on patient history, mutation carriership (BRCA1 or 
BRCA2), age at and year of breast cancer diagnosis and on locoregional/distant disease 
recurrence were extracted from the FCC database. Data on tumor size and lymph node 
metastases were extracted from pathology reports.
Histopathological features
Formalin-fixed paraffin-embedded primary breast tumor tissues were collected from 
the departments of pathology of the Erasmus MC Cancer Institute and from regional 
hospitals. A breast pathologist (C.v.D.) reviewed haematoxylin and eosin (H&E) stained 
tissue sections for assessment of histologic subtype (according to the WHO), histologic 
grade (Nottingham modification of Bloom and Richardson)16 and mitotic activity index7. 
The diagnosis of medullary carcinoma required the following histological criteria: (1) 
syncytial growth pattern, (2) absence of glandular structures, (3) diffuse moderate to 
marked inflammatory response, (4) moderate to marked nuclear pleomorphisms and 
(5) sharply defined margins. Carcinomas were classified as ‘ductal with medullary fea-
tures’ when most medullary features, but not all criteria for medullary carcinoma were 
present. Tumor-associated inflammation was defined as a diffuse lymphocytic infiltrate 
and semi-quantitatively scored into four categories (absent/minimal, mild, moderate 
or marked; Figure 1) as was described earlier by Lee and colleagues17 and analyzed 
as two categories (absent/mild versus moderate/marked). Diffuse tumor-associated 
inflammation was scored at the tumor edge. The amount of tumor-associated stroma of 
the primary tumor was scored quantitatively by one observer (R.v.B.) using a 100-point 
grid. At 100 points with an interval of 1 mm, the presence of tumor cells or stroma was 
recorded. The percentage of tumor-associated stroma was calculated by dividing the 
number of points containing stroma by the sum of scored points containing tumor cells 
or stroma. Tumor-associated stroma was classified as “stroma-poor” (< 50% stroma) or 
“stroma-rich” (≥ 50% stroma; Figure 2). Intra-tumor necrosis was defined as groups of 
necrotic cells or areas of confluent necrosis. Any inflammation, necrosis or fibrosis as-
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sociated with the biopsy site was not taken into account. Lymphovascular invasion was 
defined as presence of tumor cells within an endothelial lined space (lymphatic and/or 
blood vessel) outside the border of the invasive carcinoma13.
figure 1. Breast cancer with A absent to mild and b marked tumor-associated inflammation density
Haematoxylin and eosin stained (H&E); 10x objective
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figure 2. Breast cancer with A tumor-associated stroma < 50% (stroma-poor) and b tumor-associated 
stroma ≥ 50% (stroma-rich)
Haematoxylin and eosin stained (H&E); 5x objective
ER, PR and HER2 were assessed from Tissue Micro Arrays18 using three cores per tumor 
to account for tumor heterogeneity. ER and PR were considered positive if staining was 
seen in ≥10% of the nuclei, according to the Dutch national guidelines for breast cancer 
treatment19. HER2 receptor status was scored according to international guidelines20. 
An equivocal immunohistochemical result (2+) was followed by fluorescence in situ 
hybridization21.
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Statistical analysis
The main outcome of interest was recurrence-free survival (RFS), defined as the time 
interval between date of surgery and locoregional or distant relapse of breast cancer. 
Left truncation was used to avoid potential survival bias due to inclusion of patients who 
underwent genetic testing after breast cancer diagnosis22. Patients were censored at last 
follow-up or at death from causes unrelated to their disease. We estimated hazard ratios 
and 95% CIs for all established prognostic factors and additional histologic parameters 
using Cox regression in univariate and multivariate analysis. Variables with a P-value 
< 0.10 in univariate analysis were included in the multivariate model. We performed 
subgroup analyses on BRCA1 gene mutation carriers and on triple-negative breast can-
cer patients. In all analyses, age at and year of diagnosis were analyzed as continuous 
variables. Analyses were performed with STATA version 13.1.
RESulTS
For 175 female BRCA1/2 mutation carriers with primary breast cancer tumor slides were 
available. The main characteristics of the study population are summarized in Table 1. 
The majority of the patients were BRCA1 mutation carriers (138 BRCA1 vs. 37 BRCA2). 
Median age at diagnosis was 39.0 years. Median follow-up after primary breast cancer 
diagnosis was 9.7 years. During follow-up, 44 patients were affected by recurrent disease 
(25%) and 29 patients died of breast cancer (17%). The majority of patients (58%) had a 
tumor size of ≤ 2.0 cm (pT1) and a negative nodal status (66%). Most BRCA1/2-associated 
breast cancers were of ductal subtype (69%) and Bloom and Richardson grade III (67%). 
A triple-negative phenotype was observed in 118 (67%) of the cases, of which only 6 
(5%) were BRCA2-associated. HER2 was amplified in a minority of patients (4%).
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Table 1. Patient and tumor characteristics of BRCA1/2-associated breast cancer patients
  N % BRCA1 % BRCA2 %
Total 175   138 79% 37 21%
Age at diagnosis , years
(median, range)
39.0 24-68 38.0 24-68 41.0 32-64
Period of diagnosis            
< 1997 53 30% 45 33% 8 22%
1997 – 2000 46 26% 38 27% 8 22%
2001 – 2003 37 21% 28 20% 9 24%
> 2003 39 23% 27 20% 12 32%
Follow-up time, years
(median, range)
9.7 0.01-31.1 9.7 0.01-31.1 8.1 0.7-21.8
Tumor size            
≤ 2.0 cm 101 58% 80 58% 21 57%
2.0 – 5.0 cm 64 36% 54 40% 10 27%
> 5.0 cm 5 3% 2 1% 3 8%
Unknown 5 3% 2 1% 3 8%
Nodal status            
Negative 116 66% 99 72% 17 46%
Positive, 1-3 nodes 40 23% 26 19% 14 38%
Positive, 4 or more nodes 16 9% 11 8% 5 13%
Unknown 3 2% 2 1% 1 3%
Histological type            
Ductal 121 69% 93 68% 28 76%
Medullary (features) 38 22% 36 26% 2 5%
Other 14 8% 7 5% 7 19%
Unknown 2 1% 2 1% 0 0
Bloom and Richardson grade            
I 6 3% 2 1% 4 11%
II 50 29% 35 26% 15 40%
III 117 67% 99 72% 18 49%
Unknown 2 1% 2 1% 0 0
Estrogen receptor status            
Negative 121 69% 114 82% 7 19%
Positive 53 30% 23 17% 30 81%
Unknown 1 1% 1 1% 0 0
Progesterone receptor status            
Negative 134 77% 123 89% 11 30%
Positive 39 22% 14 10% 25 67%
Unknown 2 1% 1 1% 1 3%
HER2 expression            
Negative 166 95% 131 95% 35 95%
Positive 7 4% 5 4% 2 5
Unknown 2 1% 2 1% 0 0
Triple negative receptor status            
Yes 118 67% 112 81% 6 16%
No 57 33% 26 19% 31 84%
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Table 1. Patient and tumor characteristics of BRCA1/2-associated breast cancer patients (continued)
  N % BRCA1 % BRCA2 %
Vascular invasion            
No 139 79% 114 83% 25 68%
Yes 36 21% 24 17% 12 32%
Tumor-associated inflammation            
Absent/mild 109 62% 77 56% 32 86%
Moderate/marked 66 38% 61 44% 5 14%
Tumor-associated stroma            
< 50% (stroma-poor) 133 76% 109 79% 24 65%
≥ 50% (stroma-rich) 42 24% 29 21% 13 35%
Intra-tumor necrosis            
No 98 56% 67 49% 31 84%
Yes 77 44% 71 51% 6 16%
Tumor-associated inflammation was scored as moderate or marked in 38% of the cases. 
Stroma-rich tumors (defined as ≥50% stroma) were observed in 24% of patients. In 44% 
of all breast cancers, intra-tumor necrosis was observed.
As shown in Table 2, in univariate analyses prognostic factors for RFS were tumor size 
(HR 3.52 for >2.0 cm, vs. ≤2.0 cm; 95% CI 1.59-7.78), year of diagnosis (HR 0.86 for suc-
cessive year of diagnosis; 95% CI 0.78-0.95) and tumor-associated inflammation density 
(Figure 3; HR 0.17 for moderate/marked vs. absent/mild 95% CI 0.05-0.56). Prognostic 
factors of borderline significance were nodal status (HR 1.92 for positive vs. negative; 
95% CI, 0.92-4.00; P=0.08) and intra-tumor necrosis (HR 1.93; present vs. absent 95% CI 
0.92-4.04; P=0.08) and therefore were included in the multivariable analysis. Bloom and 
Richardson differentiation grade, nor ER and PR status were of significant prognostic 
value in univariate analysis.
In multivariable analysis, prognostic factors for RFS were tumor size (HR 2.47 for tumor 
size > 2 cm vs. ≤ 2 cm; 95% CI 1.10-5.57), tumor-associated inflammation density (HR 
0.18 for moderate/marked vs. absent/mild; 95% CI 0.05-0.61) and intra-tumor necrosis 
(HR 2.60 for presence vs. absence; 95% CI 1.12-6.05) (Table 2).
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figure 3. Recurrence-free survival (RFS) in BRCA1/2-associated breast cancer patients by inflammation 
density of the tumor
*Numbers of women at risk increase during the first years of observation because of left truncation, which 
was used to avoid potential survival bias due to inclusion of patients who underwent genetic testing after 
breast cancer diagnosis.
Subgroup of BRCA1-associated breast cancers
Patient characteristics of the BRCA1 subgroup are depicted in Table 1. Median age at di-
agnosis was 38.0 years. The majority of these breast cancers were poorly differentiated, 
stroma-poor, triple-negative and ductal carcinomas. Medullary features were observed 
in 36 cases (26%). Almost half of the breast cancers (44%) showed moderate or marked 
tumor-associated inflammation.
Results on prognostic factors with respect to RFS were comparable to the results in the 
overall group (Table 3). In univariate analysis, prognostic factors were year of diagnosis 
(HR 0.87 for increasing year of diagnosis; 95% CI 0.78-0.97), tumor size (>2.0 cm vs. ≤2 
cm HR 4.29; 95% CI 1.79-10.29) and tumor-associated inflammation density (HR 0.14; 
moderate/marked vs absent/mild 95% CI 0.04-0.47). Borderline prognostic significance 
was found for presence of intra-tumor necrosis (HR 2.04; 95% CI 0.91-4.59), which was 
included in the multivariable analysis. A medullary subtype, although frequently ob-
served in the BRCA1 subgroup, had no significant prognostic value with an HR of 0.44 
(presence vs. no medullary(-like) features, 95% CI 0.13-1.50). Neither nodal status, grade 
or ER status were of prognostic significance.
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Table 2. Clinicopathologic features of BRCA1/2-associated breast cancer patients in relation to recurrence-
free survival (RFS)
 
 
N Univariate Multivariable
  HR 95% CI HR 95% CI
Age at diagnosis (years)1   1.01 0.97 – 1.06    
BRCA mutation          
BRCA1 138 1.0      
BRCA2 37 0.42 0.13 – 1.41    
Year of diagnosis (years)1   0.862 0.78 – 0.95 0.91 0.82 – 1.00
Tumor size          
≤ 2.0 cm 101 1.0   1.0  
> 2.0 cm 69 3.522 1.59 – 7.78 2.47* 1.10 – 5.57
Nodal status          
Negative 116 1.0   1.0  
Positive 56 1.922 0.92 – 4.00 1.82 0.82 – 4.04
Histological type          
Ductal 121 1.0      
Medullary (features) 38 0.48 0.14 – 1.61    
Other 14 1.04 0.31 – 3.51    
Bloom and Richardson grade          
I/II 56 1.0      
III 117 1.16 0.51 – 2.67    
Estrogen receptor status          
Negative 121 1.0      
Positive 53 0.79 0.34 – 1.85    
Progesterone receptor status          
Negative 134 1.0      
Positive 39 0.68 0.24 – 1.97    
Vascular invasion          
No 139 1.0      
Yes 36 0.94 0.36 – 2.48    
Tumor-associated inflammation          
Absent/mild 109 1.0   1.0  
Moderate/marked 66 0.172 0.05 – 0.56 0.18* 0.05 – 0.61
Tumor-associated stroma          
< 50% (stroma poor) 133 1.0      
≥ 50% (stroma rich) 42 1.43 0.64 – 3.20    
Intra-tumor necrosis          
No 98 1.0   1.0  
Yes 77 1.932 0.92 – 4.04 2.60 1.12 – 6.05
Abbreviations: HR: Hazard Ratio; 95%CI: 95% confidence interval
1analyzed as a continuous variable
2entered in multivariable analysis
*statistically significant
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Table 3. Clinicopathologic features of BRCA1-associated breast cancer patients (N=138) in relation to re-
currence-free survival (RFS)
 
 
N Univariate Multivariable
  HR 95% CI HR 95% CI
Age at diagnosis (years)1   1.03 0.99 – 1.07    
Year of diagnosis (years)1   0.872 0.78 – 0.97 0.93 0.83 – 1.03
Tumor size          
≤ 2.0 cm 80 1.0   1.0  
> 2.0 cm 56 4.292 1.79 – 10.29 3.32* 1.32 – 8.38
Nodal status          
Negative 99 1.0      
Positive 37 1.89 0.86 – 4.14    
Histological type          
Ductal 93 1.0      
Medullary (features) 36 0.44 0.13 – 1.50    
Other 7 2.22 0.63 – 7.86    
Bloom and Richardson grade          
I/II 37 1.0      
III 99 1.41 0.52 – 3.83    
Estrogen receptor status          
Negative 114 1.0      
Positive 23 1.33 0.50 – 3.59    
Vascular invasion          
No 114 1.0      
Yes 24 1.04 0.36 – 3.06    
Tumor-associated inflammation          
Absent/mild 77 1.0   1.0  
Moderate/marked 61 0.142 0.04 – 0.47 0.17* 0.05 – 0.57
Tumor-associated stroma          
< 50% (stroma poor) 109 1.0      
≥50% (stroma rich) 29 1.42 0.58 – 3.46    
Intra-tumor necrosis          
No 67 1.0   1.0  
Yes 71 2.042 0.91 – 4.59 1.81 0.74 – 4.42
Abbreviations: HR: Hazard Ratio; 95% CI: 95% confidence interval
1analyzed as a continuous variable
2entered in multivariable analysis
*statistically significant
In multivariable analysis, tumor size and inflammation density were histologic features 
of significant prognostic value for RFS with an HR of 3.32 for tumor size (> 2.0 cm vs. ≤ 2.0 
cm; 95% CI 1.32-8.38) and 0.17 for tumor-associated inflammation (moderate/marked vs 
absent/mild; 95% CI 0.05-0.57). Intra-tumor necrosis was not a significantly prognostic 
factor in this subgroup.
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Subgroup of BRCA1/2 mutation carriers with triple-negative breast cancers
As shown in Table 4, the triple-negative subgroup comprised 118 patients, mainly being 
BRCA1-associated cases (n=112, 95%). Median age at diagnosis was 38.0 years. Because 
of the high proportion of BRCA1-associated cases, characteristics of the BRCA1-subgroup 
(Table 1) and the triple-negative subgroup were very similar (data not shown).
Table 4. Clinicopathologic features of triple-negative breast cancer patients (N=118) in relation to recur-
rence-free survival (RFS)
 
 
N Univariate Multivariable
  HR 95% CI HR 95% CI
Age at diagnosis (years)1   1.02 0.97 – 1.07    
BRCA mutation          
BRCA1 112 1.0      
BRCA2 6 0.85 0.11 – 6.38    
Year of diagnosis (years)1   0.912 0.81 – 1.01 0.95 0.85 – 1.06
Tumor size          
≤ 2.0 cm 67 1.0      
> 2.0 cm 49 5.082 1.86 – 13.88 4.89* 1.79 – 13.39
Nodal status          
Negative 86 1.0      
Positive 30 1.41 0.56 – 3.50    
Histological type          
Ductal 78 1.0      
Medullary (features) 36 0.46 0.13 – 1.58    
Other 3 5.86 1.27 – 27.07    
Bloom and Richardson grade          
I/II 20 1.0      
III 97 1.78 0.40 – 7.87    
Vascular invasion          
No 99 1.0      
Yes 19 0.87 0.25 – 2.97    
Tumor-associated inflammation          
Absent/mild 61 1.0      
Moderate/marked 57 0.152 0.04 – 0.51 0.18* 0.05 – 0.64
Tumor-associated stroma          
< 50% (stroma poor) 102 1.0      
≥ 50% (stroma rich) 16 1.90 0.68 – 5.35    
Intra-tumor necrosis          
No 51 1.0      
Yes 67 1.75 0.71 – 4.32    
HR: Hazard Ratio; 95% CI: 95% confidence interval
1analyzed as a continuous variable
2entered in multivariable analysis
*statistically significant
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Regarding prognostic factors in relation to RFS, analyses of the triple-negative 
subgroup showed similar results as for the overall group. In univariate analysis, prog-
nostic factors were tumor size (HR 5.08 for > 2.0 cm vs. ≤2 cm; 95% CI 1.86-13.88) and 
tumor-associated inflammation density (HR 0.15 for moderate/marked vs. absent/mild; 
95% CI 0.04-0.51). Year of diagnosis was of borderline prognostic significance (HR 0.91 
for increasing year of diagnosis; 95% CI 0.81-1.01) and was therefore entered in the 
multivariable analysis. Other factors (nodal status, grade, histologic subtype) were not 
significantly associated with prognosis for RFS.
Independent prognostic factors were tumor size and inflammation density with HRs 
of 4.89 (95% CI 1.79-13.39) and of 0.18 (95% CI 0.05-0.64), respectively.
dISCuSSIOn
In this study, we observed that presence of moderate/marked tumor-associated inflam-
mation, absence of intra-tumor necrosis and tumor size < 2 cm were independent favor-
able prognostic factors for RFS in BRCA1/2-associated breast cancers.
To our knowledge, this is the first study investigating the value of tumor-associated 
inflammation density as prognostic feature in BRCA1/2-associated tumors. Our finding 
that the presence of moderate/marked tumor-associated inflammation is a favorable 
prognostic marker is in line with earlier observations on sporadic breast cancer, although 
reported results are inconsistent. A recent systematic review on the prognostic value of 
tumor-associated inflammation comprised thirteen studies showing improved sporadic 
breast cancer prognosis associated with pronounced inflammation density, whereas 
seven studies reported a poorer outcome of breast cancer with pronounced inflamma-
tion and four did not find a relation with breast cancer prognosis 12.
A large proportion of BRCA1/2-associated breast cancers detected during adequate 
surveillance (including breast MRI), is smaller than 1.0 cm (pT1) and node negative 10. 
Potentially, routine assessment of tumor-associated inflammation may help to improve 
risk stratification of these early BRCA1/2-associated breast cancers to further personalize 
(adjuvant) treatment. Further, several recent studies reported that pathological com-
plete response and prognosis of breast cancer following neoadjuvant chemotherapy 
can be predicted by the amount of tumor-associated lymphocytes as assessed on tumor 
biopsies 23, 24. Future advancing insights on the host versus tumor inflammatory response 
may help in the development of new targeted therapies especially for triple-negative 
carcinomas.
A high tumor-associated inflammation density is associated with the medullary breast 
cancer subtype, which is more commonly seen in BRCA1-associated than in sporadic 
breast cancer 7. In the current analysis, the presence of medullary features was present 
in 36 BRCA1-associated breast cancers (26%). Although medullary features seemed to 
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favorably affect RFS with a univariate HR of 0.48, this was not statistically significant. This 
may partly be explained by the prominent tumor-associated inflammation often found 
in the medullary subgroup 25, which as described above also favors prognosis.
Both intra-tumor necrosis and lymphovascular invasion are discriminants of poor 
prognosis in sporadic breast cancers 26, 27 and specifically in triple-negative carcinomas 
28. However, to the best of our knowledge, no specific data exist on the prognostic 
significance of these features in breast cancers of BRCA1/2 gene mutation carriers. Intra-
tumor necrosis was present in 44% of the BRCA1/2-associated breast cancers which is 
in line with the 40-60% previously described for sporadic breast cancer 21, 29. With an 
HR of 2.60 the presence of necrosis was associated with a worse RFS. Hypoxia of the 
tumor, eventually causing necrosis, is thought to give rise to a more malignant behavior 
through induction of angiogenesis and migration, which among other factors favor 
tumor invasion and metastasis 27, 30. A higher frequency of overexpression of HIF-1alpha, 
being a key transcriptional regulator of the hypoxia response, has been reported in 
BRCA1-associated breast cancer as compared to sporadic breast cancer, suggesting an 
important role of hypoxia in this subgroup of patients 31, 32. The incidence of lympho-
vascular invasion was 21% in our series, which is in line with results of other studies on 
BRCA1/2-associated tumors (20-30%), as well as with reported incidences in sporadic 
carcinomas (20-25%) 33, 34. In the current analyses, presence of lymphovascular invasion 
was not found to be significantly associated with RFS.
The amount of tumor-associated stroma has been reported to be an independent prog-
nostic factor in the total group of breast cancer patients, but especially in triple-negative 
breast cancers with an approximately three times higher risk of relapse in stroma-rich 
as compared to stroma-poor tumors 11. No significant effect of tumor-associated stroma 
was seen in our series, not even in the triple-negative subgroup. Potential explanations 
for this discrepancy include differences in assessment methods of the amount of stroma, 
size of the study population and a different histologic phenotype of BRCA1/2-associated 
tumors as compared to sporadic breast cancer. We chose to use a grid for the assess-
ment of the amount of tumor-stroma in an attempt to achieve an objective, quantitative 
method. However, additional studies are needed to compare this method with global 
estimation. Our method with the 100-point grid was relatively laborious (5 minutes/
patient). Therefore, in case global estimation would be as accurate as using a grid, global 
estimation would be more practical for everyday practice.
A larger tumor size (>2 cm) remained an independent unfavorable prognostic fac-
tor for RFS in our series of BRCA1/2-associated breast cancer cases. In contrast, other 
established prognostic factors as differentiation grade, ER/PR status and nodal status 
were not associated with RFS, which might partly be explained, by the finding that the 
majority of the tumors were poorly differentiated (grade 3), ER/PR negative and lymph 
node negative. Likely, the number of disease recurrences was too small to detect a 
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significant influence of grade, hormone receptor and nodal status in this series. ER/PR 
positivity may be underreported in this study compared to other series, since according 
to Dutch guidelines a tumor is ER or PR positive with ≥10% staining of the nuclei, while 
ASCO guidelines recommend ≥1% of nuclear staining as ER/PR positive.
In view of the fact that BRCA1- and BRCA2-associated breast cancers have distinct 
phenotypes 7 and the overrepresentation of BRCA1-associated cases in our series, we 
separately analyzed the subgroups of BRCA1-associated and of triple-negative breast 
cancers. In these subgroup analyses, presence of intra-tumor necrosis did not remain a 
prognostic marker for RFS, possibly because of the smaller numbers, but other results 
were similar to the results observed in the overall group. The proportion of BRCA2 gene 
mutation carriers was too small to perform a separate analysis.
Although one of the weak points in this study concerns its retrospective nature, 
patient cohort data were collected in a prospective manner yielding a sufficiently long 
median follow-up time of 9.7 years after breast cancer diagnosis. Despite this follow-up 
period, there were relatively few disease recurrences, which may explain the finding 
that some of the examined histological features did not reach statistical significance. 
Another limitation is that tumor-associated inflammation, necrosis or fibrosis could be 
related to a pre-operative needle biopsy. However, this effect is probably limited since 
any inflammation, necrosis or fibrosis associated with the biopsy site was not taken into 
account. Besides, a substantial proportion of patients underwent fine needle aspiration.
In conclusion, in this unique series of BRCA1/2-associated breast cancers moderate or 
marked tumor-associated inflammation was the strongest independent favorable factor 
for RFS. Of the conventional, established prognostic factors only tumor size < 2 cm re-
mained a favorable factor. Our findings mainly concern BRCA1-associated breast cancers, 
as the number of BRCA2 mutation carriers was low. When confirmed in other and larger 
series of BRCA1/2 mutation carriers, and more specifically in BRCA2 mutation carriers, 
tumor-associated inflammation may be easily assessed in routine diagnostics and form 
a potential tool to improve breast cancer risk stratification in BRCA1/2-associated early 
breast cancer cases. Further research is warranted to elucidate the multifactorial process 
of host versus tumor immunity and to identify possible targets for adjuvant therapy with 
benefit for especially triple-negative BRCA1/2-associated carcinomas.
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AbSTRACT
Female BRCA1/2 mutation carriers affected with breast and/or ovarian cancer may 
develop new tumor deposits over time. It is of utmost importance to know the clonal 
relationships between multiple tumor localizations, enabling differentiation between 
multiple primaries or metastatic disease with consequences for therapy and prognosis. 
We evaluated the value of targeted next generation sequencing1 in the diagnostic 
workup of BRCA1/2 mutation carriers with ≥2 tumor localizations and uncertain tumor 
origins. Forty-two female BRCA1/2 mutation carriers with ≥2 tumor localizations were 
selected. Patients with inconclusive tumor origin after histopathological revision were 
‘cases’; patients with certain tumor origin of ≥3 tumors served as ‘controls’. Tumors of 
cases and controls were analyzed by targeted next generation sequencing using a panel 
including CDKN2A, PTEN and TP53, hotspot mutation sites for 27 different genes and 
143 single nucleotide polymorphisms for detection of loss of heterozygosity. Based on 
prevalence of identical or different mutations and/or loss of heterozygosity patterns, 
tumors were classified as ‘multiple primaries’ or ‘one entity’. Conventional histopathol-
ogy yielded a conclusive result in 38/42 (90%) of patients. Four cases and 10 controls 
were analyzed by next generation sequencing. In 44 tumor samples, 48 mutations 
were found; 39 (81%) concerned TP53 mutations. In all 4 cases, the intra-patient clonal 
relationships between the tumor localizations could be unequivocally identified by 
molecular analysis. In all controls, molecular outcomes matched the conventional his-
topathological results. In most BRCA1/2 mutation carriers with multiple tumors routine 
pathology work-up is sufficient to determine tumor origins and relatedness. In case of 
inconclusive conventional pathology results, molecular analyses using next generation 
sequencing can reliably determine clonal relationships between tumors, enabling opti-
mal treatment of individual patients.
Clonal relationships of BRCA1/2-associated cancers
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InTROduCTIOn
Female BRCA1/2 mutation carriers have a cumulative lifetime risk of developing breast 
cancer of 55-85% by the age of 702-5. The cumulative lifetime risk of developing ovarian 
cancer varies between 15-60% for BRCA1 and 10-35% for BRCA2 mutation carriers2-5. 
Moreover, susceptibility for other cancers also seems to be increased in BRCA1/2 muta-
tion carriers6, 7.
It has been reported that BRCA1-associated breast cancers more frequently develop 
visceral metastasis and fewer bone metastases8, 9 and BRCA2-associated breast cancers 
tend to develop more lymph node metastases compared with sporadic breast cancer9. 
Metastatic sites of sporadic ovarian cancer mostly confine to the intraperitoneal cav-
ity10, 11, whereas it has been described that BRCA1/2-associated ovarian cancer patients 
frequently (74%) present with visceral metastases to liver, lung and spleen12. Although 
this can be of some help, the non-specific metastatic patterns in BRCA1/2-associated 
breast and ovarian cancer patients impede careful differentiation between breast can-
cer, ovarian cancer and other tumor origins when multiple cancer localizations occur in 
one patient. It is of clinical importance, however, to make this distinction, as it guides 
surgical and chemotherapeutic treatment and determines prognosis13, 14.
A potentially helpful tool in determining clonal relationships between multiple tumors 
is DNA next Generation Sequencing 1, 15. With next generation sequencing, selected genes 
known to be frequently mutated in specific tumor types can be analyzed. Additionally, sin-
gle nucleotide polymorphisms can be analyzed to detect any DNA copy number changes 
present in the tumor cells. Identical molecular aberrations of different tumor localizations 
indicate a common tumor origin (e.g. metastatic disease), whereas different mutations and/
or copy number changes in different tumor samples indicate two primary malignancies.
The aim of the current study was to evaluate the value of next generation sequencing 
in the diagnostic workup of BRCA1/2-associated breast and ovarian cancer patients with 
multiple tumor localizations.
MATERIAlS And METHOdS
Patient selection: cases and controls
Patients at increased risk of breast and/or ovarian cancer visiting the Family Cancer Clinic 
of the Erasmus Medical Center Cancer Institute for counseling and surveillance programs 
are registered in an institutional ongoing database. All women provide written informed 
consent for registration of their clinical data and storage of genetic material (if relevant) 
for research purposes. From this database, we selected all female germline BRCA1 or 
BRCA2 mutation carriers with ≥2 synchronous or metachronous tumor localizations 
of which tumor material had been obtained by fine needle aspiration (FNA), biopsy or 
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surgical excision. Tumor localizations of which no suitable material was available for his-
topathological or molecular analysis were excluded. Included were BRCA1/2 mutation 
carriers with multiple tumors of which at least one was located in the breast or ovary. 
Inclusion and exclusion criteria are depicted in Table 1.
Table 1. Inclusion and exclusion criteria
Inclusion
• Women with a proven BRCA1 and/or BRCA2 mutation
• With ≥ 2 synchronous or metachronous tumor localizations 1
• Tumor material available for next generation sequencing analysis
• (obtained by fine needle aspiration, histological biopsy or surgical excision)
• One of the 4 clinical scenarios:
  1. Breast cancer and ovarian cancer
  2. Breast cancer and second other tumor
  3. Ovarian cancer and second other tumor
  4. Breast cancer, ovarian cancer, and third or additional other tumor localizations
Exclusion criteria for ‘other tumor localization’
• Hematological malignancies
• Dermatological malignancies (ie. melanomas, basal cell carcinomas)
• Ipsilateral lymph node metastases in the presence of breast cancer
• Premalignant lesions, such as ductal carcinoma in situ
• Contralateral breast cancer or second ipsilateral breast cancer, except in the presence of a third tumor 
localization
• Peritoneal tumor localization in the presence of ovarian cancer
  - If reported that the ovarian cancer was growing per continuum into the peritoneal cavity
  - Confining to the ipsilateral adnexa
1isolated site of invasive cancer as diagnosed by radiological examination, intra-operatively or during path-
ological examination
If possible, the origin of the tumor localizations was identified based on H&E staining. If 
tumor histology did not provide a conclusive diagnosis, immunohistochemical staining 
was applied. Patients for whom the origin of one or more tumor localizations remained 
uncertain after histological and immunohistochemical evaluation were selected for next 
generation sequencing molecular analysis (‘cases’). Patients with ≥3 tumor localizations 
of conclusive origin, based on histology and immunohistochemistry, served as ‘controls’. 
Controls were selected for next generation sequencing, as well, to validate the versatility 
of the next generation sequencing approach for tumor clonality determinations.
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Conventional diagnostics
Tumor histology
Formalin-fixed paraffin-embedded tumor tissues were collected from the Department 
of Pathology of the Erasmus Medical Center Cancer Institute and from regional hos-
pitals. Two pathologists specialized in breast and gynecological cancer (C.v.D., P.v.D.) 
independently reviewed haematoxylin and eosin (H&E) stained tissue sections of the 
tumor localizations for histology, with a subsequent consensus discussion.
Immunohistochemistry
Immunohistochemical tissue markers were chosen according to the institutional protocol 
and depended on clinical and histological differential diagnosis of the origin of the various 
tumor localizations. Estrogen receptor (ER) was used as a breast cancer marker. Immuno-
histochemical markers used for differentiation of ovarian cancer were cancer antigen 125 
(CA125), Wilms’ tumor 1 (WT1) and PAX-8, all known to be frequently expressed in ovarian 
cancer16-18. To differentiate with primary lung carcinoma, TTF-1 was used19.
Molecular analysis
For cases and controls, p53 immunohistochemistry was performed on all tumor tissues 
if formalin-fixed paraffin-embedded tissue blocks were available. Nuclear expression of 
p53 in tumor cells was scored as either heterogeneous (no indication for TP53 mutation), 
strong in all tumor cells (indication for missense TP53 mutation) or absent in all tumor 
cells (indication for frameshift, nonsense, or splice site TP53 mutation). For next genera-
tion sequencing analysis, normal and tumor tissues were manually microdissected from 
haematoxylin-stained tissue sections of formalin-fixed paraffin-embedded tissue blocks 
or if unavailable, from original routine H&E, immunohistochemical stained sections or 
cytological preparations. DNA was extracted using proteinase K and 5% Chelex resin, as 
previously described20; DNA concentrations were measured with the Qubit 2.0 Fluorom-
eter. To assess the quality of DNA amplification a multiplex control PCR was performed as 
previously described21; PCR products were analyzed on an agarose gel. All DNA samples 
were screened with the Ion Torrent Personal Genome Machine, with supplier’s materials 
and protocols (Life Technologies, Carlsbad, CA, USA). A custom made primer panel was 
used, designed using Ion AmpliSeq Designer 2.2.1, for diagnostic use in clonality deter-
minations of various tumor types including breast and ovarian cancer. Because this panel 
was designed for analysis of a broad range of tumor types, it includes genes frequently 
mutated in breast and ovarian cancer, as well as genes rarely mutated in these tumors. The 
panel targets almost the entire open reading frame of CDKN2A, PTEN and TP53 (coverage 
95-99%), multiple hotspot mutation sites for 27 different genes and 143 single nucleotide 
polymorphisms at 15 different loci for the detection of loss of heterozygosity (see supple-
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mentary Table 1 for primer details). In total, the panel consisted of 254 amplicons with a 
mean amplicon size of 160 base pairs. With this panel, libraries were created using the 
Ion AmpliSeq 2.0 Library Kit. Template was prepared using the Ion OneTouch 2 with the 
Ion OneTouch 200 Template Kit v2 DL or using the IonChef with the Ion Personal Genome 
Machine Hi-Q Chef Kit. Sequencing was performed on an Ion 318v2 chip with the Ion 
Personal Genome Machine sequencing 200 kit v2 or the Ion Personal Genome Machine 
Hi-Q sequencing kit. Data was analyzed with Variant Caller v4.0 or v.4.4.2.1. Annotation 
of the variants was previously described22. For mutation detection, all exonic and splice 
variants with a variant percentage ≥20% were reported, excluding synonymous single-
nucleotide variants and variants present in patient-matched normal tissue. Variants with 
a total coverage of ˂100 reads, reference coverage ˂10 reads, and/or a variant coverage of 
˂5 reads for either the forward or reverse strand were excluded. For loss of heterozygosity 
analysis, single nucleotide polymorphisms with a total coverage of ˂100 reads or a strand 
bias (ratio forward:reverse reads not between 1:10 and 10:1 for reference and/or variant 
reads) were excluded. If a mutation was detected in one or more tumor samples of a 
patient, the specific locus was manually checked using the integrative genomics viewer 
(IGV) in normal DNA as well as all tumor samples of that patient. Furthermore, TP53 was 
manually checked for mutations if no mutation was detected and immunohistochemistry 
showed aberrant staining or was unavailable.
Samples for which the control PCR showed no signal for amplicons larger than 100 
base pairs and for which next generation sequencing analysis showed ˂70% of reads 
on target and/or ˂70% of amplicons with at least 100 reads were defined low quality 
samples. For low quality samples with more than 3 variants, we focused on variants pres-
ent in other tumors of the patient, or if not present, on TP53 variants. For all low quality 
samples, mutations were confirmed by Sanger sequencing or by a second next genera-
tion sequencing run. For Sanger sequencing, primers from the AmpliSeq design were 
extended with M13 tails. PCR protocol was previously described23, data was analyzed 
using Mutation Surveyor v.4.0 software (SoftGenetics).
RESulTS
Patients
Fifty-six BRCA1/2 mutation carriers with multiple tumor localizations were selected. 
Fourteen were excluded due to missing or unsuitable tumor material, leaving 42 women 
(39 BRCA1, 3 BRCA2) for analyses. Clinical classification of tumor origins was ‘breast 
cancer + ovarian cancer’ in 31 patients, ‘breast cancer + other’ in nine, ‘ovarian cancer 
+ other’ in one, and ‘breast cancer + ovarian cancer + other’ in one woman (data not 
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shown). Median number of tumor localizations was 2 (range 2-5), and median time from 
first to last cancer diagnosis was 5 years (range 0-23).
Conventional diagnostics
For 21/42 women (50%) the origin of the tumor localizations was conclusive based on 
histology only. In an additional 17 (40%) a conclusive diagnosis was reached after im-
munohistochemistry for relevant markers. Ten of 38 women with conclusive outcomes 
based on histology and/or immunohistochemistry had ≥3 tumor localizations (controls; 
8 BRCA1 and 2 BRCA2 mutation carriers).
In four women (10%) one or more tumor localizations remained of uncertain origin after 
histological and immunohistochemical evaluation (cases; all BRCA1 mutation carriers).
Case no. 1 presented with tumors in the right and the left breast, and a tumor in the 
lung seven years later. Both breast tumors were diagnosed IDC of the breast based on HE 
staining. The lung tumor was diagnosed non-small cell carcinoma, however, conclusive 
diagnosis regarding the origin of the tumor was not possible based on HE and immuno-
histochemistry (see Figure 2A for details).
Case no. 2 presented with a tumor in the ovary and a tumor in the breast six years 
later. The tumor of the ovary was diagnosed serous carcinoma of the ovary based on 
HE staining. The breast tumor was diagnosed adenocarcinoma based on cytological 
preparations; however, no tissue was available for immunohistochemistry. Therefore, 
tumor origin could not be determined.
Case no. 3 presented with a tumor in the breast and peritonitis carcinomatosa 10 years 
later. The tumor in the breast was diagnosed IDC of the breast based on HE staining. The 
tumor cells found in the ascites were diagnosed adenocarcinoma based on cytological 
preparations. CA-125 and WT-1 immunohistochemistry performed on de-stained cyto-
logical preparations was not conclusive, therefore, determining the site of the origin of 
this tumor was not possible.
Case no. 4 presented with a tumor in the breast and tumors in the retroperitoneal 
lymph nodes as well as in the ovary and uterus three years later. The tumor in the breast 
was diagnosed IDC of the breast and the tumor in the ovary and uterus serous carci-
noma of the ovary, both based on HE staining. The tumor in the retroperitoneal lymph 
nodes was classified as a large cell carcinoma based on the HE staining. However, only a 
small biopsy was available, from which no tissue was left in the formalin-fixed paraffin-
embedded tissue block for additional analyses.
Characteristics and outcomes of tumor histology and immunohistochemistry of cases 
and controls are outlined in Table 2. Median age at first cancer diagnosis was 41.5 years 
(range 33-59). Median year of first cancer diagnosis was 1997 (range 1983-2012). Clinical 
classification of tumor origins was breast cancer + ovarian cancer in 11, breast cancer + 
other in two, and breast cancer + ovarian cancer + other in one woman.
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Table 2. Cases and controls: patient characteristics and outcomes of tumor histology, immunohistochemistry and molecular analysis
BRCA1/2+
Age
Tumor sites analyzed, timeline (years) Histology (H&E) with immunohistochemistry (IHC), if applicable Molecular analysis Agreement molecular 
analysis with histopa-
thology
Conclusive2
 
Diagnosis3 Tumor origin4 p53 
IHC4
Variants by next generation sequencing per tumor Entity5
 
Agreement with loss 
of heterozygosity 
analysis
H&E IHC
Case 1
BRCA1+
41 y
0 Right breast1 T1 +   Invasive ductal carcinoma Breast + TP53 c.646G>A; p.V216M 1
+ NA0 Left breast T2 +   Invasive ductal carcinoma Breast - TP53 c.637C>T; p.R213* 2
+7 Lung1 T3 - - Non-small cell carcinoma Unknown + TP53 c.646G>A; p.V216M 1
Case 2
BRCA1+
55 y
0 Ovary T1 +   Serous carcinoma Ovary - TP53 c.158G>A; p.W53* 1
+/- NA
+6 Breast1 T2 - ND6 Adenocarcinoma Unknown ND6 TP53 c.158G>A; p.W53* 1
Case 3
BRCA1+
33 y
0 Breast1 T1 +   Invasive ductal carcinoma Breast ND6 TP53 c.686_687del; p.C229fs*10 1
NE NA
+10 Ascites1 T2 - - Adenocarcinoma Unknown ND6 TP53 c.527G>A; p.C176Y 2
Case 4
BRCA1+
38 y
0 Breast T1 +   Invasive ductal carcinoma Breast + TP53 c.318_326delinsAAA; p.S106_F109delinsRN 1
+ NA+3 Retroperitoneal lymph node T2 - ND6 Large cell carcinoma Unknown ND6 TP53 c.514G>T; p.V172F 2
+3 Ovary & uterus T3 +   Serous carcinoma Ovary + TP53 c.514G>T; p.V172F 2
Control 1
BRCA1+
38 y
0 Right breast1 T1 +   Invasive ductal carcinoma Breast - No mutations 1
+ +
+13 Right breast T2 +   Invasive ductal carcinoma Breast + TP53 c.722C>T; p.S241F 2
  PTEN c.176C>G; p.S59*
+19 Ovary T3 - + Serous carcinoma Ovary + TP53 c.400T>G; p.F134V 3
Control 2
BRCA1+
49 y
0 Right breast1 T1 +   Invasive ductal carcinoma Breast + No mutations 1
NE
+
+2 Adnexa T2 - + Serous carcinoma Ovary + TP53 c.645T>G; p.S215R 2
+23 Left breast T3 +   Invasive ductal carcinoma Breast +/- PIK3CA c.3140A>G; p.H1047R 3
  STK11 c.484G>A; p.D162N
Control 3 
BRCA1+
37 y
0 Breast T1 +   Invasive ductal carcinoma Breast + TP53 c.817C>T; p.R273C 1
+/- +
+2 Ovary T2 - + Serous carcinoma Ovary - TP53 c.406C>T; p.Q136* 2
+5 Ovary & uterus (+inguinal & cervical 
lymph nodes)
T3 - + Serous carcinoma Ovary - TP53 c.406C>T; p.Q136* 2
Control 4
BRCA2+
60 y
0 Larynx1 T1 +   Squamous cell carcinoma Larynx - TP53 c.375_375+1delinsTT 1
+/- +
+2 Lung T2 - + Adenocarcinoma Lung + TP53 c.814G>T; p.V272L 2
  BRAF c.1405_1406delinsTT; p.G469L
+5 Uterus & omentum T3 +   Serous carcinoma Ovary - TP53 c.528C>A; p.C176* 3
+9 Breast T4 +   Invasive ductal carcinoma Breast +/- PIK3CA c.3140A>G; p.H1047R 4
Control 5
BRCA1+
37 y
0 Breast T1 +   Invasive ductal carcinoma Breast + TP53 c.743G>A; p.R248Q 1
+/- ++6 Ovary T2 +   Serous carcinoma Fallopian tube - TP53 c.395del; p.K132fs*38 2
+7 Omentum T3 +   Serous carcinoma Fallopian tube - TP53 c.395del; p.K132fs*38 2
Control 6
BRCA1+
41 y
0 Breast T1 +   Invasive ductal carcinoma Breast + TP53 c.743G>A; p.R248Q 1
+ +
0 Cervix T2 - + Adenocarcinoma Genital tract - TP53 c.721del; p.S241fs*6 2
                CAPZB c.491C>A; p.T164N  
+1 Uterus T3 - + Serous carcinoma Genital tract - TP53 c.721del; p.S241fs*6 2
                CAPZB c.491C>A; p.T164N  
+1 Omentum T4 - + Serous carcinoma Genital tract - TP53 c.721del; p.S241fs*6 2
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Table 2. Cases and controls: patient characteristics and outcomes of tumor histology, immunohistochemistry and molecular analysis
BRCA1/2+
Age
Tumor sites analyzed, timeline (years) Histology (H&E) with immunohistochemistry (IHC), if applicable Molecular analysis Agreement molecular 
analysis with histopa-
thology
Conclusive2
 
Diagnosis3 Tumor origin4 p53 
IHC4
Variants by next generation sequencing per tumor Entity5
 
Agreement with loss 
of heterozygosity 
analysis
H&E IHC
Case 1
BRCA1+
41 y
0 Right breast1 T1 +   Invasive ductal carcinoma Breast + TP53 c.646G>A; p.V216M 1
+ NA0 Left breast T2 +   Invasive ductal carcinoma Breast - TP53 c.637C>T; p.R213* 2
+7 Lung1 T3 - - Non-small cell carcinoma Unknown + TP53 c.646G>A; p.V216M 1
Case 2
BRCA1+
55 y
0 Ovary T1 +   Serous carcinoma Ovary - TP53 c.158G>A; p.W53* 1
+/- NA
+6 Breast1 T2 - ND6 Adenocarcinoma Unknown ND6 TP53 c.158G>A; p.W53* 1
Case 3
BRCA1+
33 y
0 Breast1 T1 +   Invasive ductal carcinoma Breast ND6 TP53 c.686_687del; p.C229fs*10 1
NE NA
+10 Ascites1 T2 - - Adenocarcinoma Unknown ND6 TP53 c.527G>A; p.C176Y 2
Case 4
BRCA1+
38 y
0 Breast T1 +   Invasive ductal carcinoma Breast + TP53 c.318_326delinsAAA; p.S106_F109delinsRN 1
+ NA+3 Retroperitoneal lymph node T2 - ND6 Large cell carcinoma Unknown ND6 TP53 c.514G>T; p.V172F 2
+3 Ovary & uterus T3 +   Serous carcinoma Ovary + TP53 c.514G>T; p.V172F 2
Control 1
BRCA1+
38 y
0 Right breast1 T1 +   Invasive ductal carcinoma Breast - No mutations 1
+ +
+13 Right breast T2 +   Invasive ductal carcinoma Breast + TP53 c.722C>T; p.S241F 2
  PTEN c.176C>G; p.S59*
+19 Ovary T3 - + Serous carcinoma Ovary + TP53 c.400T>G; p.F134V 3
Control 2
BRCA1+
49 y
0 Right breast1 T1 +   Invasive ductal carcinoma Breast + No mutations 1
NE
+
+2 Adnexa T2 - + Serous carcinoma Ovary + TP53 c.645T>G; p.S215R 2
+23 Left breast T3 +   Invasive ductal carcinoma Breast +/- PIK3CA c.3140A>G; p.H1047R 3
  STK11 c.484G>A; p.D162N
Control 3 
BRCA1+
37 y
0 Breast T1 +   Invasive ductal carcinoma Breast + TP53 c.817C>T; p.R273C 1
+/- +
+2 Ovary T2 - + Serous carcinoma Ovary - TP53 c.406C>T; p.Q136* 2
+5 Ovary & uterus (+inguinal & cervical 
lymph nodes)
T3 - + Serous carcinoma Ovary - TP53 c.406C>T; p.Q136* 2
Control 4
BRCA2+
60 y
0 Larynx1 T1 +   Squamous cell carcinoma Larynx - TP53 c.375_375+1delinsTT 1
+/- +
+2 Lung T2 - + Adenocarcinoma Lung + TP53 c.814G>T; p.V272L 2
  BRAF c.1405_1406delinsTT; p.G469L
+5 Uterus & omentum T3 +   Serous carcinoma Ovary - TP53 c.528C>A; p.C176* 3
+9 Breast T4 +   Invasive ductal carcinoma Breast +/- PIK3CA c.3140A>G; p.H1047R 4
Control 5
BRCA1+
37 y
0 Breast T1 +   Invasive ductal carcinoma Breast + TP53 c.743G>A; p.R248Q 1
+/- ++6 Ovary T2 +   Serous carcinoma Fallopian tube - TP53 c.395del; p.K132fs*38 2
+7 Omentum T3 +   Serous carcinoma Fallopian tube - TP53 c.395del; p.K132fs*38 2
Control 6
BRCA1+
41 y
0 Breast T1 +   Invasive ductal carcinoma Breast + TP53 c.743G>A; p.R248Q 1
+ +
0 Cervix T2 - + Adenocarcinoma Genital tract - TP53 c.721del; p.S241fs*6 2
                CAPZB c.491C>A; p.T164N  
+1 Uterus T3 - + Serous carcinoma Genital tract - TP53 c.721del; p.S241fs*6 2
                CAPZB c.491C>A; p.T164N  
+1 Omentum T4 - + Serous carcinoma Genital tract - TP53 c.721del; p.S241fs*6 2
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Table 2. Cases and controls: patient characteristics and outcomes of tumor histology, immunohistochemistry and molecular analysis (continued)
BRCA1/2+
Age
Tumor sites analyzed, timeline (years) Histology (H&E) with immunohistochemistry (IHC), if applicable Molecular analysis Agreement molecular 
analysis with histopa-
thology
Conclusive2 Diagnosis3 Tumor origin4 p53 
IHC4
Variants by next generation sequencing per tumor Entity5
 
Agreement with loss 
of heterozygosity 
analysis
H&E IHC
Control 7
BRCA1+
50 y
0 Ovary T1 +   Serous carcinoma Ovary + TP53 c.722C>A; p.S241Y 1
+ ++4 Breast T2 +   Invasive ductal carcinoma Breast +/- No mutations 2
+4 Rectosigmoid T3 +   Serous carcinoma Ovary + TP53 c.722C>A; p.S241Y 1
Control 8
BRCA1+
42 y
0 Ovary T1 +   Serous carcinoma Ovary + TP53 c.818G>T; p.R273L 1
+ +
0 Omentum T2 +   Serous carcinoma Ovary + TP53 c.818G>T; p.R273L 1
0 Breast T3 - + Invasive ductal carcinoma Breast ND6 TP53 c.524G>A; p.R175H 2
+1 Abdominal wall (scar) 1 T4 +   Serous carcinoma Ovary ND6 TP53 c.818G>T; p.R273L 1
+1 Pleural effusion T5 - + Serous carcinoma Ovary + TP53 c.818G>T; p.R273L 1
Control 9
BRCA2+
59 y
0 Breast T1 +   Invasive ductal carcinoma Breast - TP53 c.327_328dup; p.R110fs*14 1
+ +
+2 Ovary1 T2 - + Serous carcinoma Ovary - TP53 c.112del; p.Q38fs*6 2
                FBXW7 c.1347G>C; p.E449D  
+2 Uterus T3 - + Serous carcinoma Ovary - TP53 c.112del; p.Q38fs*6 2
                FBXW7 c.1347G>C; p.E449D  
Control 10
BRCA1+
45 y
0 Breast T1 +   Metaplastic carcinoma Breast + TP53 c.488A>G; p.Y163C 1
+ ++6 Adnexa T2 +   Serous carcinoma Ovary + TP53 c.524G>A; p.R175H 2
+6 Rectouterine pouch T3 +   Serous carcinoma Ovary + TP53 c.524G>A; p.R175H 2
H&E: haematoxylin and eosin stained slides
IHC: immunohistochemical analysis
NA: not applicable
ND: not done
NE: not evaluable
1 Low quality sample
2 Conclusive diagnosis, based on tumor histology (H&E) and immunohistochemistry, if applicable: 
yes (+) or no (-)
3 Based on tumor histology (H&E) and immunohistochemistry if applicable
4 Nuclear expression of p53 in tumor cells was scored as either heterogeneous (+-), strong in all tumor 
cells (+) or absent in all tumor cells (-)
5 Entity: tumor or tumors most probably of the same origin (clonally identical). 1 is one independent 
entity, 2 is a second independent entity, etc. Various tumors that form one entity may present advanced 
disease, cancer relapse, or distant metastases.
6 No formalin-fixed paraffin-embedded tissue block available or no tissue left in the formalin-fixed 
paraffin-embedded tissue block.
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Table 2. Cases and controls: patient characteristics and outcomes of tumor histology, immunohistochemistry and molecular analysis (continued)
BRCA1/2+
Age
Tumor sites analyzed, timeline (years) Histology (H&E) with immunohistochemistry (IHC), if applicable Molecular analysis Agreement molecular 
analysis with histopa-
thology
Conclusive2 Diagnosis3 Tumor origin4 p53 
IHC4
Variants by next generation sequencing per tumor Entity5
 
Agreement with loss 
of heterozygosity 
analysis
H&E IHC
Control 7
BRCA1+
50 y
0 Ovary T1 +   Serous carcinoma Ovary + TP53 c.722C>A; p.S241Y 1
+ ++4 Breast T2 +   Invasive ductal carcinoma Breast +/- No mutations 2
+4 Rectosigmoid T3 +   Serous carcinoma Ovary + TP53 c.722C>A; p.S241Y 1
Control 8
BRCA1+
42 y
0 Ovary T1 +   Serous carcinoma Ovary + TP53 c.818G>T; p.R273L 1
+ +
0 Omentum T2 +   Serous carcinoma Ovary + TP53 c.818G>T; p.R273L 1
0 Breast T3 - + Invasive ductal carcinoma Breast ND6 TP53 c.524G>A; p.R175H 2
+1 Abdominal wall (scar) 1 T4 +   Serous carcinoma Ovary ND6 TP53 c.818G>T; p.R273L 1
+1 Pleural effusion T5 - + Serous carcinoma Ovary + TP53 c.818G>T; p.R273L 1
Control 9
BRCA2+
59 y
0 Breast T1 +   Invasive ductal carcinoma Breast - TP53 c.327_328dup; p.R110fs*14 1
+ +
+2 Ovary1 T2 - + Serous carcinoma Ovary - TP53 c.112del; p.Q38fs*6 2
                FBXW7 c.1347G>C; p.E449D  
+2 Uterus T3 - + Serous carcinoma Ovary - TP53 c.112del; p.Q38fs*6 2
                FBXW7 c.1347G>C; p.E449D  
Control 10
BRCA1+
45 y
0 Breast T1 +   Metaplastic carcinoma Breast + TP53 c.488A>G; p.Y163C 1
+ ++6 Adnexa T2 +   Serous carcinoma Ovary + TP53 c.524G>A; p.R175H 2
+6 Rectouterine pouch T3 +   Serous carcinoma Ovary + TP53 c.524G>A; p.R175H 2
H&E: haematoxylin and eosin stained slides
IHC: immunohistochemical analysis
NA: not applicable
ND: not done
NE: not evaluable
1 Low quality sample
2 Conclusive diagnosis, based on tumor histology (H&E) and immunohistochemistry, if applicable: 
yes (+) or no (-)
3 Based on tumor histology (H&E) and immunohistochemistry if applicable
4 Nuclear expression of p53 in tumor cells was scored as either heterogeneous (+-), strong in all tumor 
cells (+) or absent in all tumor cells (-)
5 Entity: tumor or tumors most probably of the same origin (clonally identical). 1 is one independent 
entity, 2 is a second independent entity, etc. Various tumors that form one entity may present advanced 
disease, cancer relapse, or distant metastases.
6 No formalin-fixed paraffin-embedded tissue block available or no tissue left in the formalin-fixed 
paraffin-embedded tissue block.
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Molecular analysis
Outcomes of molecular analysis are depicted in Table 2. The formalin-fixed paraffin-
embedded tissues used for DNA isolation were relatively old, ranging from 2 to 32 years 
old at time of isolation. Six out of 38 (16%) DNA samples isolated from formalin-fixed 
paraffin-embedded tumor tissue were of low quality (see Supplementary table 2 for 
quality parameters). For 6 tumors no formalin-fixed paraffin-embedded tissue was 
available and DNA was isolated from original routine HE and/or immunohistochemical 
sections or from cytology preparations. Four out of 6 (67%) DNA samples isolated from 
original sections were of low quality.
In total, 167 tumor-specific variants were detected in the 44 analyzed tumors (Supple-
mentary table 3). Up to 27 variants were detected in the low quality tumor samples, 
compared to only 1 or 2 variants for good quality tumor samples. Additionally, some 
multinucleotide changes were incorrectly reported as 2 or 3 separate variants. Finally, 
48 mutations were either detected in good quality samples or confirmed in low qual-
ity samples. In the majority of tumors (n=34, 77%), one mutation was found; 7 tumors 
harbored two mutations. Thirty-nine (81%) of all 48 variants concerned a mutation in 
figure 1. Loss of heterozygosity analysis   →
Variant allele frequencies for single nucleotide polymorphisms at 15 different loci on 11 different chro-
mosomes (indicated on the y-axis) for the tumors samples of all patients analyzed are shown. The variant 
allele frequencies for the different single nucleotide polymorphisms are indicated by different colors. The 
example (bottom right) shows an A/T single nucleotide polymorphism, A representing the reference allele 
and T the variant allele. For any informative single nucleotide polymorphism without loss of heterozygos-
ity, a variant allele frequency of 0.5 is expected (grey). If there is loss of the reference allele, a variant al-
lele frequency >0.5 is expected (red). Alternatively, loss of the variant allele would result in a variant allele 
frequency <0.5 (green). A more intense color, either red or green, represents a variant allele frequency 
deviating further from 0.5, indicating a higher tumor percentage. Regardless of the actual nucleotides, 
green represents the reference allele and red the variant allele for all single nucleotide polymorphisms. 
Non-informative single nucleotide polymorphisms or single nucleotide polymorphisms with a strand bias 
or coverage <100 reads are not shown. If multiple tumors of a patient show largely concordant loss of het-
erozygosity patterns (all tumors show either red or green), this indicates that these tumors are most likely 
clonally related. Alternatively, differences in the loss of heterozygosity patterns between multiple tumors 
of one patient indicate multiple primary tumors.
Twelve patients (all patients except control no. 4 and 9) are BRCA1 mutation carriers. 10/12 patients show a 
concordant loss of heterozygosity pattern for the BRCA1 locus in their multiple tumors. Control no. 2 shows 
an equivocal loss of heterozygosity pattern, which is probably due to the low quality of the data. For case 
no. 3 only 1 informative marker is available which does not show clear loss of heterozygosity for T1 (variant 
allele frequency of 0.41). Control no. 4 and 9 are BRCA2 mutations carriers. Control no. 9 shows a concor-
dant loss of heterozygosity pattern for the BRCA2 locus for the three analyzed tumor samples. Control no. 4 
shows a concordant loss of heterozygosity pattern for samples T2 and T3, a different loss of heterozygosity 
pattern for sample T1 and no loss of heterozygosity for T4.
Chr: Chromosome
LOH: loss of heterozygosity
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the TP53 gene; in 39 of the 44 tumors (89%) a TP53 mutation was found. Other variants 
included PTEN,
PIK3CA and STK11 mutations in tumors located in the breast; a CAPZB mutation in tu-
mors in the uterus and cervix; a FBXW7 mutation in tumors in the ovary and uterus; and 
a BRAF mutation in a lung lesion (Table 2). Parallel to molecular analysis, p53 immuno-
histochemistry was conducted and showed results consistent with molecular outcomes 
(Table 2). In two low quality samples with aberrant p53 staining, no TP53 mutation was 
detected, probably due to insufficient coverage of TP53 (<100 reads for 8/19 amplicons 
for control no. 2, T1) or the type of TP53 mutation (possible intronic mutation or homo-
zygous deletion for control no. 1, T1).
As further shown in Table 2, based on the molecular analysis, all tumor localizations 
analyzed could be classified into one or more entities concerning their origins. Addi-
tional loss of heterozygosity analyses of the 143 single nucleotide polymorphisms at 15 
different loci were confirmative of the classifications made in 8/14 patients (Figure 1; + 
Supplementary Table 4 showing all single nucleotide polymorphism data). In the group 
of cases, where conventional histology and immunohistochemistry were not conclusive, 
molecular outcomes were decisive for all tumors (see Figure 2 for an example). In the 
group of controls, all molecular outcomes matched the diagnosis given by conventional 
histopathological diagnostics.
figure 2. Conventional diagnostics and molecular analysis results for case no. 1 (continued)   →
A Both tumors in the breast (T1 and T2) could be conclusively diagnosed invasive ductal carcinoma of the 
breast based on haematoxylin and eosin (H&E) stainings only. Additionally, ER and HER2NEU stainings are 
shown, which were negative in both tumors. Conclusive diagnosis regarding the origin of the non-small cell 
carcinoma in the lung (T3) based on HE stainings and immunohistochemistry (P63 and TTF1 both negative) 
was not possible.
As part of the molecular analysis p53 immunohistochemistry was performed, showing strong nuclear ex-
pression in the tumor cells of T1 and T3, and absent expression in the tumor cells of T2. Scale bars represent 
50 μm.
b Targeted next generation sequencing results of TP53 exon 6 for DNA isolated from normal and tumor 
tissues of the patient. Each grey line represents an individual read; only aberrations from the wildtype se-
quence are indicated. Sequencing results are shown in reverse complement, which means that TCG is actu-
ally CGA. T1 and T3 show an identical PT53 missense mutation (c.646G>A; p.V216M), whereas T2 shows a 
different TP53 nonsense mutation (c.637C>T; p.R213*).
C Loss of heterozygosity was analyzed using single nucleotide polymorphisms, the variant allele frequen-
cies of 17 single nucleotide polymorphisms at 5 different loci (chromosome 8p, PTEN, BRCA2, BRCA1 and 
SMAD4) are shown for the three tumor samples. Loss of the reference allele is indicated in red and loss of 
the variant allele in green; a more intense color (either red or green) indicates a higher tumor percentage. 
As expected for a BRCA1 germline mutation carrier, all tumor samples show loss of the same BRCA1 allele. 
For all other loci shown, T1 and T3 show corresponding loss of heterozygosity patterns (both tumors show 
either red or green), whereas T2 shows a different loss of heterozygosity pattern.
Chr: Chromosome
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figure 2. Conventional diagnostics and molecular analysis results for case no. 1
Case no. 1 presented with tumors of the right (T1) and the left (T2) breast, and a tumor in the lung 7 years 
later (T3).
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dISCuSSIOn
For 38/42 (90%) BRCA1/2 mutation carriers with multiple tumor localizations, conven-
tional histopathological analyses (histology, immunohistochemistry) were sufficient to 
determine tumor origins. Results obtained by next generation sequencing provided de-
cisive information in all four cases with inconclusive results from conventional diagnos-
tics, enabling accurate differentiation between a second primary or metastatic cancer. 
Next generation sequencing conducted on 10 control cases with ≥3 tumor localizations, 
unequivocally showed the same results as obtained by conventional histopathology, 
and indicate that next generation sequencing analysis of multiple tumors within one 
patient is a versatile procedure to determine clonal relationships between the lesions. 
Next generation sequencing analysis can be useful in case of ambiguous histopathology 
results, or if no formalin-fixed paraffin-embedded tissue block is available for immuno-
histochemistry.
As an illustration, the results of two patients are discussed below. First, case no. 2 
comprises ovarian cancer followed by thoracic wall and axillary lymph node metastases 
three years later. There were no signs of breast cancer, suggesting that the ovarian 
cancer had metastasized to the thoracic wall and the axilla. After another three years, 
synchronously with progressive metastatic disease, a small breast cancer was detected. 
After extensive diagnostic work-up it was concluded that thoracic wall and axillary le-
sions actually were metastases of this formerly subclinical primary breast cancer and 
the patient was treated accordingly. However, retrospectively, our findings of identical 
TP53 variants in the ovarian cancer and breast cancer strongly suggest that the breast 
cancer was actually metastatic ovarian cancer. Unfortunately, no suitable material of the 
thoracic wall and axillary lesions was left for molecular analysis in this study. Since the 
primary tumor origin determines the therapy of choice for metastatic disease, it is es-
sential to have no doubt about the origin of the metastases. The above-mentioned case 
is an example of how next generation sequencing can be decisive.
Second, control no. 1 comprises two ipsilateral breast cancers with a 13-year interval, 
both classified as invasive ductal carcinoma by histopathology, and ovarian cancer 6 
years later. Histopathological analysis is not always able to differentiate between local 
recurrent and second primary breast cancer. The location of the breast cancer may help, 
but in this case, the first breast cancer was located in the medial upper quadrant while 
the second breast cancer was located centrally, leaving both options open. Some data 
suggest that BRCA1/2 mutation carriers, especially when young (<40 years), show longer 
intervals to local recurrent breast cancer24, 25. However, since the prognosis of a second 
ipsilateral breast cancer occurring <5 years is worse than after >5 years, late-recurring 
breast cancer are probably more often second primary tumors26, 27 and it is justifiable 
that they are treated accordingly. It is likely that the recurrent breast cancer after 13 
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years in this case was a second primary breast cancer. Molecular analysis confirmed that 
these tumors were two different entities.
Loss of heterozygosity -patterns were supportive of the results obtained by variant 
analysis in more than half of cases and controls (Figure 1). Almost all cases and controls 
showed corresponding loss of heterozygosity of BRCA1 or BRCA2 in all tumors, repre-
senting the ‘second hit’ of the functioning BRCA wild-type allele. For BRCA1 mutation 
carriers, exceptions were case no. 3 with no clear loss of heterozygosity of BRCA1 for 
the breast cancer and control no. 2 with no evaluable loss of heterozygosity results. 
For BRCA2 mutations carriers, an exception was control no. 4 with four primary tumors 
showing loss of one allele of BRCA2 in the larynx tumor, loss of the other allele in both 
the lung tumor and the uterus/omentum tumor, and no loss of BRCA2 in the breast 
tumor. So far, BRCA2 mutation carriers are not associated with elevated risk of lung 
cancer and an increased risk of laryngeal carcinoma seems improbable28-31. Additional 
Sanger sequencing showed loss of the mutated BRCA2 allele for the tumor located in 
the larynx and loss of the wild-type allele for the lung lesion and the uterus/omentum 
tumor localizations (data not shown). The laryngeal carcinoma therefore is most likely a 
sporadic tumor. Loss of the wild-type BRCA2 allele in the lung tumor may indicate either 
sporadic or BRCA2-related carcinogenesis. Furthermore, it has been described that loss 
of heterozygosity causes the second hit in only 80% of BRCA1-associated and in 60-70% 
of BRCA2-associated breast cancer32,1,33, fitting with the fact that we did not find (clear) 
loss of heterozygosity in two breast tumors. Possible alternative ‘second hit’ mechanisms 
include mutations and deletions of the wild-type allele. Epigenetic silencing as a second 
hit, to our knowledge, is rare in germline BRCA1/2 mutation carriers and therefore not a 
plausible explanation32.
The diagnostic panel used in this study covered the exonic regions of the genes 
CDKN2A,
PTEN and TP53 almost completely, multiple hotspot mutation sites for 27 genes, and 
single nucleotide polymorphisms (Supplementary Table 1). In the majority of cases and 
controls a conclusive diagnosis concerning tumor site clonality could be made based on 
different or similar TP53 variants. A PTEN mutation was only found once and none of the 
tumors harbored CDKN2A mutations. Up to 97% of all high grade serous ovarian cancer, 
typically occurring in BRCA1/2 germline mutation carriers, harbor somatic TP53 muta-
tions13, 34. TP53 is affected in 16% to 84% of BRCA1/2-associated breast cancer, and in up 
to 97% of BRCA1-associated basal-like breast cancer35,36. Our finding of TP53 mutations 
in 93% of all tumors (39/44 confirmed and 2/44 based on p53 immunohistochemistry) 
is in line with the high percentages found in the literature. It suggests that molecular 
diagnostic workup may simply consist of TP53 analysis, rather than next generation se-
quencing of an entire panel. However, in two tumors without TP53 mutations, we found 
mutations in other genes (PIK3CA and STK11), providing also a conclusive diagnosis for 
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these tumor localizations. Additionally, loss of heterozygosity analysis was not only 
confirmative of the classifications made for most of the patients, but was also helpful 
if ‘hotspot’ TP53 mutations were found. An example is control no. 10, for which both T2 
and T3 harbor a TP53 R175H mutation. Since according to somatic mutation databases 
this is a common TP53 mutation these tumors potentially could still be different primary 
tumors. However, because loss of heterozygosity patterns were identical, we were able 
to reliably classify these tumors as one entity.
Immunohistochemical tissue markers were chosen according to institutional protocol 
depending on clinical and histological differential diagnosis of the tumor origin. Various 
different immunohistochemical markers of breast cancer have been investigated, such 
as GATA3, GCDFP, mammaglobin and SOX10. Although of potential value for differenti-
ating breast cancer, as yet, their applicability seems limited or has not been validated 
well enough in triple negative breast cancer 37-39.
A limitation of our study was that 10/44 tumor samples analyzed with next generation 
sequencing were of low quality, mostly due to fixation artefacts or a low amount of start-
ing material, resulting in less reliable variant calling. Variants in low quality samples were 
therefore confirmed by Sanger sequencing or by a second next generation sequencing 
run. Furthermore, loss of heterozygosity analysis of these samples was difficult, resulting 
in non-evaluable loss of heterozygosity data in two patients with one or more tumor 
samples of low quality. Nevertheless, using a combined approach of multiple molecular 
analyses resulted in reliable classification of the tumors into one or more entities for all 
patients. Another limitation was that, due to the specific selection criteria, the study 
sample size was small.
In conclusion, during diagnostic workup of BRCA1/2-associated breast cancer and 
ovarian cancer patients with multiple tumor localizations, analysis of tumor histology 
and immunohistochemistry by a specialized pathologist may be sufficiently conclusive 
in most cases. However when routine pathology is inconclusive, molecular analysis 
using next generation sequencing can reliably determine the relationships between 
the tumor localizations and as such guide the most appropriate treatment for each 
individual patient.
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AbSTRACT
background The majority of BRCA1/2-associated breast cancers (BC) is of high histologic 
grade and most BRCA1-associated BCs are triple-negative. Therefore, the value of con-
ventional prognostic markers such as grade and hormone receptor status is limited in 
these patients. The aim of the present study was to assess the presence and prognostic 
significance of β-catenin expression in BRCA1/2-associated BC patients.
Methods We included female BRCA1/2 gene mutation carriers diagnosed with BC be-
tween 1982 and 2014. Patient demographics, tumor characteristics and recurrence-free 
survival (RFS) were extracted from an ongoing institutional database. BC slides were 
centrally reviewed for histologic subtype and grade. Immunohistochemical β-catenin 
staining was classified as membranous, cytoplasmic and/or nuclear staining, and scored 
as negative/weak, moderate or strong.
Results Ninety-two BRCA1 (73%) and 28 BRCA2 (27%) mutation carriers were included. 
Median follow-up was 7.7 years (range 0.6-32.6). Thirty-eight per cent of BCs showed 
nuclear β-catenin expression. In univariable analyses, tumor size and membrane-
associated β-catenin staining (HR 0.11 for strong vs. negative/weak; 95%CI 0.01-0.97) 
were significantly associated with RFS. In multivariable analyses, the only significant 
prognostic factor remained strongly positive membrane-associated β-catenin staining 
(HR 0.19; 95%CI 0.05-0.73).
Conclusion The presence of nuclear β-catenin expression in a substantial proportion of 
BRCA1/2-associated BC suggests a potential role of Wnt signalling in hereditary breast 
cancer. Besides, membranous b-catenin expression was associated with a favorable RFS. 
Confirmation of these results in larger series may improve risk stratification in these 
patients.
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bACkGROund
Women with germ line BRCA1 or BRCA2 gene mutations have cumulative lifetime risks 
of 55-85% of a first breast cancer (BC) and 20-60% of a contralateral BC by the age of 
70 years1-5. Therefore, these women may opt for either risk-reducing mastectomy or 
frequent BC screening. Modern screening programs for BRCA1/2 gene mutation carriers 
comprise alternating mammography and magnetic resonance imaging (MRI). As a result, 
the majority of BRCA1/2-associated BC is detected in an early stage (43% is detected at 
stage T1a/b and 79% is lymph node negative)6.
Both BRCA1- and BRCA2-associated BC typically are poorly differentiated7-9 and about 
70% of BRCA1-associated tumors are triple-negative (negative for estrogen receptor 
(ER), progesterone receptor (PR) and HER29. These findings limit the value of established 
prognostic markers for risk stratification in BRCA1/2-associated BC. Therefore, the identi-
fication of additional prognostic parameters is warranted.
Wnt signaling, mediated by β-catenin, is known to play an important role in tumori-
genesis of colorectal cancers and several other solid tumors including breast cancer10, 11. 
Beside induction of tumorigenesis, the Wnt pathway accounts for the regulation of a 
broad range of cell functions such as proliferation, survival and cell matrix modeling10.
In the absence of Wnt, an intracellular complex is formed containing the proteins 
GSK3β, APC and Axin. This complex binds and phosphorylates membranous β-catenin, 
which is then ubiquitinated and destructed. When Wnt is activated, the GSK3β/Axin/APC 
destruction complex cannot be formed. Unphosphorylated β-catenin thus accumulates 
in the cytoplasm where it enters the nucleus10, 12, 13. Previous studies on Wnt activity 
as a prognostic factor in BC, based on the expression of β-catenin, yielded conflicting 
results13-19. There is some evidence that the prognostic value of Wnt signaling depends 
on the molecular BC subtype and may be stronger in basal-like BC20, 21, which suggests a 
potential prognostic value of the Wnt/β-catenin pathway in BRCA-associated BC. Besides, 
several members of the Wnt cascade were reported to be deregulated in a substantial 
proportion of breast carcinomas by methylation rather than by specific gene mutations, 
which makes it an attractive potential target for pharmacological inhibition22.
Another role of membranous b-catenin concerns cell-cell adhesion through the bind-
ing of E-cadherin on the extracellular cell membrane. Loss of b-catenin at the membrane 
may lead to epithelial-mesenchymal transition (EMT), which is required for metastasis 
of tumor cells17. The b-catenin that binds E-cadherin is likely distinct from the b-catenin 
that mediates Wnt signaling23. The aim of the present study was to assess Wnt activity, 
by using nuclear β-catenin expression as a read-out, in BRCA1/2-associated BC. Second, 
we tested the value of membranous, cytosolic and nuclear β-catenin expression as a 
potential novel prognostic marker in this subgroup.
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METHOdS
Patients
After written informed consent, the Family Cancer Clinic of the Erasmus MC Cancer In-
stitute registers patients with an increased BC risk in an institutional ongoing database. 
From this database we selected women with a proven BRCA1/2 gene mutation who were 
diagnosed with BC between 1982 and 2014 and for whom BC tumor material was avail-
able for immunohistochemical staining.
In- and exclusion criteria have been described before24. In short, patients with a history 
of a malignancy other than BC at the time of BC diagnosis except for basal cell carcinoma, 
neoadjuvant chemotherapy or radiotherapy administered for the primary BC or distant 
metastasis at the time of BC diagnosis were excluded. Women with contralateral BC were 
included in the analysis since low stage contralateral BCs, as typically detected during 
screening in BRCA1/2 gene mutation carriers, do not influence primary breast cancer 
prognosis25. In case of synchronous contralateral BC, the tumor with the highest stage 
was included. Patient history, mutation carriership (BRCA1 or BRCA2), age and year of 
BC diagnosis and data on locoregional/distant disease recurrence were extracted from 
the Family Cancer Clinic database. Data on tumor size and lymph node metastases were 
extracted from pathology reports.
Histopathological features
Formalin-fixed paraffin-embedded primary BC tissues were collected from the depart-
ments of pathology of the Erasmus MC Cancer Institute. A breast pathologist (C.v.D.) 
reviewed haematoxylin and eosin (H&E) stained tissue sections for assessment of histo-
logic subtype (according to the WHO) and histologic grade (Nottingham modification of 
Bloom and Richardson)26.
ER, PR and HER2 status were extracted from pathology reports or assessed from Tissue 
Micro Arrays (TMA) using three cores per tumor. ER and PR were considered positive if 
staining was seen in ≥10% of the nuclei, according to the Dutch national BC guidelines27. 
HER2 receptor status was scored according to international guidelines28.
β-catenin staining
A breast pathologist (C.v.D.) assessed immunohistochemical β-catenin staining (BD 
610154 14/Beta-Catenin monoclonal antibody; dilution 1:200) of tumor cell membrane, 
cytoplasm and nucleus, using a positive and negative control (colon carcinoma and 
lobular BC respectively). Normal epithelial breast tissue was used as an internal refer-
ence regarding intensity of membrane staining. The scoring method was adapted from 
Khramtsov et al.20, resulting in a semi quantitative final score for membrane and cyto-
plasmic β-catenin staining. The final score (1-7) consisted of the sum of separate scores 
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for intensity of staining (0: no staining – 3: maximum staining intensity) and for the 
percentage of tumor cells that show β-catenin staining (1:0-10%, 2: 11-30%, 3: 31-70%, 
4: 71-100%). Three categories were derived from the final score: 1-3: negative/weakly 
positive, 4-5: moderately positive and 6-7: strongly positive β-catenin staining.
A binary score was used for nuclear β-catenin staining (0: no nuclear staining, 1: 
nuclear staining in any tumor cells).
Statistical analysis
The statistical methods used in this study were described before24. Lobular BCs were 
used as negative control for β-catenin staining. Therefore, to prevent confounding 
women with lobular BC were excluded. The main outcome of interest was recurrence-
free survival (RFS), defined as the time interval between date of primary BC surgery and 
locoregional or distant BC relapse. To avoid potential survival bias due to inclusion of 
patients who underwent genetic testing after BC diagnosis left truncation was used29. 
Patients were censored at last follow-up or at death. We estimated hazard ratios and 95% 
CIs for established prognostic factors and additional histologic parameters using Cox 
regression in univariable and multivariable analysis. Variables with a P-value < 0.10 in 
univariable analysis were included in the multivariable model. We performed subgroup 
analyses on BRCA1 gene mutation carriers and on triple-negative BC patients. Associa-
tions of categorical data were analyzed using a Chi-Square test. In all analyses, age at 
and year of diagnosis were analyzed as continuous variables. Analyses were performed 
with STATA version 13.1.
RESulTS
Patient and tumor characteristics
In total, 146 female BRCA1/2 mutations carriers were selected from the database. Of 
them, 16 women were excluded due to missing tumor material. Two had metastatic 
disease at the time of diagnosis. Eight had lobular BC and were excluded. Characteristics 
of the remaining 120 BC patients are shown in Table 1. The group consisted of 92 BRCA1 
(77%) and 28 BRCA2 (23%) mutation carriers. Median age at BC diagnosis was 38.5 years 
(range 21-68). Median follow-up was 7.7 years (range 0.6-32.6) since primary BC diagno-
sis. During follow-up, 9 patients (8%) were affected by recurrent (local or distant) BC. The 
majority of the patients (83; 69%) had a pT1 tumor (≤2.0 cm diameter) and a negative 
nodal status (94; 78%). The majority of tumors were grade 3 (78; 65%). Seventy-seven 
(64%) BCs were triple-negative (71 BRCA1, 77%; 6 BRCA2, 21%).
108
Chapter 6
Table 1. Patient and tumor characteristics of BRCA1/2-associated breast cancers
  N % BRCA1 % BRCA2 %
Total 120   92 77% 28 23%
Age at diagnosis, years
(median, range)
38.0 21-68 37.0 23-65 42.0 21-68
Tumor size            
≤ 2.0 cm 83 69% 62 67% 21 75%
2.0 – 5.0 cm 31 26% 27 29% 4 14%
> 5.0 cm 4 3% 2 2% 2 7%
Unknown 2 2% 1 1% 1 4%
Nodal status            
Negative 94 78% 76 83% 18 64%
Positive 26 22% 16 17% 10 36%
Histological type            
Ductal 111 92% 85 92% 26 93%
Other 9 8% 7 8% 2 7%
Bloom and Richardson grade            
I 5 4% 1 1% 4 14%
II 35 29% 22 24% 13 46%
III 78 65% 68 74% 10 36%
Unknown 2 2% 1 1% 1 4%
Estrogen receptor status            
Negative 79 66% 72 78% 7 25%
Positive 38 32% 18 20% 20 71%
Unknown 3 2% 2 2% 1 4%
Progesterone receptor status            
Negative 90 75% 80 87% 10 36%
Positive 6 22% 10 11% 16 57%
Unknown 4 3% 2 2% 2 7%
HER2 status            
Negative 108 90% 82 89% 26 93%
Positive 8 7% 7 8% 1 4%
Unknown 4 3% 3 3% 1 4%
Triple-negative receptor status            
No 40 33% 19 21% 21 75%
Yes 77 64% 71 77% 6 21%
Unknown 3 3% 2 2% 1 4%
Membrane-associated β-catenin            
Negative/ weakly positive 3 3% 3 3% 0 0%
Moderately positive 21 17% 11 12% 10 36%
Strongly positive 96 80% 78 85% 18 64%
Cytoplasmic β-catenin            
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Table 1. Patient and tumor characteristics of BRCA1/2-associated breast cancers (continued)
  N % BRCA1 % BRCA2 %
Negative/ weakly positive 25 21% 16 17% 9 32%
Moderately positive 73 61% 56 61% 17 61%
Strongly positive 22 18% 20 22% 2 7%
Nuclear β-catenin            
Negative 73 61% 50 54% 23 82%
Positive 46 38% 41 45% 5 18%
Unknown 1 1% 1 1%    
Nucleus-associated β-catenin staining was classified as ‘negative’ in 61% vs. ‘positive’ 
in 38% of cases. In one case the classification of nuclear β-catenin staining remained 
unclear (1%). In all cases scored as ‘positive’ for nuclear staining, only a small proportion 
of cells were positive (<5%), as illustrated in Figure 1. None of the cases showed stromal 
nuclear staining.
figure 1. An example of a breast cancer case with positive nucleus-associated β-catenin staining
Cytoplasmic β-catenin staining was classified as ‘moderately positive’ in the majority of 
cases: 61%, vs. 21% ‘negative/weakly positive’ and 18% ‘strongly positive’. Membranous 
β-catenin staining was classified as ‘strongly positive’ in the majority of cases: 80%, vs. 
17% ‘moderately’ and 3% ‘negative/weakly positive’. Figure 2 provides an example of a 
BC with strong membranous β-catenin staining (A) and negative/weak staining (B).
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figure 2. Examples of breast cancer cases with A. strong membranous β-catenin staining and B. negative/
weak membranous β-catenin staining
Membranous b-catenin was not significantly associated with histologic grade (P= 0.17; 
Chi-square test). There was a significant association of nuclear b-catenin expression 
with triple-negative receptor status (P<0.001; Chi-square test). Loss of membranous 
b-catenin expression was not correlated with nuclear b-catenin expression (P 0.67).
β-catenin staining in relation to recurrence-free survival (RfS)
In univariable analyses (Table 2), a larger tumor size was related to a poor RFS (HR 1.06 
per millimeter; 95%CI 1.02-1.10). Strong membranous β-catenin staining was a favor-
able prognostic factor (HR 0.11; 95%CI 0.01-0.97). Five-year RFS was 90% in the group 
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with strong membranous b-catenin staining; vs. 51% in the groups with negative/weak 
and moderate membranous b-catenin staining (Figure 3). Nuclear β-catenin staining 
was of no prognostic value.
	
Figure.	RFS	in	BRCA1/2-associated	BC	patients	by	membrane	β-catenin	staining	
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figure 3. Recurrence free survival (RFS) in BRCA1/2-associated breast cancer patients by membranous 
β-catenin stai ing
Numbers of women at risk increase during the first years of observation because of left truncation, which 
was used to avoid potential survival bias due to inclusion of patients who underwent genetic testing after 
breast cancer diagnosis.
In multivariable analyses, strong membranous b-catenin staining remained the only 
significant prognostic factor with favorable impact on RFS (HR 0.19; 95%CI 0.05-0.73).
β-catenin staining in the subgroup of BRCA1-associated breast cancers
Patient characteristics of the BRCA1-associated subgroup are shown in Table 1. In uni-
variable analyses (Table 3), a larger tumor size (HR 1.15 per millimeter; 95%CI 1.07-1.25) 
was associated with a poor RFS. Strongly positive membrane β-catenin staining was a 
favorable prognostic factor (HR 0.13; 95%CI 0.03-0.60). In multivariable analyses, the only 
significant factor remained a larger tumor size (HR 1.14 per millimeter; 95%CI 1.04-1.24).
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Table 2. Clinicopathologic features of BRCA1/2-associated breast cancers in relation to recurrence-free 
survival (RFS)
 
 
N Univariate Multivariable
  HR 95% CI HR 95% CI
Age at diagnosis (years)*   0.92 0.84 – 1.00** 0.97 0.89 – 1.05
BRCA mutation          
BRCA1 92 1.0      
BRCA2 28 0.72 0.15 – 3.48    
Year of diagnosis (years)*   0.96 0.83 – 1.13    
Tumor size (mm)*   1.06 1.02 – 1.10** 1.05 1.00 – 1.11
Nodal status          
Negative 94 1.0      
Positive 26 2.33 0.58 – 9.31    
Histological type          
Ductal 111 1.0      
Other 9 2.68 0.33 – 21.5    
Bloom and Richardson grade          
I/II 40 1.0      
III 78 1.55 0.32 – 7.49    
Estrogen receptor status          
Negative 79 1.0      
Positive 38 1.07 0.27 – 4.30    
Progesterone receptor status          
Negative 90 1.0      
Positive 26 1.09 0.23 – 5.26    
HER2 status          
Negative 108 1.0      
Positive 8 1.59 0.20 – 12.7    
Membrane-associated β-catenin          
Negative/ Weakly positive 3 1.0      
Moderately positive 21 0.58 0.06 – 5.70    
Strongly positive 96 0.11 0.01 – 0.97** 0.19*** 0.05 – 0.73
Cytosolic β-catenin          
Negative/ Weakly positive 25 1.0      
Moderately positive 73 0.33 0.08 – 1.33    
Strongly positive 22 0.38 0.04 – 3.39    
Nuclear β-catenin          
Negative 73 1.0      
Positive 46 1.57 0.42 – 5.90    
HR: Hazard Ratio; 95%CI: 95% confidence interval
*analyzed as a continuous variable
**entered in multivariable analysis
***strong vs negative/weak/moderate
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Table 3. Clinicopathologic features of BRCA1-associated breast cancers (N=92) in relation to recurrence-
free survival (RFS)
 
 
N Univariate Multivariable
  HR 95% CI HR 95% CI
Age at diagnosis (years)*   0.89 0.78 – 1.02    
Year of diagnosis (years)*   1.00 0.84 – 1.19    
Tumor size (mm)*   1.15** 1.07 – 1.24 1.14 1.04 – 1.24
Nodal status          
Negative 76 1.0      
Positive 16 4.89 1.09 – 21.9    
Estrogen receptor status          
Negative 72 1.0      
Positive 18 0.87 0.10 – 7.22    
HER2 status          
Negative 82 1.0      
Positive 7 1.51 0.18 – 12.6    
Membrane-associated β-catenin          
Neg/Weakly/Moderately positive 14 1.0      
Strongly positive 78 0.13** 0.03 – 0.60 0.49 0.07 – 3.21
Cytosolic β-catenin          
Negative/ Weakly positive 16 1.0      
Moderately/ Strongly positive 76 0.57 0.11 – 2.96    
Nuclear β-catenin          
Negative 50 1.0      
Positive 41 1.93 0.43 – 8.66    
HR: Hazard Ratio; 95% CI: 95% confidence interval
*analyzed as a continuous variable
**entered in multivariable analysis
dISCuSSIOn
To our knowledge, this is the first study investigating β-catenin expression in BRCA1 and 
BRCA2-associated BC. A substantial proportion of BC cases showed nuclear staining and 
strong membranous staining was a potential favorable marker for RFS.
In line with our results, previous studies on sporadic BC reported patterns of reduced 
membranous b-catenin expression being associated with a worse outcome16, 19, 20, 30, 31. 
These studies are in conflict with reports that did not find a clear association between 
β-catenin expression and prognosis14, 32. The finding of reduced membranous b-catenin 
expression as an unfavorable prognostic marker is unlikely to be correlated with Wnt 
activation. If Wnt activation would play an important role, β-catenin expression should 
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not only be reduced at the membrane, but should become positive in the nucleus, since 
nuclear expression is seen as a read-out of Wnt activation10. In the present study we 
did not find an association of loss of membranous β-catenin expression with marked 
nuclear β-catenin expression. As membranous b-catenin also plays a role in cell-cell 
adhesion through binding of E-cadherin, reduced membranous b-catenin expression 
may be a marker of loss of epithelial differentiation, and in this way be a marker of 
poor prognosis17, 31. A substantial proportion of BCs (38%, mainly triple-negative cases) 
showed nuclear β-catenin expression, which seemed of no prognostic value. However, 
we never found nuclear expression in more than a few tumor cells per case. In BC, data 
are limited regarding nuclear b-catenin expression as a prognostic marker13, 33, but an as-
sociation between nuclear b-catenin expression and poor outcome has been reported 
in basal-like BC20. Nonetheless, in sporadic BC, there is ample evidence for a role of aber-
rant Wnt activation in tumorigenesis12, 34, although the exact mechanism remains to be 
elucidated.
No studies have been published examining the presence and significance of b-catenin 
expression in BRCA1/2-associated BC. As described before, this subgroup of patients 
lacks valuable prognostic markers and therapeutic targets, due to the high rate of early-
detected (node-negative) BC in combination with a high rate of high grade and triple-
negative cancers. Therefore, the identification of additional prognostic parameters is 
warranted.
This study has several limitations. Although the group of BRCA1/2 gene mutation car-
riers was relatively large and median follow-up was 7.7 years, there were only 9 events 
of locoregional or distant disease recurrence. This limited the amount of covariates en-
tered in the multivariable analyses and probably has limited the statistical power of our 
outcomes. Further, the scoring and classification system used in this study, which was 
adapted from Khramtsov et al., has never been validated. Some authors advocate using 
a computerized quantitative scoring system16. A more universal and validated classifica-
tion system is warranted to be able to compare and combine different study results.
In conclusion, we reported nuclear β-catenin expression in a substantial proportion of 
(mainly triple-negative) BC, which suggests a potential role of Wnt activity in BRCA1/2-
associated BC. Confirmation of these results, preferably by the identification of target 
genes may help to identify potentially therapeutic markers. Besides, membranous 
β-catenin expression was associated with a favorable RFS, which could improve risk 
stratification in this patient population.
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AbSTRACT
Prophylactic skin-sparing mastectomy (SSM) is associated with major breast cancer risk 
reduction in high-risk patients. In prophylactic nipple- and skin-sparing mastectomy 
(NSM) it is unknown how many terminal duct lobular units (TDLUs) remain behind the 
nipple-areola complex (NAC) additionally to those behind the skin flap. Therefore safety 
of NSM can be doubted. We compared amounts of TDLUs behind the NAC as compared 
to the skin. In prophylactic SSM and conventional therapeutic mastectomy patients, the 
NAC and an adjacent skin island (SI) were resected as if it were an NSM. NAC and SI were 
serially sectioned perpendicularly to the skin and analyzed for the amount of TDLUs 
present. Slides of NAC and SI were scanned and slide surface areas (cm2) were measured. 
TDLUs/cm2 in NAC- versus SI-specimen, representing TDLU density, were analyzed pair-
wise. In total 105 NACs and SIs of 90 women were analyzed. Sixty-four NACs (61%) vs. 
25 SIs (24%) contained ≥1 TDLUs. Median TDLU density was higher in NAC-specimens 
(0.2 TDLUs/cm2) as compared to SI-specimens (0.0 TDLUs/cm2; P<0.01). Independent risk 
factors for presence of TDLUs in the NAC-specimen were younger age and parity (versus 
nulliparity). The finding of higher TDLU density behind the NAC as compared to the skin 
flap suggests that sparing the NAC in prophylactic NSM in high-risk patients possibly 
may increase postoperative breast cancer risk as compared to prophylactic SSM. Studies 
with long-term follow-up after NSM are warranted to estimate the level of residual risk.
TDLU’s behind the nipple-areola and skin
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bACkGROund
BRCA1/2 mutation carriers have a cumulative lifetime breast cancer risk of 55-85% by 
the age of 701-5. As an alternative to surveillance, BRCA1/2 mutation carriers and other 
high risk patients may choose to undergo prophylactic bilateral mastectomy and breast 
reconstruction, achieving risk reductions of 90-100% after 3-13 years of follow-up6-10.
To allow for direct breast reconstruction after mastectomy, the technique of skin-
envelope preserving mastectomy (skin-sparing mastectomy; SSM) aims to spare the 
skin of the breast. In SSM, a periareolar incision is used (see Figure 1A and B, which show 
a circular (A) and a drop-shaped (B) incision as used in SSM). Breast glandular tissue 
is excised subcutaneously creating a skin envelope while preserving a thin subcutane-
ous layer to support skin vascularization. Nipple-papilla and surrounding pigmented 
areola (nipple-areola complex; NAC) are removed. Additionally, a breast reconstruction 
is performed. SSM is generally considered oncologically safe for prophylactic and thera-
peutic indications, although no prospective randomized controlled trials have been 
conducted6-11.
A B 
C 
Skin island 
Skin of mastectomy specimen 
Mastectomy incision 
Nipple-areola complex (NAC) 
Inframammary fold 
Incision of NAC & skin island 
figure 1 Examples of incisions around the nipple-areola complex (NAC) and skin island (SI) in A skin-spar-
ing mastectomy, b and C in conventional, non-skin-sparing mastectomies
Preservation of the NAC in SSM (nipple-sparing mastectomy; NSM) may further improve 
cosmetic outcome and patient satisfaction12. In NSM, a semicircular incision is used to 
create a skin envelope as in SSM (see Figure 2C, which shows a semicircular incision as 
used in NSM). The NAC is dissected as thin as possible by macroscopically removing all 
breast glandular tissue while preserving vascularization (see Figure 3A, which shows 
intra-operative dissection of the NAC). The nipple-papilla is ‘cored’ by inverting it and 
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excising residual breast glandular tissue (see Figure 3B, which illustrates the ‘coring’ of 
the nipple-papilla)13. The NAC is then left in situ adherent to the skin envelope. NSM has 
been reported safe for selected patients with small, peripherally located breast cancers14. 
However, long-term oncological safety of NSM for breast cancer prophylaxis in BRCA1/2 
mutation carriers and other women with high breast cancer risk is still subject to debate. 
Various authors have found terminal duct lobular units (TDLUs) in and/or closely behind 
the NAC15-17. TDLUs in the mammary gland are defi ned as a terminal duct combined with 
an associated lobule and are known as the origin of invasive breast cancer18, 19. Theo-
retically, any residual TDLUs behind skin or behind NAC may remain a lifelong potential 
hazard for developing DCIS or invasive breast cancer. Although SSM is considered a safe 
risk-reducing option, residual TDLUs have also been found behind skin fl aps after SSM20. 
Several studies have reported safety of NSM in high-risk patients, but they lack follow-
up21, 22. Lifelong follow-up of BRCA1/2 mutation carriers would be necessary to estimate 
the remaining oncological risk of any residual breast tissue after prophylactic surgery 
and particularly NSM. We compared presence and amounts of TDLUs remaining behind 
the NAC with presence and amounts of TDLUs behind the skin fl ap, to assess whether 
NSM would lead to a signifi cant increase in remaining TDLUs as compared to SSM.
A   B   C  
figure 2 Incisions used for A and b skin-sparing mastectomy (SSM) and C nipple-sparing mastectomy 
(NSM)
TDLU’s behind the nipple-areola and skin
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A   B  
figure 3 Sparing the nipple-areola complex (NAC) in nipple-sparing mastectomy (NSM). A Dissecting the 
nipple-areola and b Coring the nipple-papilla
METHOdS
Patients
Women ≥18 years who underwent conventional mastectomy or non-nipple-sparing SSM 
for prophylactic or therapeutic indications were eligible. Exclusion criteria were gross 
abnormalities of the nipple (flat, inverted, retracted or Paget’s disease) accountable to 
nipple-involvement of the tumor, a malignancy with radiological nipple-involvement, a 
malignancy at ≤1 cm distance to nipple or skin, a history of radiotherapy of the breast or 
an earlier operation in the NAC or skin area. Parameters such as age, body mass index, 
breast size, menopausal status, parity, history of breast feeding and history of chemo-
therapy were collected from medical files.
The institutional Medical Ethical Board approved the study. According to the Dutch 
‘Code of Conduct’ for secondary use of human tissue, the use of excised tissue for re-
search purposes after standard diagnostic procedures is part of the standard treatment 
agreement in the Netherlands.
Surgical technique
Oncological surgeons from four centers participated in this study. All of them were ex-
perienced in performing NSMs. The participating surgeons were assisted by one of the 
researchers at their first inclusions to ensure that identical techniques were used (Figure 
1, Figure 3). In a conventional (non-skin-sparing) or skin-sparing mastectomy, circles 
were drawn around the NAC and around an as large as possible periareolar circular skin-
island (SI) representing the skin flap which would be spared in SSM or NSM (Figure 1). 
The periareolar location of the SI was chosen because of the assumed pyramid shape 
of the breast gland and therefore expecting most TDLUs behind the skin near the NAC. 
Diameters of NAC and SI were measured before excision. Then the NAC was excised as 
thin as possible (i.e. without compromising blood flow and consequently induct necrosis; 
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Figure 3a) as if it were a real NSM. The nipple-papilla was cored (Figure 3b)13. The SI was 
excised subcutaneously as if it were a skin flap in SSM or NSM. NAC and SI excisions 
were completely executed intra-operatively (‘in vivo’; see Figure 4, which shows intra-
operative incisions around NAC and SI).
figure 4 Intra-operative dissection of the nipple-areola complex (NAC) and skin-island (SI)
Analysis of Tdlus
NAC and SI specimens were formalin fixed, serially sectioned perpendicularly to the skin 
into 2 mm thick slices, paraffin embedded and entirely submitted for routine haema-
toxylin and eosin (H&E) staining (Figure 5). Microscopic examination was performed by 
two breast pathologists (C.v.D. and P.W.) after obtaining consensus on TDLU definition 
and specification of anatomical locations. A TDLU was defined as a terminal duct and 
its associated lobule (Figure 6), characterized by (1) the presence of a loose intralobular 
stroma that was different from the surrounding, denser, more collagenized interlobular 
stroma and (2) presence of a typical double cell layer confining the lobular acini23.TDLUs 
were counted and their anatomical locations (‘dermis’, ‘breast stroma’ or ‘fat’) were noted.
TDLU’s behind the nipple-areola and skin
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2 mm 
A 
B 
Slide area of 1 H&E slide (cm2) 
NAC or SI 
Perpendicular sectioning of NAC and SI specimen 
figure 5 Perpendicular serial sectioning in 2 mm thickness for quantification of TDLUs in haematoxylin 
and eosin (H&E) slides of A nipple-areola complex (NAC) and b skin islands (SI). Slides were scanned and 
slide areas were measured in Adobe Photoshop®. TDLU density= TDLUs/Σ slide areas (cm2)
A   
1 mm
  B  
200 μm
figure 6 Terminal duct lobular unit (TDLU) consisting of a terminal duct with and associated lobule: A 
low-power view of a TDLU with associated lactiferous ducts and b medium-power view of one TDLU; hae-
matoxylin and eosin (H&E) staining.
H&E slides of NAC and SI specimens were scanned. Surface areas of slides (slide area, cm2) 
were calculated using Adobe Photoshop®. Total TDLU quantities were corrected for the 
sum of slide areas, representing density of TDLUs in NAC or in SI: TDLU density=TDLUs/Σ 
slide areas (cm2) (Figure 5).
Statistical analysis
Differences in amounts of TDLUs in NAC as compared to SI were tested pairwise by us-
ing Wilcoxon’s Signed Rank test. Binary logistic regression was used for multivariable 
analysis of factors that may influence the presence of TDLUs in the NAC, including the 
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interaction term age x menopausal status. Variables with a P-value of <0.1 in univariable 
analysis were included in the multivariable analysis. All P-values were two-sided and a 
significance level of α=0.05 was used. The SPSS computer package (version 20.0) was 
used for statistical analyses.
RESulTS
After 75 unilateral and 30 bilateral mastectomies in 90 women, 105 NACs and skin islands 
were available for analysis. The indication for mastectomy was prophylactic in 31, thera-
peutic (in situ or invasive carcinoma) in 71 and symptomatic (chronic mastodynia) in 3 
cases. Median age at unilateral or bilateral mastectomy was 49 years (range 26-86) and 
59 women (56%) were post-menopausal (Table 1). In 14 of them, menopause had been 
induced by bilateral oophorectomy at premenopausal age. Four women had undergone 
neoadjuvant chemotherapy, nine women had a history of adjuvant chemotherapy for 
breast cancer and four women had a history of chemotherapy for another indication.
Tdlus in nipple-areola complex (nAC) specimen and in skin-island (SI) 
specimen
Median diameter of the NAC was 4.0 cm (range 1.2-7.0 cm) and of the SI 4.0 cm (range 
1.0-7.0 cm). In 64 NAC specimen (61%) ≥1 TDLUs were found, as compared to 25 SI 
specimen (24%, P<0.01). In 21 mastectomies TDLUs were found in both NAC and SI, in 
37 mastectomies TDLUs were found neither in NAC nor in SI. In 43 mastectomies TDLUs 
were merely found in the NAC, whereas in four mastectomies TDLUs were found only in 
the SI.
Median amount of total TDLUs in the NAC specimen was 2 (range 0-186) vs. 0 in the 
SI specimen (range 0-48) with a median difference of 1 TDLU (P<0.01) in paired analysis. 
Median slide areas were 15.9 cm2 (range 3.7-40.0) for NAC and 9.9 cm2 (range 0.3-57.4) 
for SI. With adjustment for slide areas, TDLU density was 0.2/cm2 in the NAC (range 0.0-
8.5) vs. 0.0/cm2 in the SI (range 0.0-0.5; P<0.01).
Anatomically, in the NACs most TDLUs (95%) were located in breast stroma and only 
3% of TDLUs in the fat tissue. In contrast, in the SIs only 33% of TDLUs was located in 
breast stroma and 66% of TDLUs in the fat tissue. Location of TDLUs in the dermis was 
rare (2% in NACs and 1% in SIs).
Presence of Tdlus in the nipple-areola complex (nAC)
The influence on the presence of TDLUs in the NAC of the variables age, menopausal 
status, BRCA1/2 mutation status, history of chemotherapy, parity, breastfeeding, body 
mass index (BMI), breast size and participating hospital was assessed by univariable 
logistic regression analysis (Table 2). Age and BMI were entered as continuous variables. 
TDLU’s behind the nipple-areola and skin
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Table 1. Patient and mastectomy characteristics
Mastectomies (n) 105  
unilateral 75 (71%)
bilateral 30 (29%)
Age, years (median, range) 49 (26-86)
Genetic status    
BRCA1/BRCA2 gene mutation 32 (30%)
No gene mutation or not tested 73 (70%)
Menopausal status    
Pre- 35 (33%)
Peri-* 6 (6%)
Post- 45 (43%)
Bilateral salpingo-oophorectomy (premenopausal) 14 (13%)
Not known 5 (5%)
Chemotherapy    
neoadjuvant; for ipsilateral breast cancer 4 (4%)
history of; for contralateral breast cancer 9 (8%)
history of; for other malignancy 4 (4%)
none 88 (84%)
Nullipara** 16  
Para** 57  
number of children (median, range) 2 (1-7)
Unknown 32  
History of breastfeeding    
Yes 32 (30%)
months of breastfeeding (median, range) 4 (0.3-18)
No 28 (27%)
Not known 45 (43%)
Body Mass Index, kg/m2 (median, range) 26.1 (18.2-50.1)
Breast size    
Small (AA-B) 21 (20%)
Large (≥ C) 42 (40%)
Unknown 42 (40%)
Mastectomies included per hospital    
1 64 (61%)
2 18 (17%)
3 4 (4%)
4 19 (18%)
Diameters measured before excision, cm (median, range)    
nipple-areola complex (NAC) 4.0 (1.2-7.0)
skin-island (SI) 4.0 (1.0-7.0)
*Perimenopausal status: defined as a reported changed or irregular menstrual cycle around the age of 50
**Nullipara=no childbirth; para=≥1 childbirth
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After univariable analysis the variables age, menopausal status, parity and breastfeeding 
and the interaction variable ‘age x menopausal status’ were entered in the multivariable 
model. Risk factors for presence of TDLUs in the NAC were younger age (OR 0.93; 95%CI 
0.89-0.98) and parity (≥1 childbirths as compared to nullipara, OR 7.6; 95%CI 1.8-32.3).
Table 2. Univariable and multivariable logistic regression analyses of factors influencing the presence of 
TDLUs in nipple-areola complex (NAC)
 
 
Univariable   Multivariable#  
OR 95% CI P OR 95% CI P
Age* 0.95 0.93-0.98 <0.01 0.93** 0.89-0.98 <0.01
Menopausal status            
Postmenopausal 1.0          
Pre- or perimenopausal 3.4 1.4-8.4 0.01 1.5** 0.3-8.9 0.65
History of chemotherapy (vs. no) 1.2 0.4-3.6 0.77      
BRCA1/2 gene mutation (vs. no) 2.0 0.8-4.9 0.14      
Parity            
Nulliparous 1.0          
1 or more children 4.3 1.3-13.7 0.01 7.6** 1.8-32.3 <0.01
Breastfeeding (vs. no) 3.0 1.0-8.9 0.05 1.7** 0.3-8.7 0.53
Body Mass Index* 1.0 0.9-1.1 0.93      
Breast size            
Large (≥ C) 1.0          
Small (AA-B) 1.5 0.5-4.8 0.46      
Hospital of mastectomy            
1 1.0          
2 0.8 0.3-2.3 0.63      
3 0.2 0.0-1.7 0.13      
4 0.4 0.2-1.2 0.12      
# Interaction term Age x menopause was included.
OR= Odds Ratio; 95%CI= 95% Confidence Interval
*Entered in the model as continuous variable; i.e. presented OR is per year of increasing age
**Variables included in multivariable analysis: age, menopausal status, parity, breastfeeding
dISCuSSIOn
BRCA1/2 mutation carriers have the option to undergo prophylactic bilateral mastec-
tomy and breast reconstruction in order to reduce breast cancer risk. Sparing the nipple-
areola complex (NAC) is an alternative to skin-sparing mastectomy, which is thought 
to be oncologically safe. To estimate safety of the NAC (and skin) sparing technique we 
assessed presence and quantities of TDLUs behind the NAC as compared to the skin in 
women undergoing a prophylactic skin-sparing mastectomy or a therapeutic mastec-
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tomy. We compared the amount of TDLUs behind NAC and skin which would remain if 
NAC and skin had been spared. Since NAC and SI were surgically dissected as in NSM, 
results are clinically applicable.
Quantities of TDLUs in NAC and SI were analyzed pairwise to correct for possible influ-
ences on breast gland development and TDLUs such as patient related factors, hormonal 
factors and chemotherapy. Amounts of TDLUs were presented per cm2 of slide surface 
areas of NAC or SI to correct for differences in size at excision (Figure 5). Median TDLU 
density was higher in NACs (0.2/cm2) as compared to SIs (0.0/cm2; P<0.01).
Several studies have reported on TDLUs in the NAC or behind the skin15-17, 20, 24. Reyn-
olds et al. found TDLUs in only 24% of examined NACs, compared to 60% of NACs in 
this series. The NACs were retrieved ex vivo from mastectomy specimens, possibly using 
more shallow incisions creating thinner NACs as compared to our study with in vivo dis-
section of the NAC (and skin island)15. Stolier et al. found TDLUs in 3 of 32 (9%) nipples 
and recently Kryvenko et al. found TDLUs in 17 of 65 (26%) examined nipples16, 17. In 
these two studies, however, only the nipple-papilla was examined after transection at 
its basis. Nipple-basis and areola, possibly containing more TDLUs than the papilla, were 
not analyzed. One study evaluated 42 skin flaps that would have remained after SSM 
and that presumably were considerably larger than the SIs in the current study. Conse-
quently, the authors found TDLUs in almost 60% of the skin flaps, in contrast with our 
study with TDLUs in 22% of SIs. They found that presence of TDLUs behind the skin flap 
was associated with a skin flap thicker than 5 mm20. In general, differences of our results 
with existing literature may partly be explained by differences in dissection methods. In 
our dissection method we took the viability of the spared NAC or SI into account, while 
trying to macroscopically remove all breast tissue. The observation that, microscopically, 
only 2% of TDLUs in the NAC and 1% in the SI were located in the dermis supports the 
idea that a thinner dissection minimizes remaining TDLUs.
Risk factors for presence of TDLUs were a younger age and a history of lactation (Table 
2), but not BMI or breast size. We hypothesized that a smaller breast size and/or a lower 
BMI might be risk factors because the ratio breast glandular tissue/adipose tissue may 
be larger, resulting in a higher density of TDLUs. However, breast size and BMI did not 
significantly influence the presence of TDLUs behind the NAC. Hypothetically, adipose 
tissue is located more peripherally in the breast, while the concentration of breast glan-
dular tissue centrally behind the nipple is independent of the amount of adipose breast 
tissue25. The highest number of TDLUs behind the NAC (186 TDLUs) was found in a 26-
year old woman who had one child and who had recently lactated for 18 months (results 
not shown). Lactation and young age were risk factors for TDLU presence in the NAC. 
Moreover, this specific NAC was very large with a diameter of 7.0 cm (median diameter 
of the NAC was 4.0, range 1.2-7.0). All these factors may have contributed to this high 
amount of TDLUs. The next highest number of TDLUs we found was 121 in a NAC of 7.0 
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cm belonging to a 40-year old patient with two children and a history of lactation of 
three months (results not shown).
Since breast cancer risks in high-risk patients such as BRCA1/2 mutation carriers do 
not necessarily diminish by increasing follow-up time, the strongest evidence for on-
cological safety of NSM can be retrieved by a study with long or lifetime follow-up after 
risk-reducing mastectomies. The Rotterdam series recently published by Heemskerk-
Gerritsen et al. reported no primary breast cancers after 6.3 years median follow-up of 
424 prophylactic mastectomies7. Of these, 40 were NSMs with a median follow-up of 
3.3 years (unpublished data). As an alternative approach, we assessed the amount of 
glandular tissue remaining at risk for breast cancer if it would be a prophylactic NSM. 
Comparable amounts of TDLUs behind NAC and skin would suggest comparable breast 
cancer risks after NSM and SSM. As we found significantly more TDLUs behind the NAC 
as compared to the SI, that conclusion seems not applicable. On the contrary, our results 
show that TDLU density is higher behind the NAC than behind the SI and that sparing the 
NAC hypothetically may be less safe than sparing only the skin-envelope. However, the 
clinical relevance of these differences in TDLUs is unknown and must be placed into per-
spective for various reasons. First, it is unclear how many TDLUs the female breast gland 
comprises in total. Breast gland development and amounts of TDLUs may vary broadly 
inter-individually. The amounts of TDLUs we found behind NAC and SI are absolute, but 
their proportion to the total of TDLUs removed during NSM is unknown. Concerning 
pathological measurements, the quantity of TDLUs may be observer dependent. The 
two involved breast pathologists participating in this study (C.v.D. and P.W.) obtained 
consensus on TDLU quantity measurement and specification of TDLU location.
Second, in this study skin islands were examined, representing only part of the skin 
fold. This was an important weakness of our study. Because of the pyramid shaped 
breast gland TDLU density may decrease more peripherally in the skin fold. However, 
the total area of the spared skin fold, including the periareolar skin, is up to a few times 
larger than the skin island we excised (with a median diameter of 4.0 cm) and therefore 
is likely to contain more TDLUs than we found in the skin island. This may assume that 
the difference in remaining TDLUs between NAC and skin is actually smaller than we 
found. Third, primary breast cancers occasionally do occur after prophylactic NSM (and 
SSM), but are mostly located in the axillary tail or in the upper-outer quadrant of the 
breast and very rarely in the NAC. In the rare event of a developing malignancy after 
NSM, a superficially located tumor of the skin or NAC combined with closely underly-
ing breast prosthesis might be easily detectable at physical examination, contrasting 
tumors of the axilla. During mastectomies it is not always easy to grossly identify the 
lateral edge of the breast gland and therefore glandular tissue may remain near and in 
the axilla26, 27. Sacchini et al. reported two new breast cancers located in the axillary tail 
and the outer upper quadrant after 24.4 and 61.8 months of follow-up, respectively, in 
TDLU’s behind the nipple-areola and skin
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a series of 124 prophylactic NSMs with a mean follow-up of 24.6 months28. Hartmann et 
al. reported 6 primary breast cancers and 1 metastasis in a large series comprising 1146, 
partially nipple-sparing, prophylactic mastectomies, in moderate and high risk patients 
with a median follow-up of 14 years: 1 breast cancer in the NAC after 6 years follow-up 
and 1 above the areola after 5 years, while the other 4 were located near the chest wall 
or elsewhere in the neo-breast29. Another more recent article on 330 prophylactic NSMs 
described no new breast cancers after a mean follow-up of 22 months. Unfortunately, 
BRCA1/2 mutation status in these series was unknown or not reported. Studies reporting 
prophylactic NSM in BRCA1/2 mutation carriers are scarce and an overview is given in 
Table 3. In summary, in eight studies containing a total of 232 prophylactic NSMs in 
BRCA1/2 mutation carriers with mean follow-up ranging between 10 and 63 months, no 
primary breast cancers were found.
Table 3. Overview of literature describing prophylactic nipple-sparing mastectomies (NSMs) in BRCA1/2 
gene mutation carriers
Author & year Total no. 
NSMs
No. of 
prophylactic 
NSMs in 
established 
BRCA1/2+
Follow-up 
(months)
Primary breast cancers 
after prophylactic NSM
Primary 
breast 
cancers 
located in 
NAC or skin
de Alcantara et al. 2011 19 353 44 10.4 0 0
Harness et al. 2011 28 60 7 18.5 0 0
Heemskerk-Gerritsen et al. 
2013* 7
40 40 62.8 0 0
Peled et al. 2013 29 212 52 51.4 0 0
Spear et al. 2011 20 162 36 43 1 metastasis of 
unknown primary after 
9 years, BRCA1/2 status 
unknown
0
Voltura et al. 2008 30 51 4 18 0 0
Warren Peled et al. 2012 31 657 38 28 0 0
Wijayanayagam et al. 2008 32 64 11 NR 0 0
NSM= nipple-sparing mastectomy; NAC= nipple-areola complex; NR= not reported
* Unpublished data
Since breast cancer incidences after NSM and SSM are very low, studies not only with 
long follow-up but also with a large study population are needed to possibly find a 
significant difference in risk reduction between NSM and SSM. Furthermore, very few 
studies assessed and report superiority of NSM in cosmetic outcome and quality of life 
as compared to SSM combined with nipple reconstruction 12. Therefore, more studies are 
warranted to compare patient reported outcomes after both procedures.
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Important strengths of our study concern the clinical applicability of the results be-
cause of in vivo dissection of NAC and SI by experienced breast surgeons. Additionally, 
breast pathologists had consensus about quantitation of TDLUs. And finally our paired 
analysis corrected for patient-related influences of breast gland development.
In summary, it is important that physicians and patients opting for NSM are aware 
that NACs may harbor risk for developing breast cancer, albeit very small. However, this 
may also apply to the spared skin and possibly even more for the lateral quadrants and 
the axillary tail. To obtain quantification of additional breast cancer risk after NSM for 
prophylactic indications as compared to SSM large studies with long follow-up are war-
ranted.
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AbSTRACT
Purpose Lacking a comprehensible and widely applicable Dutch test to assess body 
image changes in cancer patients, we validated Hopwood’s Body Image Scale (BIS) for 
the Dutch language.
Methods The BIS consists of 10 items scored 0-3. Total scores range from 0 (minimum 
body image-related distress) to 30 (maximum distress). After forward and backward 
translation of the BIS we evaluated its psychometric characteristics in breast cancer pa-
tients. We assessed feasibility by missing answer rates and positive response prevalence 
(score ≥1) per item (criterion ≥30%), test-retest reliability with a two-week interval, inter-
nal consistence using Cronbach’s α and discriminant ability by comparing body image 
after breast-conserving therapy (BCT) versus mastectomy.
Results Psychometric evaluation of 108 BCT and 101 mastectomy patients showed 
high feasibility (0.2% missing answers), high positive response prevalence of ≥30% in 
9/10 items and high internal consistency (α>0.90). Test-retest reliability and correlation 
were high with 5.78 (test) vs. 5.75 (retest; P=0.86) and Spearman’s ρ=0.92 (P<0.01). 
Discriminant ability was good with BIS scores of 4.56 after BCT vs. 7.19 after mastectomy 
(P<0.01). All results were comparable to the results of the original BIS.
Conclusion The Dutch translated BIS showed excellent psychometric results very similar 
to the original BIS. Its concise and simple design further supports wide application in 
clinical practice.
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InTROduCTIOn
Health care quality indicators are increasingly determined by patient-reported outcome 
measures (PROMs). Commonly used PROMs are quality of life (QoL) assessments of which 
body image is one of the presumed determinants1, 2. Several types of cancer and cancer 
treatments may cause body image changes. The majority of studies assessing body im-
age changes in cancer patients have focused on breast cancer patients3-6 but other types 
of cancer are likely to induce body image distress as well1, 7-9. Lacking a comprehensible 
and widely applicable Dutch test to assess body image changes in cancer patients, we 
validated Hopwood’s Body Image Scale (BIS)10 for the Dutch language.
PATIEnTS And METHOdS
Hopwood’s body Image Scale (bIS)
The BIS assesses body image and body image changes after cancer treatment (Figure 
1). Respondents are asked to answer questions with reference to the past week. The 
scale consists of ten items including affective items (e.g. feeling “self-conscious”, “less 
feminine/masculine”, “less physically attractive”), cognitive items (e.g. dissatisfied “with 
appearance”, “with scar”) and behavioral items (e.g. “avoid people”, “difficult to look at 
yourself naked”). Response options range from “not at all” (score 0), “a little” (score 1), 
“quite a bit” (score 2) to “very much” (score 3). Question 10 (“dissatisfied with scar”) has 
an additional response option “not applicable”. Summing up the scores, a total score 
ranging from 0-30 per patient is obtained with 0 representing no distress or symptoms, 
whereas increasing scores represent increasing distress and symptoms.
Translation and adaptation of the bIS
The adaptation process was previously described by Bullinger et al11. Three Dutch native 
speakers with extensive knowledge of the English language provided a forward transla-
tion into Dutch. Emphasis was lying on conceptual equivalence using simple language, 
rather than achieving literal translation. Translators discussed difficulties with the prin-
cipal investigator until consensus was reached on one optimal Dutch formulation. Two 
native English speakers who were fluent in Dutch provided a backward translation to 
English. Both backward translations were compared with the original BIS and any dif-
ferences were analyzed. Finally, necessary adaptations of the Dutch version were made. 
The resulting version (Figure 2) was given to three patients who had been treated for 
breast cancer. They were asked to comment on readability and comprehension of the 
scale. After this last test no adaptations had to be made and the scale was administered 
to the study population for psychometric data collection.
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Appendix 1. The Dutch translation of the Body Image Scale (BIS)
  Body Image Scale items Helemaal 
niet
Een beetje Nogal Heel erg  
1.  Heeft u zich onzeker gevoeld over uw 
uiterlijk?
☐ ☐ ☐ ☐  
2.  Heeft u zich lichamelijk minder 
aantrekkelijk gevoeld door uw ziekte of 
behandeling?
☐ ☐ ☐ ☐  
3.  Bent u ontevreden geweest over uw 
uiterlijk als u aangekleed was?
☐ ☐ ☐ ☐  
4.  Heeft u zich minder vrouwelijk gevoeld 
door uw ziekte of behandeling?
☐ ☐ ☐ ☐  
5.  Heeft u moeite gehad om uzelf naakt 
te zien?
☐ ☐ ☐ ☐  
6.  Heeft u zichzelf seksueel minder 
aantrekkelijk gevoeld door uw ziekte of 
behandeling?
☐ ☐ ☐ ☐  
7.  Heeft u andere mensen vermeden 
vanwege hoe u zich voelde over uw 
uiterlijk?
☐ ☐ ☐ ☐  
8.  Heeft u het gevoel dat de behandeling 
uw lichaam minder compleet heeft 
gemaakt?
☐ ☐ ☐ ☐  
9.  Bent u ontevreden geweest over uw 
lichaam?
☐ ☐ ☐ ☐  
10.  Bent u ontevreden geweest over hoe 
uw litteken eruit ziet?
☐ ☐ ☐ ☐ n.v.t.☐
n.v.t.: niet van toepassing
Study population and data collection
We chose to conduct psychometric evaluation in breast cancer patients, since this sub-
group of patients is relatively large, homogeneous and likely to have body image related 
distress due the type of surgery. The fact that the original version was (partly) validated 
in breast cancer patients easies the comparison10. Female breast cancer patients ≥18 
years who visited our outpatient clinic for follow-up were eligible. We aimed to include 
100 breast conserving therapy (BCT) and 100 mastectomy patients. Exclusion criteria 
were breast reconstruction after mastectomy and insufficient knowledge of the Dutch 
language. In order to determine test-retest reliability, participants were asked to com-
plete the Dutch BIS twice with a two-week interval. Patients who had to undergo breast 
cancer treatment between the test and the retest or who did not return the second copy 
by mail were excluded. Medical ethical board approval was obtained. All participants 
gave written informed consent.
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validation
The SPSS computer package (version 20.0) was used for statistical analyses. Psychomet-
ric results are compared to the results of the psychometric evaluation of the final version 
of the original BIS.
Feasibility
Missing or non-unique responses (0 or >1 box ticked, respectively) were considered 
invalid. Questionnaires with <9/10 valid responses to all items were excluded from 
analyses. When one item was not answered, the maximum score possible at that item 
was subtracted from the maximum achievable score of the scale (30 points). A valid 
score was calculated by dividing the achieved total score by the new maximum score 
and multiplying this by 30. Feasibility of the scale was evaluated by response rates and 
missing answers. Response prevalence was defined as the frequency of positive ratings 
(score of ≥1) for each item, indicating a change in some aspect of body image. Per item 
a criterion of ≥ 30% of positive ratings of the total sample was used.
Reliability
To assess whether items evaluate the same concept (e.g. body image) internal consis-
tency of scale items was measured using Cronbach’s α, which should exceed 0.7012. 
Test-retest reliability was tested using Spearman’s correlation coefficient rho (ρ), paired 
Student’s T-tests and effect size (Cohen’s d=0.2: small effect, d=0.5: medium effect and d 
>0.8: large effect size)13, 14.
Clinical validity
Discriminant ability between lumpectomy and the mastectomy subgroups was assessed 
using Student’s T-tests and effect size13, 14.
RESulTS
Response rates and feasibility
Both questionnaires were returned by 108/150 BCT patients (72%) and by 101/150 mas-
tectomy patients (67%; Table 1). In both questionnaires, a total of 0.2% of all answers 
was missing. There were no non-unique answers. None of the questionnaires had >1 
invalid responses. All items reached the 30% response prevalence criterion, except for 
item 7 (‘avoid people because of the way you felt about your appearance?’) which had a 
response prevalence of 12%. In the first version of the original BIS, three items including 
item 7 had a response prevalence of ≤30%, which decreased to zero items in the final 
version10.
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Table 1. Hopwood’s Body Image Scale (BIS)
Body image scale items Not at all A little Quite a bit Very much  
1.  Have you been feeling self-conscious 
about your appearance?
☐ ☐ ☐ ☐  
2.  Have you felt less physically attractive as 
a result of your disease or treatment?
☐ ☐ ☐ ☐  
3.  Have you been dissatisfied with your 
appearance when dressed?
☐ ☐ ☐ ☐  
4.  Have you been feeling less feminine/
masculine as a result of your disease or 
treatment?
☐ ☐ ☐ ☐  
5.  Did you find it difficult to look at 
yourself naked?
☐ ☐ ☐ ☐  
6.  Have you been feeling less sexually 
attractive as a result of your disease or 
treatment?
☐ ☐ ☐ ☐  
7.  Did you avoid people because of the 
way you felt about your appearance?
☐ ☐ ☐ ☐  
8.  Have you been feeling the treatment 
has left your body less whole?
☐ ☐ ☐ ☐  
9.  Have you felt dissatisfied with your 
body?
☐ ☐ ☐ ☐  
10.  Have you been dissatisfied with the 
appearance of your scar?
☐ ☐ ☐ ☐ N/A ☐
N/A: not applicable
Test-retest reliability and internal consistency
Test-retest reliability was high. Mean BIS scores were 5.78 (95%CI 4.97-6.59) in Ques-
tionnaire 1 vs. 5.75 (95%CI 4.93-6.57) in Questionnaire 2 (P=0.86). This is in line with 
the outcomes of the original BIS with test-retest scores of 8.1 and 9.0, respectively, in 
the breast subgroup10. Correlation between the questionnaires was high for total BIS 
score (ρ=0.92; P<0.01) as well as for all items (Table 2), comparable to the correlation 
coefficient of the original BIS (ρ=0.70; P<0.01)10. Test-retest effect size was low (Cohen’s 
d=0.005). Both questionnaires showed high internal consistency with Cronbach’s α of 
0.91 and 0.92, respectively, similar to the 0.93 of the original BIS10.
Validation of the Dutch Body Image Scale
145
Table 2. Patient characteristics
  BCT group Mastectomy group
Total patients 108   101  
Age, years (median, range) 59.0 (32.0-82.0) 60.0 (33.0-92.0)
Follow-up since surgery, years (median, range) 4.0 (1.0-13.0) 4.0 (1.0-20.0)
History of        
Chemotherapy 52 (49%) 65 (65%)
Radiotherapy 97 (91%) 39 (39%)
Hormonal therapy 49 (46%) 60 (61%)
BCT: Breast conserving therapy
Clinical validity: discriminant ability between breast conserving therapy and 
mastectomy
Mean total BIS scores of both questionnaires were 4.56 (95%CI 3.49-5.41) in the BCT 
group and 7.19 (95%CI 5.91-8.48) in the mastectomy group (P<0.01; Table 3) represent-
ing good discriminant ability. Cohen’s d was 0.47, representing medium effect size. In 
the original BIS, this difference was even more pronounced with median total scores of 
2.5 after BCT and 12.0 after mastectomy (P<0.01)10.
Table 3. Scores of Body Image Scale (BIS) items, total BIS scores and test-retest reliability
BIS item Questionnaire 1 – Test Questionnaire 2 – Retest Correlation
  Mean score 95% CI Mean score 95% CI ρ P-value1
1. 0.80 (0.69-0.92) 0.72 (0.61-0.83) 0.80 < 0.01
2. 0.80 (0.68-0.92) 0.79 (0.68-0.91) 0.80 < 0.01
3. 0.40 (0.30-0.49) 0.39 (0.30-0.47) 0.68 < 0.01
4. 0.59 (0.47-0.70) 0.51 (0.40-0.61) 0.74 < 0.01
5. 0.59 (0.47-0.71) 0.65 (0.52-0.77) 0.80 < 0.01
6. 0.70 (0.58-0.82) 0.75 (0.62-0.87) 0.80 < 0.01
7. 0.17 (0.10-0.24) 0.17 (0.11-0.24) 0.63 < 0.01
8. 0.65 (0.54-0.76) 0.63 (0.52-0.75) 0.73 < 0.01
9. 0.63 (0.53-0.74) 0.67 (0.56-0.78) 0.72 < 0.01
10. 0.45 (0.34-0.56) 0.47 (0.36-0.58) 0.79 < 0.01
Total BIS 5.78 (4.97-6.59) 5.75 (4.93-6.57) 0.92 < 0.01
95% CI: 95% Confidence Interval; ρ: Spearman’s correlation coefficient ρ
1P-value of Spearman’s correlation coefficient
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Table 4. Discriminative ability of the Body Image Scale (BIS)
 
 
BCT group Mastectomy  
Total BIS score of   N= 108 N=101  
  N Mean score 95% CI Mean score 95% CI P-value
All questionnaires 418 4.56 (3.85-5.26) 7.05 (6.16-7.94) < 0.01
Questionnaire 1 – Test 209 4.45 (3.49-5.41) 7.19 (5.91-8.48) < 0.01
Questionnaire 2 – Retest 209 4.66 (3.61-5.71) 6.90 (5.65-8.16) < 0.01
BCT: Breast conserving therapy
dISCuSSIOn
The original BIS was developed in 2000 in the United Kingdom for use in clinical trials 
to assess body image changes in cancer patients, resulting from changes in a patient’s 
appearance due to cancer treatment10. The scale assesses affective, behavioral and cog-
nitive changes corresponding with a multidimensional approach of body image15-17. We 
validated the Dutch translated version of the BIS.
Psychometric evaluation of the Dutch BIS showed results comparable to the original 
version. Internal consistency was high with Cronbach’s α of 0.92 and 0.91, similar to the 
original BIS18. Clinical validity based on response prevalence indicating a change in an 
aspect of body image also was comparable to the original tool10. Only one item, ‘avoid-
ance of other people because of the way a patient feels about his or her appearance’, 
failed to reach the response prevalence criterion of ≥30% compared with none of the 
items in the original version10. This item indeed addresses an issue of body image likely 
not frequently impacted in breast cancer patients because the breast surgical area is 
hidden in most social situations. Discriminant ability was moderate to good between 
breast cancer patients treated by mastectomy and BCT, representing two groups with 
expected differences in body image changes. BIS scores differed significantly between 
the groups but the effect size was only moderate. The discriminant ability between BCT 
and mastectomy was comparable to the original BIS, although the difference between 
the two groups was larger in the original tool10. A possible explanation for the moderate 
effect size is that body image distress may not simply be related to the amount of breast 
tissue visibly removed during surgery. For example, body image distress is also found 
to be highly impacted after mastectomy followed by direct breast reconstruction3. Both 
the original and the Dutch BIS showed high test-retest reliability10.
A limitation of this study was the fact that many women did not return the second 
questionnaire and were excluded, most likely due to unawareness that it was important 
to complete the same questionnaire twice. Comprehensibility of the scale did not seem 
to be a problem since rates of missing or non-unique answers were very low. After start-
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ing to emphasize on the importance of the second questionnaire at inclusion, response 
rates improved.
Potential future applications of the BIS include its use as a health care quality indica-
tor, for example in combination with assessment of QoL or satisfaction with care. Health 
care quality indicators, however, are not yet well-defined19, 20. To our knowledge, the BIS 
is not yet being implemented for assessment of quality of care. Potential applications 
of interest include screening for body image-related issues after cancer surgery and 
evaluation of treatment effects after psychological therapy or reconstructive surgery. 
Before the BIS can be used for evaluation of treatment effects, however, further specific 
validation is warranted.
To conclude, psychometric evaluation of the Dutch BIS showed excellent results that 
were comparable those of the original version. The concise and simple design makes 
the Dutch BIS suitable for assessment of body image issues in routine clinical practice.
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AbSTRACT
background Prophylactic skin-sparing mastectomy (SSM) and nipple-sparing mastec-
tomy (NSM) both are associated with major risk reduction in women with high breast 
cancer risk. SSM followed by nipple areola complex (NAC) reconstruction is standard 
of care, but NSM is increasingly being performed. Preservation of the NAC in NSM may 
increase patient satisfaction. Therefore, we measured NAC sensitivity after NSM and 
compared patient satisfaction as well as body image after SSM with NSM.
Methods Women who underwent prophylactic bilateral SSM or NSM and immediate 
implant breast reconstruction between 2002 and 2012 were eligible. Patient satisfac-
tion was assessed using the Breast-Q Reconstruction questionnaire, body image using 
Hopwood’s Body Image Scale (BIS) and satisfaction with the (reconstructed) NAC using 
a study-specific questionnaire. In the NSM group, NAC sensitivity was assessed using 
Semmes Weinstein monofilaments with a five-point scale and compared with NAC 
sensitivity in a non-operated control group.
Results The SSM group comprised 25 women (50 SSMs) and the NSM group 20 women 
(39 NSMs). Median follow-up was 65 months in the SSM group compared with 27 
months in the NSM group (p<0.01). In univariable analyses, Breast-Q scores were favor-
able in the SSM group compared with the NSM group with trends for higher ‘satisfaction 
with breasts’ (66.2 vs. 56.6; p=0.06) and ‘satisfaction with outcome’ (76.1 vs. 61.5; p=0.09). 
Mean BIS score of 7.1/30 in the SSM group and 9.3/30 in the NSM group (p=0.35). Ad-
justed for follow-up, there were no significant differences in Breast-Q scores, nor in BIS 
scores. Interestingly, satisfaction with the (reconstructed) NAC was similar after SSM 
and NSM. NAC sensitivity was lower in the NSM group (mean score 1.9, 95%CI 1.5-2.3) 
compared with the control group (mean score 4.7, 95%CI 4.6-4.9; p<0.01).
Conclusion Breast-Q scores regarding satisfaction with breasts and overall outcome 
were in favor of the SSM group. Residual NAC sensitivity after NSM was low. This suggests 
that SSM followed by NAC reconstruction is a balanced alternative to NSM. We observed 
no significant differences in body image and NAC-specific satisfaction between the NSM 
and SSM groups.
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InTROduCTIOn
BRCA1 and BRCA2 gene mutation carriers and other women at high breast cancer risk 
may choose to undergo prophylactic bilateral mastectomy, achieving risk reductions 
of 90-100% after 3-13 years of follow-up1-5. Skin-sparing mastectomy (SSM) and nipple-
sparing mastectomy (NSM) are frequently used (Figures 1 and 2). Both procedures aim 
to remove all breast glandular tissue while sparing the breast skin envelope to allow 
for immediate breast reconstruction. In SSM, breast glandular tissue is subcutaneously 
excised together with the nipple-areola complex (NAC). In a later stage, SSM can be fol-
lowed by NAC reconstruction using local skin flaps and intradermal tattooing6. In NSM, 
the same subcutaneous procedure is carried out as in SSM while the NAC is left in situ 
together with the skin envelope.
figure 1. Outcomes after skin-sparing mastectomy (SSM) and breast reconstruction by tissue expander 
and implant followed by reconstruction of the nipple-areola complex (NAC).
A A 24-year old patient 28 months after SSM and immediate breast reconstruction and 17 months after 
NAC reconstruction. An Allergan style 133 textured, anatomically shaped tissue expander filled with 420 cc 
was used, followed by Allergan style 410 medium height, full projection implants of 295 cc.
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b A 35-year old patient 24 months after SSM and immediate breast reconstruction and 12 months after 
NAC reconstruction. An Allergan style 133 textured, anatomically shaped tissue expander filled with 800 cc 
was used, followed by Allergan style 410 full height, extra full projection implants of 690 cc.
Preservation of the NAC potentially may improve aesthetic outcome and patient sat-
isfaction7-9. However, oncological safety of NSM is still subject to debate especially in 
women with high breast cancer risk. SSM on the other hand is generally considered 
oncologically safe for breast cancer prophylaxis, although no prospective randomized 
controlled trials have been conducted1-5, 10. Various authors, including our own group, 
have described remaining breast glandular tissue behind the NAC potentially forming a 
life-long breast cancer risk11-13. Studies with long-term follow-up after NSM in BRCA1/2 
mutation carriers are scarce. So far, data suggest that the incidence of primary breast 
cancer behind the NAC following prophylactic NSM is negligible14, 15. During the past 
years the proportion of prophylactic NSMs performed at our institute has steadily in-
creased.
Although blood supply of the NAC can be preserved by the dermal plexus as well as 
residual subcutaneous tissue, partial or full thickness necrosis of the NAC is reported 
to occur in 11-30%. This can lead to scarring, pigmentation changes, loss of projection 
or the need for total removal of the NAC15-18. Other complications of NSM include mal-
position or asymmetry of the NACs (14-70%) and decreased NAC sensitivity16, 19. As an 
alternative to NAC-sparing, SSM followed by nipple reconstruction avoids NSM-related 
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complications and aims to achieve at least comparable results in patient satisfaction 
and aesthetic outcome. Disadvantages of nipple reconstruction are the need for an ad-
ditional surgical intervention, loss of nipple projection and fading of the tattooed areola 
over time6.
The primary aim of this study was to assess satisfaction, body image and satisfaction 
with the spared or reconstructed NAC in women at high breast cancer risk after prophy-
lactic SSM as compared with prophylactic NSM. The secondary aim was to measure NAC 
sensitivity after NSM, compared with healthy controls.
PATIEnTS And METHOdS
Patients
Women who underwent prophylactic SSM or NSM between 2002 and 2012 followed by 
immediate tissue expander-implant breast reconstruction with a follow-up period ex-
ceeding 12 months since mastectomy and who had completed the entire breast recon-
struction course were eligible for inclusion. Participants were retrospectively collected 
from a prospective cohort study on prophylactic mastectomy or during outpatient 
follow-up visits for the cross-sectional questionnaire study and, in case of NSM, for NAC 
sensitivity examination. Demographics and data on smoking, body mass index (BMI), 
oncological history, history of radiation or chemotherapy, surgical techniques and post-
operative complications were retrospectively collected from medical charts. Incisions 
and operative techniques were at the discretion of the oncological and plastic surgeon 
and mostly consisted of a circumareolar incision with caudal extension if necessary in 
SSM and a periareolar infero-lateral incision with caudal extension or inframammary 
incision in NSM (Figure 2A and B). In accordance with local protocol, Allergan style 133 
textured, anatomically shaped tissue expanders with integrated Magna-Site injection 
site, followed by style 410 textured, highly cohesive anatomically shaped silicone-filled 
breast implants were used for breast reconstruction. Implant size, projection, height and 
width depended on preoperative patient dimensions and were at the discretion of the 
plastic surgeon.
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figure 2. Nipple-sparing mastectomy (NSM) and immediate breast reconstruction in a 37-year old patient. 
An Allergan style 133 textured, anatomically shaped tissue expander filled with 520 cc was used, followed 
by Allergan style 410 full height, full projection implants of 465 cc.
A Latero-inferior incisions preoperatively, b shortly postoperatively, C and d outcome 6 months after NSM 
and breast reconstruction and 2 months after definitive implant placement.
Women were asked to participate during an outpatient clinic visit or by telephone. The 
institutional Medical Ethical Board approved the study. All participants signed informed 
consent forms for completion of questionnaires and in the NSM group for additional 
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examination of NAC and breast sensitivity. A control group for sensitivity of NAC and 
periareolar skin consisted of healthy female volunteers without a history of breast 
surgery.
Primary outcomes: patient reported outcomes
Women in the SSM and NSM groups were asked to complete three questionnaires at 
home and to return them anonymized by mail. Questionnaires were administered at the 
outpatient clinic or sent by mail. The Breast-Q reconstruction module assesses breast 
reconstruction-related quality of life (QoL) and satisfaction20. In this study, 5 of the 19 in-
dependent Breast-Q scales were used: (1) ‘satisfaction with breasts’, 16 items measuring 
satisfaction with appearance clothed and unclothed, with breast shape and symmetry; 
(2) ‘satisfaction with outcome’, 7 items assessing whether a patient’s expectations of the 
breast surgery are met; (3) ‘psychosocial well-being’, 10 items rating a patient’s social 
confidence, how normal and how equal to other women she feels; (4) ‘sexual well-being’, 
6 items addressing the impact of the breast surgery and reconstruction on her sex 
life; and (5) ‘physical well-being’, 16 items on how often a patient experiences pain or 
discomfort in the breast area and the upper body. Additionally, Hopwood’s Body Image 
Scale (BIS; Figure 3) consists of 10 questions concerning body image with four response 
options per question: “not at all” (score 0), “a little” (score 1), “quite a bit” (score 2) and “very 
much” (score 3)21. A total score ranging from 0-30 was obtained, where 0 represents no 
distress or symptoms while higher scores represent increasing symptoms and distress. 
To assess patient satisfaction with the spared or reconstructed NAC, subjective NAC 
sensitivity and the role of NAC and breast in sexuality, we administered a NAC-specific 
questionnaire comprising 8 items for the SSM group and 9 items for the NSM group that 
were scored on a 5-point Likert scale (Figure 4). One open-ended question was added 
to explore other factors that could have influenced patient feelings about their breast 
reconstruction, about the spared or reconstructed NAC and about changes in sexuality.
Did you/ Have you been feeling: Not at 
all 
A 
little 
Quite 
a bit 
Very 
much 
 1. Self-conscious about appearance? - - - - 
 2. Less physically attractive as a result of disease or treatment? - - - - 
 3. Dissatisfied with appearance when dressed? - - - - 
 4. Less feminine as a result of disease or treatment? - - - - 
 5. Find it difficult to look at yourself naked? - - - - 
 6. Sexually less attractive as a result of disease or treatment? - - - - 
 7. Avoid people because of how you felt about your appearance? - - - - 
 8. That the treatment has left your body less whole? - - - - 
 9. Dissatisfied with your body? - - - - 
10. Dissatisfied with the appearance of your scar? - - - - 
	
figure 3. Hopwood’s Body Image Scale (BIS)
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  1 2 3 4 5 
1 NAC sensitivity compared with 
before the operation 
insensitive 
 
less 
sensitive 
 
the same 
 
very 
sensitive 
 
hypersensitiv
e 
2 Significance of breast for sexuality 
a) Before operation 
 
b) Now 
unimportant not very 
important 
neither important 
or unimportant 
important very 
important 
3 Significance of NAC for sexuality 
a) Before operation 
 
b) Now 
unimportant not very 
important 
neither important 
or unimportant 
important very 
important 
4 Did sexual pleasure change since the 
operation because of loss of NAC 
sensitivity? 
absent decreased 
a lot 
substantial 
decrease 
a little 
decrease 
unchanged 
5 Touching of the NAC is very 
unpleasant 
unpleasant neither pleasant 
nor unpleasant 
pleasant 
 
very pleasant 
6 Change of nipple reaction to cold or 
touch* 
no reaction a lot 
weaker 
weaker hardly 
changed 
unchanged 
7 a) Satisfaction with position of 
NAC on the breast 
very 
unsatisfied 
unsatisfied neither satisfied 
nor unsatisfied 
satisfied very satisfied 
 b) Not satisfied (score 1-3 in a) 
because NAC is too…                 
 
lateral 
 
caudal 
 
cranial 
 
medial 
 
N/A 
8 Would choose the same operation 
again 
certainly not probably 
not 
maybe probably certainly 
9 Would advise this operation to other 
women 
certainly not probably 
not 
maybe probably certainly 
	
figure 4. Nipple-areola complex (NAC)-specific questionnaire on satisfaction of the reconstructed or 
spared NAC, sensitivity and the role of the breast reconstruction and the NAC for sexuality
*Nipple-sparing mastectomy (NSM) group only
Secondary outcomes: sensitivity of the nAC and periareolar skin
In the NSM group and in the control group, tactile sensitivity was tested on 9 predetermined 
sites of NAC and surrounding skin using Semmes Weinstein monofilaments, starting with 
the thinnest and progressing to thicker monofilaments. Participants were asked to report 
touching of a monofilament with their eyes closed. Scores were ascribed per spot to the 
thinnest monofilament noticed: score 5 for the thinnest monofilament which was equiva-
lent to 0.07 grams, score 4 for 0.4 grams, score 3 for 2.0 grams, score 2 for 4.0 grams, score 1 
for 300 grams and score 0 if none of the monofilaments was noticed. Consequently, mean 
scores ranging from 0 to 5 per site and per breast were obtained, where score “0” represents 
complete absence of sensitivity and score ”5” represents maximum vital sensitivity.
Statistical analysis
Outcomes of the Breast-Q Reconstruction questionnaire, the BIS and the sensitivity tests 
were scored and analyzed as continuous variables and of the NAC-specific question-
naire as categorical variables. Missing or non-unique answers were considered invalid. 
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Breast-Q scores of the independent scales were calculated using the QScore Scoring 
Software, which provides a total score per scale that ranges from 0-100 with a higher 
score representing greater satisfaction or better quality of life20. The Shapiro-Wilk test 
was used to test for normal distribution of continuous variables. Consequently, Breast-Q 
scores were analyzed using Student’s T-tests and BIS scores and sensitivity scores were 
analyzed using Mann-Whitney U-tests. Categorical variables were analyzed using Chi-
Square tests or Fisher’s Exact tests. All p values were 2-sided and a significance level 
of α=0.05 was used. Outcomes were adjusted for differences in baseline characteristics 
with p ≤ 0.10 using multivariable linear regression. The SPSS computer package (version 
20.0) was used for statistical analyses.
RESulTS
Patients
The SSM group consisted of 25 women who underwent 50 SSMs and the NSM group 
comprised 20 women who underwent 39 NSMs (Table 1). All women had completed 
breast reconstruction with a definitive silicone implant in place at the time of inclusion. 
One patient who underwent unilateral SSM for breast cancer without NAC reconstruc-
tion and contralateral prophylactic NSM was analyzed in the NSM group. Median follow-
up was significantly longer in the SSM group (65 months, range 43-136) than in the 
NSM group (27 months, range 10-58; p<0.01). In the SSM group, 20/25 women (80%) 
underwent bilateral mastectomy for prophylactic indications; 5/25 women (20%) had a 
history or current diagnosis of breast cancer. The majority (20/25, 80%) opted for NAC 
reconstruction with local transposition flaps and intradermal tattooing. Four women 
(16%) chose reconstruction by intradermal tattooing only and one woman decided not 
to have a NAC reconstruction. Mastectomy skin flap necrosis occurred in 2/25 (8%) of 
the cases, in one case (4%) necessitating partial resection of the affected skin flap. In 
the NSM group, 15/20 women (75%) underwent bilateral mastectomy for prophylactic 
indications; 5/20 women (25%) had a history or current diagnosis of breast cancer. In 
one patient who underwent bilateral NSM one NAC was removed in a later stage after 
finding an occult malignancy in the mastectomy specimen. In another patient both 
NACs had to be removed for an occult malignancy; she was excluded from sensitivity 
examination. Partial necrosis of the NAC occurred in 7 patients (35%) after NSM; none of 
them needed secondary NAC removal. Infectious complications occurred in 6 patients 
(25%) after SSM compared with 3 (15%) after NSM. Overall rates of reoperations were 
higher in the NSM group (50%); half of them were due to an unsatisfactory aesthetic 
outcome. The control group consisted of 21 healthy, non-operated female volunteers for 
assessment of NAC sensitivity at a median age of 30 years (range 20-58).
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Table 1. Demographics, clinical characteristics and complication rates in nipple-sparing mastectomy 
(NSM) group and skin-sparing mastectomy (SSM) group
 
 
SSM group NSM group  
N (%) N (%) P
Total patients 25   20    
Median age at examination (years, range) 40 (26-71) 40 (27-60) 1.00*
BRCA1 mutation
BRCA2 mutation
BRCA1 and 2 mutation
Non-BRCA associated familial breast cancer risk
16
7
2
0
(64%)
(28%)
(8%)
-
10
5
1
4
(50%)
(25%)
(5%)
(20%)
 
Mastectomy
Bilateral prophylactic
Unilateral therapeutic, unilateral prophylactic
Bilateral therapeutic
 
20
5
0
 
(80%)
(20%)
-
 
15
3
2
 
(75%)
(15%)
(10%)
 
Median age at mastectomy and reconstruction (years, range) 34 (21-59) 37 (26-57) 0.43*
Follow-up: months from reconstruction (median, range) 65 (43-136) 27 (10-58) <0.01*
History of or current breast cancer 6 (24%) 5 (25%) 1.00**
Exposures, total
Current smoker
Chemotherapy
prior to reconstruction
after reconstruction
Radiation prior to reconstruction
10
8
 
1
2
0
(42%)
(33%)
 
(4%)
(8%)
-
6
5
 
1
1
2
(30%)
(25%)
 
(5%)
(5%)
(10%)
0.53**
Comorbity, total
Body mass index > 25
Malignancy other than breast cancer
Other
6
3
2
1
(25%)
(13%)
(8%)
(4%)
3
0
2
1
(15%)
-
(10%)
(5%)
0.48**
History of (prophylactic) oophorectomy 10 (40%) 6 (30%) 0.54**
Cup size at mastectomy
A
B
C
D
unknown
 
2
7
6
4
6
 
(10%)
(37%)
(32%)
(21%)
 
2
8
4
0
6
 
(14%)
(57%)
(29%)
-
 
0.28**
Incisions
Circumareolar with or without extension
Inferolateral periareolar with caudal extension
Inframammary
 
25
0
0
 
(100%)
-
-
 
0
15
5
 
-
(75%)
(25%)
 
N/A
Definitive implant size, cc (median, range)
unknown (n)
475
4
(295-690) 445
1
(315-620) 0.89*
Nipple reconstruction
Skin flaps and intradermal tattooing
Intradermal tattooing only
No reconstruction
 
20
4
1
 
(80%)
(16%)
(4%)
 
0
1
19
 
-
(5%)
(95%)
 
N/A
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Table 1. Demographics, clinical characteristics and complication rates in nipple-sparing mastectomy (NSM) 
group and skin-sparing mastectomy (SSM) group (continued)
 
 
SSM group NSM group  
N (%) N (%) P
Complications, total
Infection
Necrosis - partial or full-thickness - of
NAC***
Mastectomy skin flap
NAC*** loss
Due to malignancy
Due to necrosis
Other complications
9
6
 
0
2
 
0
0
1
(38%)
(25%)
 
-
(8%)
 
-
-
 
12
3
 
7
0
 
1
0
1
(60%)
(15%)
 
(35%)
-
 
(5%)
-
 
0.14**
 
Reoperations, total
For
infection
necrosis
unsatisfactory aesthetic result
other reason
7
 
5
1
0
1
(29%)
 
(21%)
(4%)
-
(4%)
10
 
3
0
5
2
(50%)
 
(15%)
-
(25%)
(10%)
0.13**
*Mann-Whitney U-test
**Chi-square test
***NAC: nipple-areola complex; spared or reconstructed
Sensitivity of nAC and periareolar skin in nSM group and control group
NAC sensitivity was tested in 19 women in the NSM group with 36 spared NACs in situ 
and in 42 NACs in the control group. Results are summarized in Figure 5. In the NSM 
group, periareolar skin flap sensitivity was best preserved on sites medial and cranial 
of the NAC with a mean score of 2.7/5.0 for both sites, compared with mean scores of 
4.9/5.0 in the control group (p<0.001). Skin sites lateral and caudal to the NAC scored 2.5 
and 2.3/5.0, respectively, compared with 4.9/5.0 for both lateral and caudal sites in the 
control group (p<0.01). In line with skin sensitivity, sensitivity of the spared areola was 
best preserved medially and cranially (1.6/5.0 for both sites) compared with the control 
group (4.5 and 4.9/5.0, respectively; <0.01). Sensitivity of the spared NAC was 1.2/5.0 
in the lateral areola and 1.3/5.0 in the caudal areola compared with 4.5 and 4.6/5.0, 
respectively, in the control group (p<0.01). Sensitivity of the nipple-papilla was 1.4/5.0 
in the NSM group compared with 4.9/5.0 in the control group (p<0.01).
body image and patient satisfaction after SSM and nSM: bIS and breast-q
In total, 22/25 (88%) of women in the SSM group and 18/20 (90%) of women in the 
NSM group returned their questionnaires after completion. Results are shown in Table 
2. In univariable analyses, BIS scores did not differ between groups with a mean score 
of 7.1 in the SSM group (95% CI 4.6-9.6) as compared with 9.3 in the NSM group (95% 
CI 6.2-12.3; p=0.24). Breast-Q scores were favorable in the SSM group compared with 
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the NSM group with trends for higher ‘satisfaction with breasts’ in the SSM group (mean 
score 66.2; 95% CI 59.0-73.4) compared with the NSM group (mean score 56.6, 95% CI 
51.6-61.6; p=0.06) and for higher ‘satisfaction with outcome’ in the SSM group (mean 
score 76.1; 95% CI 65.7-86.5) compared with the NSM group (mean score 61.5; 95% CI 
50.2-72.9; p=0.09). After adjustment for follow-up, outcomes of Breast-Q scales and BIS 
did not significantly differ between SSM and NSM groups (Table 2).
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2.3
1.61.4
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1.6
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4.9
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Control group
n=42
Sensitivity scores per site 0-5 illustrated in a right breast; left breasts are mirrored
Mean scores all sites NSM group = 1.9 (95% CI 1.5-2.3) 
    Control group = 4.7 (95% CI 4.6-4.9)
    p < 0.01
nipple-papilla
areola
peri-areolar skin
inferolateral periareolar incision in NSM
figure 5. Sensitivity of the nipple-areola complex (NAC) and the surrounding skin after nipple-sparing 
mastectomy (NSM) tested using Semmes Weinstein monofilaments, as compared with a non-operated 
control group
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Table 2. Mean scores of Body Image Scale (BIS) and Breast-Q Reconstruction Questionnaire scales after 
skin-sparing mastectomy (SSM group) and nipple-sparing mastectomy (NSM group)
 
 
SSM group NSM group  
Mean (95% CI) Mean (95% CI) Mean ∆ P Adjusted
P-value***
Body Image Scale (BIS) 7.1 (4.6-9.6) 9.3 (6.2-12.3) 2.2 0.35* 0.21
Breast-Q Reconstruction              
Satisfaction with breasts 66.2 (59.0-73.4) 56.6 (51.6-61.6) 8.4 0.06** 0.69
Satisfaction with outcome 76.1 (65.7-86.5) 61.5 (50.2-72.9) 12.3 0.09** 0.18
Psychosocial well-being 79.2 (70.7-87.6) 69.7 (59.3-80.1) 9.2 0.14** 0.28
Sexual well-being 58.1 (47.4-68.9) 53.2 (43.7-62.6) 5.0 0.48** 0.89
Physical well-being: chest 72.0 (64.1-80.0) 63.7 (55.8-71.5) 7.7 0.16** 0.73
*Mann Whitney U test; 2-sided P-values
**Student’s T-test; 2-sided P-values
***Multivariable linear regression, adjusted for follow-up time
BIS: total scores range from 0 (no distress or symptoms) to 30 (maximum distress or symptoms)
Breast-Q: scores per scale range from 0 (minimum satisfaction or quality of life) to 100 (maximum satisfac-
tion or quality of life)
nAC-specific questionnaire in the SSM and nSM group
Subjective NAC sensitivity was reported decreased or absent since mastectomy by 
17/17 women who scored sensitivity of the reconstructed NAC after SSM as compared 
with 16/18 women (89%) in the NSM group (p=0.49). Two women complained about 
NAC hypersensitivity to touch and/or cold after NSM. Before mastectomy, breasts were 
important or very important for sexuality in 15/22 women (68%) in the SSM group 
compared to 10/18 women (56%; p=0.52) in the NSM group, which decreased to 4/22 
(18%) and 4/18 (22%) after mastectomy, respectively (p=1.0). Before mastectomy, the 
NAC had been important to very important for sexuality to 13/22 women (59%) in the 
SSM group and for 10/18 women (56%) in the NSM group (p=1.0), decreasing in both 
groups to 3/18 (17%) and 2/22 (9%), respectively, after mastectomy (p=0.64). Due to the 
loss of NAC sensitivity after mastectomy sexual pleasure had substantially decreased or 
was absent in 6/22 women (27%) in the SSM group and in 6/18 women (33%) in the NSM 
group (p=0.74). Touching of the NAC by themselves or by their partners was unpleasant 
or very unpleasant for 2 women (9%) in the SSM group and 3 women (18%) in the NSM 
group (p=0.64). Still, in the NSM group, 12/18 women (67%) reported erection of the 
nipple to cold and/or touch as weaker to unchanged. In the SSM group, 4 women (19%) 
were not satisfied with the position of the (reconstructed) NAC versus 10 women (56%) 
in the NSM group (p=0.02). Of the 4 women in the SSM group who were not satisfied 
with the position of the NAC, 1 woman found the position of the reconstructed NAC too 
lateral, 1 too caudal, 1 found it too cranial and 1 did not further specify. Of the 10 women 
in the NSM group who were not satisfied with the position of the NAC, 6 specified that 
Nipple-sparing mastectomy versus skin-sparing mastectomy
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the NAC position was too lateral, 2 that it was too caudal, 1 found it too cranial and 1 did 
not further specify. If they could choose again, 18/22 women (82%) in the SSM group 
would opt for this procedure again, as compared with 17/18 women (94%) in the NSM 
group (p=0.36). In the SSM group, 16/22 women (73%) would advise an SSM followed by 
a NAC reconstruction to other women and in the NSM group 15/18 women (83%) would 
recommend to undergo an NSM to other women (p=0.48).
dISCuSSIOn
We assessed various patient reported outcomes after SSM and NSM as performed in our 
clinic in a high breast cancer risk population who chose prophylactic mastectomy for 
risk reduction. In addition, sensitivity of the NAC was compared with NAC sensitivity in a 
healthy control group. In line with the conclusion of Didier et al. in 2009 we hypothesized 
that prophylactic NSM would result in higher patient satisfaction as compared with SSM 
followed by NAC reconstruction8.
Body image did not differ significantly between the SSM and NSM groups. Body image 
scale (BIS) scores were low in most patients, representing relatively low levels of body 
image related distress, which may have been due to the fact that all patients underwent 
immediate breast reconstruction and therefore feelings of mutilation may have been 
limited22. Earlier studies, however, have reported a strong negative psychological impact 
of prophylactic mastectomy even after immediate breast reconstruction23, 24. In contrast, 
a study on delayed breast reconstruction reported improved body image25, likely be-
cause breast reconstruction was an improvement compared with the post-mastectomy 
situation. Patient satisfaction and QoL as assessed by Breast-Q scales was high26, 27 and 
did not differ between groups after adjustment for the longer follow-up in the SSM 
group. Therefore, trends for lower ‘satisfaction with breasts’ and ‘satisfaction with out-
come’ in the NSM group in univariable analysis were probably attributable to a short 
follow up, causing incomplete recovery and adaptation at the time of examination26. 
Other possible factors of influence may have been the higher rates of necrotic complica-
tions and reoperations in the NSM group (Table 1). The SSM group, on the other hand, 
comprised higher comorbidity rates, higher exposure rates to smoking, chemotherapy 
and radiation and more infectious complications. Despite these unfavorable factors, 
body image, patient satisfaction and QoL were similar in both groups.
In line with previous studies, subjective NAC sensitivity was described as minimal or 
absent by all women with NAC reconstruction and by most women after NSM28, 29. Two 
women after NSM reported an unpleasant hypersensitivity of the spared NAC to cold 
and/or touch. No differences in the role of the breast or NAC for sexuality were found. 
Sexual pleasure decreased similarly after SSM and NSM. This is in line with previous stud-
ies on sexuality after NAC reconstruction and NSM8, 29 and contradicts the argument that 
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NSM may protect from sexual problems. In total, 36% had a history of prophylactic oo-
phorectomy, which may have further aggravated sexual problems after mastectomy30. 
In the SSM group, some patients complained about the loss of projection of the NAC 
reconstruction or too much projection causing visibility of the NAC when dressed. In 
the NSM group on the other hand, significantly more patients were unsatisfied with the 
position of the spared NACs. Loss of projection of a NAC reconstruction after SSM and 
malposition of a spared NAC after NSM both are frequently reported challenges6, 16.
To more objectively quantify residual or regained sensitivity we tested NAC and skin 
flap sensitivity after NSM and - lacking preoperative sensitivity measurements - com-
pared it with sensitivity in a non-operated control group. Sensitivity of all nine tested 
sites was low after NSM, and significantly higher in the control group (Figure 5). Remark-
ably, in the NSM group sensitivity of the NAC and surrounding skin flap was lowest at 
laterocaudal sites, which corresponds with the inferolateral periareolar incisional site in 
the majority of NSMs (Table 1). Therefore, although the Semmes Weinstein test is only 
validated for quantification of limb sensitivity31, 32, its discriminatory ability seemed also 
adequate for our purpose. Sensitivity was similarly low in 5 women who underwent 
NSM through an inframammary incision (data not shown). Despite the low sensitivity 
as tested and reported by women in the NAC-specific questionnaire, nipple erection 
as a reaction to touch and/or cold was reported present in 67% of women after NSM. 
This was also observed during the Semmes Weinstein sensitivity tests (data not shown). 
Previously, nipple erection has been used as an instrument to measure sensitivity of the 
NAC after NSM and was found to be present in all cases after NSM19; our data show that 
by these means sensitivity after NSM is most likely overrated. Nipple erection is most 
likely innervated by the autonomous nerve system and is therefore not the same as 
NAC sensation through somatosensory nerves. Nonetheless, an intact nipple erection 
may contribute to a woman’s feeling of a more natural NAC after NSM than after NAC 
reconstruction28. The expectation of preserving NAC sensitivity should not be a motiva-
tion for choosing NSM over SSM and NAC reconstruction.
The value of a spared or reconstructed NAC for psychological adjustment after breast 
surgery has been described before8, 9. In this study we did not specifically evaluate 
motivations for choosing SSM or NSM. As reported postoperatively, there were no pre-
operative differences between groups in importance of the breast or NAC for sexuality. 
However, some women in the NSM group explained that their breast reconstruction felt 
more natural because of the spared NAC. As a contrast, in the SSM group, several women 
commented that their breasts had always represented a high cancer risk and that they 
had felt detached from their breasts since long before mastectomy. Remarkably, in 
the NSM group 5 women underwent reoperations for dissatisfaction with aesthetic 
outcome compared with 0 in the SSM group. Although this may be due to different 
aesthetic outcomes after NSM versus SSM, higher or distinct preoperative expectations 
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may have played a role33. Interestingly, a recent study summarized the psychological 
advantage of a spared NAC over a reconstructed NAC as follows: NSM is a ‘conservative’ 
procedure while NAC reconstruction after SSM is mainly a ‘restorative’ procedure33. Pos-
sibly these differences result in distinct motivations for choosing SSM or NSM, since for 
some patients a spared NAC may unpleasantly remind them of their own breast and the 
concurrent breast cancer risk. In this study for example, in the NSM group 4 women did 
not have a proven BRCA1/2 gene mutation versus 0 in the SSM group. We speculate that 
the population at high breast cancer risk, especially with a BRCA1/2 gene mutation, is 
distinct with respect to some of their motivations for choosing prophylactic NSM or SSM 
with NAC reconstruction, as compared with the sporadic breast cancer population un-
dergoing prophylactic surgery. A qualitative study regarding the motivations to choose 
for prophylactic NSM should be performed to explore this hypothesis.
To our knowledge, this is the first study evaluating sensitivity of the NAC in combi-
nation with patient satisfaction specifically in women with high breast cancer risk 
undergoing NSM compared with prophylactic SSM and NAC reconstruction. Another 
important strength was the use of the Breast-Q and the BIS, two validated and widely 
used questionnaires. However, there are several limitations. First, because of the small 
groups we may have missed differences in outcomes between the groups. This is mainly 
attributable to the select population of BRCA1/2 gene mutation carriers and other 
women at high breast cancer risk that were eligible for this study. Second, as addressed 
above the NSM group had a significantly shorter follow-up which may have resulted in 
an incomplete coping and/or recovery process at the time of examination. This is partly 
attributable to the cross-sectional design of this study and the observation that the fre-
quency of NSM has increased in the past years in our institute. Finally, lacking a validated 
questionnaire for satisfaction and sexuality with respect to a spared or reconstructed 
NAC, specifically, we designed a NAC specific questionnaire that did not undergo formal 
psychometric evaluation.
In conclusion, in this population of women at high breast cancer risk patient satis-
faction and body image was similar after SSM and NSM. Both reported and measured 
NAC sensitivity was low after NSM and therefore NSM should not be recommended for 
preservation of NAC sensitivity. SSM followed by NAC reconstruction and NSM led to 
comparable results in satisfaction with the NAC. Therefore, SSM is a balanced alternative 
for NSM in a high breast cancer risk population. Motivations and preferences of patients 
may differ and should be explored before choosing either SSM or NSM as a risk reducing 
option.
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AbSTRACT
background Challenges of direct-to-implant breast reconstruction are to achieve 
sufficient implant coverage and lower pole projection. We assessed reoperation rates, 
long-term patient satisfaction and aesthetic outcome after direct-to-implant BR without 
acellular dermal matrix (ADM) in women with high breast cancer risk.
Methods Women who underwent bilateral mastectomy and immediate direct-to-
implant BR between 1994-2006 completed a survey on reoperations and the Breast-Q 
Reconstruction questionnaire. Photographs taken during follow-up were rated for long-
term aesthetic outcome (scale 1-10) by five plastic surgeons. Outcomes were compared 
between women who never underwent unanticipated reoperations after immediate BR 
and women who underwent one or more reoperations, adjusted for potential confound-
ers using multivariable linear regression.
Results Seventy women (49%) were never reoperated and 73 (51%) had undergone 
reoperations. Median follow-up was 12 years in both groups (range 7-17 and 6-19 years, 
respectively). Baseline characteristics were comparable except for history of prophylac-
tic oophorectomy with 81% in the no-reoperations group versus 66% in the reoperated 
group (P=0.03). Breast-Q scores were 59.7±17.3 vs. 58.0±17.8 (P=0.67) for ‘satisfaction 
with breasts’ and 71.1±20.3 vs. 68.1±22.9 (P=0.47) for ‘satisfaction with outcome’ in the 
no-reoperation versus reoperation group, respectively. Aesthetic outcome was scored 
5.8±1.1 in the no-reoperation group versus 5.3±1.3 in the reoperation group (P=0.01).
Conclusion The single-stage intent did not prevent unanticipated surgical reinterven-
tions in 51% of the patients. Long-term patient satisfaction was reasonable and not 
affected by reoperations. Aesthetic outcome, however, was only poor to reasonable and 
scores were significantly lower in the reoperated group.
Long-term follow-up of direct-to-implant breast reconstruction
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InTROduCTIOn
BRCA1/2 gene mutation carriers and other women at high breast cancer risk may 
choose to undergo risk-reducing mastectomy (RRM) followed by immediate breast 
reconstruction1. Bilateral mastectomy reduces breast cancer risk by 90-100% after 3-13 
years of follow-up2-6. The various BR options after mastectomy are typically grouped in 
autologous BR, implant-based BR or a combination of both. Compared with implant-
based techniques, autologous BRs are associated with a superior, more natural result, 
at the expense of more complex surgical procedures with higher risk of more severe 
complications and additional donor site morbidity7, 8. Modern implant-based BR tech-
niques typically consist of expanding of the subpectoral pocket using a tissue expander 
(TE), followed by placement of a permanent implant in a second stage. Implant-based 
BR is indicated in women with small to moderate breast volume requirements without 
previous breast irradiation and in women unwilling or physically unsuitable to undergo 
autologous BR7, 8.
To avoid the additional operation for permanent implant placement after TE, interest 
in single-stage direct-to-implant BRs has been increasing. The challenge of single-stage 
procedures is that implant coverage needs to be achieved by the unexpanded pectoral 
muscle to protect the implant and avoid complications including mastectomy skin flap 
thinning, skin flap necrosis, infection, implant loss and capsular contracture7-10. Fur-
thermore, breast asymmetry is a frequent complication after single-stage subpectoral 
implant placement11. Alternatively, acellular dermal matrix (ADM) products have gained 
interest to provide a better inframammary fold (IMF) definition, better lower pole pro-
jection as well as coverage of the implant in combination with the pectoral muscle1 12. 
Because of higher early complication rates and costs compared to submuscular implant 
techniques12, 13, the use of ADM products is not undisputed. To our knowledge, long-term 
outcomes of direct-to-implant reconstruction without ADM have never been reported 
and patient-reported outcomes are unknown.
Between 1994 and 2006, direct-to-implant BRs were frequently performed at our 
centre in BRCA1/2 mutation carriers and other women at high breast cancer risk opting 
for risk reducing mastectomy. The aims of the current study were 1) to assess long-term 
aesthetic outcome, quality of life (QoL) and patient satisfaction after bilateral direct-
to-implant BR, and 2) to investigate the impact of complications and re-operations. 
Therefore, long-term aesthetic outcome, QoL and patient satisfaction were compared 
between patients who did not undergo reoperations and patients who underwent one 
or more reoperations. In addition, to assess long-term aesthetic outcome photographs 
were scored by an expert panel.
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PATIEnTS And METHOdS
Patients
Between 1994 and 2006, all female BRCA1/2 mutation carriers and other women at in-
creased breast cancer risk ≥21 years who opted for RRM were prospectively included in 
a follow-up database after written informed consent. Photographs were taken at regular 
time points during follow-up after BR.
Patients with bilateral skin-sparing or nipple-sparing mastectomy and immediate di-
rect-to-implant BR were selected from the database. Patients with unilateral therapeutic 
mastectomy without BR followed by secondary contralateral RRM and bilateral BR were 
also eligible. All BRs were performed by a single plastic and reconstructive surgeon. The 
implant was placed underneath the pectoralis major muscle, which was opened in the 
muscle fibre course or lifted at the inferior edge. Implant size largely depended on the 
limited submuscular space that could be created, which was preoperatively discussed 
with the patient.
Follow-up started at BR or, if applicable, at nipple-areola complex (NAC) reconstruc-
tion. Exclusion criteria were a body mass index (BMI) ≥30 kg/m2 at BR - based on current 
national guidelines that women with a BMI ≥30 are at increased risk for complications 
and poor outcome after implant-based BR, BR using tissue expanders, an autologous 
flap or an autologous flap-implant combination. The institutional ethics committee ap-
proved the study.
Data on complications and reoperations were collected from medical records, taking 
into account that women may have consulted another clinic for follow-up or reopera-
tions, and by means of a telephonic patient survey. Women who were eligible received 
a written notification and were called within two weeks for completion of the survey. 
Patients who did not complete the telephonic survey were excluded from analyses. Af-
ter completing the telephonic survey patients were mailed the Breast-Q Reconstruction 
questionnaire and a paid return envelope, if necessary followed by one telephonic and 
one written reminder.
Patient groups
We identified two groups. Group 1 consisted of patients without any reoperation since 
bilateral implant BR ± NAC reconstruction. Patients who had undergone a single reopera-
tion because of hematoma at the surgical site within 24 hours from BR were also included 
in this group. Group 2 consisted of patients who had undergone ≥1 reoperations >24 
hours after mastectomy and BR, who either still had subpectoral breast implants at the 
time of patient survey or who had undergone a tertiary revision BR over time. Tertiary 
reconstructions were defined as tissue expander-assisted BR’s, implant reconstructions 
in combination with an autologous flap and autologous reconstructions.
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Primary outcomes
Reoperations
Between March 2013 and November 2013 patients were interviewed by telephone 
regarding primary BR, experienced complications and unanticipated reoperations (date, 
indication and type of reoperation), history of breast cancer and comorbidity. Informa-
tion from the telephonic patient survey was validated and complemented with informa-
tion from the follow-up database and medical records. An unanticipated reoperation 
was defined as a reoperation ± implant revision. NAC reconstruction was not considered 
an unanticipated reoperation.
Patient reported outcomes
The Breast-Q Reconstruction module was used to assess BR-related quality of life (QoL) 
and patient satisfaction. The Breast-Q was developed by Pusic et al with good reported 
validity and reliability14. After completion of the telephonic survey, Breast-Q question-
naires were sent by mail. For the current study, six of the 19 independent Breast-Q scales 
were used: (1) ‘satisfaction with breasts’, measuring satisfaction with breast appearance, 
shape and symmetry; (2) ‘satisfaction with outcome’, assessing whether patients’ expec-
tations were met;15 ‘psychosocial well-being’, rating social confidence and feelings of 
normalcy and equality; (4) ‘sexual well-being’, addressing the impact of breast surgery 
and reconstruction on sexuality; (5) ‘satisfaction with nipple reconstruction’, measur-
ing satisfaction with the appearance and symmetry of the NAC reconstruction and (6) 
‘physical well-being’, assessing the frequency of pain or discomfort in the breast area 
and the upper body. Breast-Q scores of the independent scales were calculated using 
the Q-Score Scoring Software, which provides a total score per scale that ranges from 
0-100 with a higher score representing greater satisfaction or better quality of life. Miss-
ing or non-unique answers were invalid.
Secondary outcomes
Panel evaluation of aesthetic result
During follow-up, all women underwent photographic assessment of the BR at various 
time points resulting in ≥1 photograph per patient. To objectively evaluate aesthetic 
outcome an expert panel of five plastic breast surgeons (three male, two female) as-
sessed the most recent photograph that was taken at least 12 months after the last 
surgical intervention (BR, NAC reconstruction or reoperation). Evaluated parameters 
were symmetry, shape, size, position of the IMF, definition of IMF, NAC reconstruction, 
appearance of the scar and overall aesthetic result16. One (mean) score was given for 
both breasts. Outcomes were measured using 5-point Likert Scales with ‘1’ indicating a 
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very poor outcome and ‘5’ indicating an excellent outcome. Overall aesthetic outcome 
was rated ranging from ‘1’ (very poor) to ‘10’ (excellent). To avoid observer bias, photo-
graphs were anonymised. To assess intra-observer variability, 20 random photographs 
were added in twofold and spread over the set.
Statistical analysis
Continuous variables were analysed using Mann-Whitney U tests and categorical vari-
ables using Chi-Square tests or Fisher’s Exact tests. The cumulative per cent of women 
undergoing a first reoperation over time was illustrated by a Kaplan-Meier survival curve. 
Outcomes of Breast-Q scales and panel scores were analysed as continuous variables. 
Impact of differences in baseline characteristics with P ≤0.10 on outcomes was tested by 
univariate linear regression analysis and, if P ≤0.10, adjusted for by multivariable linear 
regression analysis. Inter- and intra-observer variance of the mean of panel scores and of 
the overall aesthetic result was assessed using intraclass correlation coefficients (ICCs). 
All P-values were two-sided and α ≤0.05 was considered statistically significant. SPSS 
(version 21.0) was used for statistical analyses.
RESulTS
Patients
In total, 182 women with bilateral mastectomy followed by direct-to-implant BR 
between 1994 and 2006 were identified from the database. Thirteen had a BMI ≥ 30 
kg/m2, 22 did not respond, two did not want to participate, one could not be reached 
due to emigration and one had died. Therefore, 143 (79%) were eligible for analyses. 
As shown in Table 1, 70 patients (49%) did not undergo any reoperation (Group 1). 
Seventy-three patients (51%) underwent ≥1 unanticipated surgical intervention after 
BR ± NAC reconstruction (Group 2). Baseline characteristics at immediate BR, follow-up, 
oncological history and comorbidity were comparable between the two groups. History 
of risk-reducing oophorectomy differed with 81% in the no-reoperation group vs. 66% 
in the reoperated group (P=0.03).
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Table 1. Demographics, follow-up, clinical and primary breast reconstruction characteristics
 
 
Group 1: No reoperations Group 2: ≥ 1 reoperations P
n (%) n (%)  
Total number of patients 70 (49%) 73 (51%)  
Response with      
Breast-Q 61 (87%) 60 (82%)  
Interview only 9 (13%) 13 (18%)  
Follow-up      
BR- Time to Breast-Q, years (median, range) 12.0 (7.0-17.0) 12.0 (6.0-19.0) 0.41*
Patient characteristics      
Age at BR
years (median, range) 38.5 (23.0-55.0) 36.0 (24.0-58.0) 0.33*
Period of BR
year (median, range) 2001 (1996-2006) 2000 (1994-2006) 0.41*
Body Mass Index at time of BR
kg/m2 (mean, ± SD) 22.5 (± 2.4) 23.1 (± 2.8) 0.32*
Prophylactic oophorectomy prior to/ after BR      
Yes 57 (81%) 48 (66%) 0.03**
No 13 (19%) 25 (34%)  
Oncological history      
Indication prophylactic mastectomy      
BRCA1 mutation 51(73%) 45 (62%) 0.29**
BRCA2 mutation 10 (14%) 12 (16%)  
Non-BRCA familial breast cancer risk 9 (13%) 16 (22%)  
       
History of, or breast cancer at time of mastectomy      
Yes 17 (24%) 22 (30%) 0.43**
No 53 (76%) 51 (70%)  
Mastectomy      
Bilateral prophylactic 58 (83%) 57 (78%) 0.47**
Unilateral therapeutic, unilateral prophylactic 12 (17%) 16 (22%)  
Oncological history, other than breast cancer      
Yes 4 (6%) 4 (6%) 1.00**
No 66 (94%) 69 (94%)  
Risk factors      
Smoking at time of BR*      
Yes 15 (28%) 20 (33%) 0.56**
No 39 (72%) 41 (67%)  
Unknown 16 12  
Diabetes at time of BR1      
Yes 1 (2%) 1 (2%) 1.00**
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Table 1. Demographics, follow-up, clinical and primary breast reconstruction characteristics (continued)
 
 
Group 1: No reoperations Group 2: ≥ 1 reoperations P
n (%) n (%)  
No 63 (98%) 63 (98%)  
Unknown 6 9  
Chemotherapy for breast cancer prior to/ after BR      
Yes 12 (17%) 12 (16%) 0.91**
No 58 (83%) 61 (84%)  
Radiation history prior to/ after BR1      
Yes 4 (6%) 10 (11%) 0.26**
No 66 (94%) 65 (89%)  
Primary BR      
Implant size
cc (mean ± SD)
 
339 (± 68.5)
 
342 (± 78.6)
 
0.88*
Nipple-areola complex (NAC)      
Reconstruction1 53 (76%) 60 (82%) 0.57**
Nipple-areola sparing 2 (3%) 4 (6%)  
No reconstruction or sparing of the NAC 15 (21%) 9 (12%)  
BR: direct-to-implant breast reconstruction; SD: standard deviation; cc: cubic centimeter
1Nipple-areola complex (NAC) reconstruction by dermal graft or skin flap and/or intradermal tattoo
*Mann-Whitney U Test
**Chi-square Test
***Fisher’s Exact Test
Reoperations and indications in Group 2
Mean number of reoperations per patient was 2.2 (±1.9; Table 2). Most indications for 
reoperations concerned implant related issues, with capsular contracture being the 
most frequent indication (n=32, 44%). Nine of 17 women with a tertiary reconstruction 
received a latissimus dorsi flap (LD). Median time to first reoperation was 20.5 months 
(range 0-204), meaning that approximately 50% of the first reoperations were performed 
in the first 24 months after primary BR.
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Table 2. Indications for reoperations and tertiary reconstructions
  N (% of 73 reoperated patients)
Number of reoperations
Total per patient (mean, ± SD)
 
2.2 (±1.9)
Postoperative complications (> 24 hours postoperative)  
Surgical site infection 6 (8%)
Wound dehiscence 1 (1%)
Seroma 1 (1%)
Implant related issues  
Capsular contracture 32 (45%)
Implant size related 24 (33%)
Implant position related 17 (24%)
Implant rupture 14 (20%)
Mastectomy skin flap necrosis 3 (4%)
Passed implant expiration date 1 (1%)
Unknown 1 (1%)
Local recurrence of breast cancer 3 (4%)
Pain 10 (14%)
Breast contour and scar related issues* 12 (17%)
Tertiary reconstructions 17 (23%)
Latissimus dorsi flap 9 (12%)
Tissue expander and breast implant 5 (7%)
DIEP flap 3 (4%)
Multiple complications per patient and per operation were possible.
SD: standard deviation; DIEP flap: Deep Inferior Epigastric artery Perforator flap
1i.e. correction of dogears, scar, skin excess
Patient satisfaction and quality of life (qol)
Breast-Q Reconstruction questionnaires were completed and returned by 61 patients 
(86%) in Group 1, and by 60 patients (82%) in Group 2 (Table 3). There were neither 
significant differences between both groups in ‘satisfaction with breasts’ or ‘satisfaction 
with overall outcome’, nor in the QoL scales regarding ‘psychosocial’, ‘sexual’ and ‘physi-
cal well-being’, nor in ‘satisfaction with nipples’. Differences between groups regarding 
‘risk-reducing oophorectomy’ did not affect Breast-Q scores as tested by univariate lin-
ear regression (data not shown). A subgroup analysis in women who underwent tertiary 
BR showed patient satisfaction and QoL comparable to the group without reoperations 
(Table 4).
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Table 3. Patient satisfaction and quality of life assessed by Breast-Q Reconstruction scales
  Group 1:
No reoperations
 
Group 2:
≥ 1 reoperations
 
   
Number of patients 71 85    
Number of Breast-Q’s (% of group) 61 (86%) 70 (82%)    
Breast-Q scales Mean ± SD Mean ± SD Mean score 
difference
P-value1
Satisfaction with breasts 59.7 ±17.3 58.0 ± 17.8 1.7 0.67
Satisfaction with overall outcome 71.1 ± 20.3 68.1 ± 22.9 3.0 0.47
Psychosocial well-being 70.8 ±17.8 70.1 ± 20.0 0.6 0.69
Sexual well-being 59.8 ± 22.2 57.7 ± 21.9 2.1 0.45
Physical well-being 78.6 ± 15.1 72.9 ± 20.0 5.7 0.14
Breast-Q scores ranged from 0 (minimal satisfaction or quality of life) to 100 (maximum satisfaction or qual-
ity of life)
1Mann-Whitney U Test
Table 4. Patient satisfaction and quality of life after tertiary reconstruction assessed versus without reop-
erations by Breast-Q Reconstruction scales
  Group 1:
No reoperations
 
Tertiary 
reconstruction
 
   
Number of patients 71 17    
Number of Breast-Qs (% of group) 61 (86%) 12 (74%)    
Breast-Q scales Mean ± SD Mean ± SD Mean score 
difference
P-value1
Satisfaction with breasts 59.7 ± 17.3 61.8 ± 17.4 -2.2 0.86
Satisfaction with overall outcome 71.1 ± 20.3 64.2 ± 22.2 6.9 0.32
Psychosocial well-being 70.8 ± 17.8 63.5 ± 17.6 7.3 0.14
Sexual well-being 59.8 ± 22.2 59.2 ± 20.8 0.6 0.97
Physical well-being 78.6 ± 15.1 70.2 ± 21.6 8.4 0.14
Breast-Q scores ranged from 0 (minimal satisfaction or quality of life) to 100 (maximum satisfaction or qual-
ity of life)
1Mann-Whitney U Test
Panel evaluation of photographs
Photographs of 69 women in Group 1 and of 68 in Group 2 were suitable for panel evalu-
ation (Table 5; Figures 1-4). Median follow-up since BR was 7.0 years (range 1.0-11.0) 
and 6.5 years (range 1.0-17.0), respectively. In Group 2, 40 patients (28%) underwent 
reoperations (mean 1.0 ±1.6) after the photograph used for panel evaluation. Panel 
scores were significantly favourable in Group 1 vs. Group 2 for the items ‘symmetry’ (3.17 
±0.57 vs. 2.96 ±0.70; P=0.02), ‘shape’ (3.02 ±0.57 vs. 2.78 ±0.69; p=0.02), ‘definition of 
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IMF’ (3.02 ±0.63 vs. 2.78 ±0.68; p=0.03), ‘NAC reconstruction’ (3.42 ±0.57 vs. 3.17 ±0.67; 
p=0.05). Overall aesthetic result (scale 1-10) was 5.82 ±1.14 in Group 1 vs. 5.31 ±1.31 in 
Group 2 (P=0.01). ‘Risk-reducing oophorectomy’ did not affect panel outcomes as tested 
by univariate linear regression, except for the item ‘position of IMF’ with B=0.22 (P=0.06) 
in univariate and B=0.19 (P=0.11) in multivariable linear regression analyses (data not 
shown). Consequently, outcome of ‘position IMF’ was adjusted for ‘risk-reducing oo-
phorectomy’. Inter-observer variability was satisfactory for the mean of scored scales 
(ICC=0.66) and for the overall aesthetic result (ICC=0.68). Intra-observer variability 
ranged from satisfactory (0.63) to excellent (0.94) (Table 6).
184
Chapter 10
A  
B  
C  
figure 1. Panel photographs 1 year after direct-to-implant breast reconstruction. No reoperations had 
been performed before panel photograph but four years after panel photograph the patient underwent 
capsulotomy and revision of the implants to larger implants. Photographs were rated by the panel 7.8/10 
points for overall aesthetic outcome (ranging from 1: very poor to 10: excellent aesthetic outcome). A Fron-
tal b and C oblique views.
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figure 2. Panel photographs 6 years after direct-to-implant breast reconstruction. No reoperations had 
been performed. Photographs were rated by the panel with a mean of 2.8/10 points for overall aesthetic 
(ranging from 1: very poor to 10: excellent aesthetic outcome). A Frontal b and C oblique views.
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figure 3. Panel photographs 4 years after direct-to-implant breast reconstruction. The patient needed 
excision of the scar due to breast cancer recurrence. Photographs were rated by the panel with a mean of 
2.6/10 points for overall aesthetic outcome (ranging from 1: very poor to 10: excellent aesthetic outcome). 
A Frontal b and C oblique views.
Long-term follow-up of direct-to-implant breast reconstruction
187
A  
B  
C  
figure 4. Panel photographs 7 years after direct-to-implant breast reconstruction. The patient was reoper-
ated once due to capsular contraction 4 years after BR. Photographs were rated by the panel with a mean of 
6.0/10 points for overall aesthetic outcome (ranging from 1: very poor to 10: excellent aesthetic outcome). 
A Frontal b and C oblique views.
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Table 5. Panel evaluation of postoperative photographs
  Group 1: No 
reoperations
Group 2: ≥ 1 
reoperations
P-value3
Number of patients 70 73  
Number of photographs (% of group) 69 (99%) 68 (88%)  
Years BR – panel photograph (median, range) 7.0 (1.0-11.0) 6.5 (1.0-17.0) 0.82
Satisfaction with1 Mean ± SD Mean ± SD  
Symmetry 3.17 ± 0.57 2.96 ± 0.70 0.02
Shape 3.02 ± 0.57 2.78 ± 0.69 0.02
Size 3.22 ± 0.95 2.99 ± 0.72 0.14
Position IMF 3.24 ± 0.57 3.05 ± 0.65 0.14*
Definition IMF 3.02 ± 0.63 2.78 ± 0.68 0.03
NAC reconstruction 3.42 ± 0.57 3.17 ± 0.67 0.05
Scar 3.11 ± 0.44 3.05 ± 0.45 0.43
Overall aesthetic result2 5.82 ± 1.14 5.31 ± 1.30 0.01
BR: breast reconstruction; SD: standard deviation; IMF: inframammary fold;
1Items scored on a Likert scale ranging from 1 (very poor result) to 5 (excellent result)
2Overall aesthetic result scored on a 10-point scale ranging from 1 (very poor result) to 10 (excellent result)
3Mann-Whitney U Test
*P-value adjusted for ‘prophylactic oophorectomy’ using linear regression. Potential confounding of ‘pro-
phylactic oophorectomy’ on outcome of ‘position IMF’ was found with B=0.22 (P=0.06) in univariate and 
B=0.19 (P=0.11) in multivariable analyses.
Table 6. Inter-observer and intra-observer variability of five panel members
  Inter-observer Intra-observer variability3
  5 panel 
members
1 2 3 4 5
Satisfaction with ICC scores ICC scores ICC scores ICC scores ICC scores ICC scores
Symmetry1 0.54 0.88 0.66 0.54 0.61 0.83
Shape1 0.55 0.86 0.70 0.51 0.73 0.76
Size1 0.18 0.75 0.47 0.31 0.69 0.44
Position IMF1 0.51 0.76 0.70 0.43 0.42 0.54
Definition IMF1 0.55 0.87 0.71 0.79 0.71 0.43
NAC reconstruction1 0.44 0.81 0.47 0.66 0.82 0.61
Scar1 0.30 0.71 0.41 0.47 0.69 0.67
Overall aesthetic result2 0.67 0.94 0.82 0.63 0.84 0.90
ICC: Intraclass correlation coefficient (0= no agreement, 1= perfect agreement), IMF: inframammary fold
1Scored on a Likert scale ranging from 1 (very poor result) to 5 (excellent result)
2Scored on a 10-point scale ranging from 1 (very poor result) to 10 (excellent result)
3Intra-observer variability based on 20 random panel photographs that were added in twofold and spread 
over the set
Long-term follow-up of direct-to-implant breast reconstruction
189
dISCuSSIOn
Interest in direct-to-implant BR has been increasing since the introduction of ADM 
products for implant coverage. For women who chose BR after mastectomy, direct-to-
implant BR without the use of ADM used to be standard of care at our centre until the 
expander/implant technique was introduced in 2006 because of promising results. This 
prompted us to evaluate reoperation rates, long-term patient satisfaction and aesthetic 
outcomes by use of a prospectively collected database between 1994 and 2006.
Strikingly, despite the single-stage intent, over time 51% needed ≥1 unanticipated 
reoperations. Indications for reoperations could be medical, such as surgical site infec-
tions or capsular contractures or for aesthetic reasons, such as dissatisfaction with size 
or symmetry. Reoperations for surgical site infections or capsular contractures may 
compromise aesthetic outcome, while reoperations for purely aesthetic dissatisfac-
tion should increase aesthetic outcome. In the current study, most reoperations were 
performed for a combination of indications. Capsular contracture was reported most 
frequently as a reason for reoperation (45% of reoperations), in line with expander/im-
plant BR17. Various studies have evaluated reoperations after implant BR15, 17-21 and found 
that direct-to-implant BR is associated with significantly more early complications (≤30 
days after BR) due to implant failure compared with expander/implant BR15, 19. Although 
a 51% reoperation rate is high, comparable percentages have been reported after TE/
implant and autologous BR in other studies20, 22.
A panel of five plastic surgeons assessed aesthetic outcome. Photographs had been 
taken during the postoperative course with a median follow-up of 7 years. Scores on 
symmetry, shape, definition of IMF and NAC reconstruction were significantly lower in 
the reoperated group. Specifically, scores on size and shape were low in both groups 
ranging between 2.80 and 3.04 out of 5. The low scores on size possibly reflect the 
difficulty to achieve enough breast volume in direct-to-implant BR due to the limited 
non-expanded subpectoral space. Overall aesthetic outcome was scored poor to rea-
sonable in both groups, but significantly lower in the reoperations group compared 
with the no-reoperation group (Table 5). The panel outcomes were not in line with 
Breast-Q outcomes, which show significant differences between both groups (Table 3). 
Previous studies reported that satisfaction of plastic surgeons with aesthetic outcome 
is significantly lower than patient satisfaction16, 23. It is hypothesized that due to their 
professional expectations plastic and reconstructive surgeons are trained to focus on 
technical imperfections that could easily be refined by additional surgery, while patients 
compare the overall result with the preoperative situation16.
To our knowledge, the present study is the first to use the Breast-Q Reconstruction 
questionnaire after direct-to-implant BR. After a median follow-up of 12 years since BR, 
we found no differences in patient satisfaction or QoL between patients with and with-
out reoperations (Table 3). In both groups, scores on satisfaction with breasts (Breast-Q 
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scores 59.7 in the non-operated and 58.0 in the operated group) and overall outcome 
(Breast-Q scores, 71.1 and 68.1, respectively) were comparable with studies that used 
the Breast-Q after expander/implant BR (satisfaction with breasts 52.5-67.8; satisfaction 
with outcome 65.8-74.8)24-27. Considering that long-term satisfaction with implant BR 
may further decrease with time27, 28 and the studies referred to had much shorter follow-
up periods than our study, Breast-Q scores in the present study were very reasonable. 
This may implicate that patient satisfaction does not necessarily decrease as much as 
expected when considering the rather moderate panel outcomes and the large amount 
of reoperations needed.
The finding that undergoing one or more unanticipated reoperations did not signifi-
cantly affect patient satisfaction or QoL was unexpected. Satisfaction after complicated 
BR has previously been assessed with conflicting outcomes. Three relatively old and 
small studies did not find any association between satisfaction and surgical complica-
tions after expander/implant BR29-31, while more recent, larger studies found decreased 
satisfaction, and even increase of anxiety and depressive symptoms after complicated 
expander/implant BR17, 32. These studies, however, had a shorter median follow-up of less 
than three years. Other studies with comparable long-term follow-up are not available. 
After 12 years follow-up, as in the present study, adequate coping of patients with a poor 
result or following adverse events may have caused a relatively mild rating of outcome. 
Of all patients, 17 (12%) had chosen to undergo a tertiary reconstruction over time and 
12 of them completed and returned the Breast-Q. A subgroup analysis showed lower 
outcomes on satisfaction and QoL compared with the no-reoperation group, except 
for a higher ‘satisfaction with breasts’ (Table 4). None of these differences, however, 
were statistically significant and the group was too small and heterogeneous regarding 
tertiary BR methods to draw conclusions from. An earlier analysis by Visser et al. of 42 
women from our centre with tertiary reconstructions partly covered our study popula-
tion and did show higher patient satisfaction after tertiary autologous reconstruction 
using free flaps16.
An important strength of this study was the long follow-up period. To our knowledge 
no other studies have described patient reported outcomes of direct-to-implant re-
construction after comparable follow-up. Response rates were high. To collect as much 
information as possible patients had to complete a telephonic survey on complications 
and reoperations. Recall-bias was minimized by validating survey information with 
information from the follow-up database and medical charts. Another strength of the 
current analysis was the use of the Breast-Q. Patient reported outcomes are important 
indicators of health care quality and the Breast-Q Reconstruction module is a frequently 
used instrument. The most important limitation of the present study was that 28% still 
needed an additional reoperation after the panel photograph. Therefore, the correla-
tion between long-term Breast-Q outcomes and panel evaluation was limited. Being 
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a standardized questionnaire for breast reconstruction, the Breast-Q may have missed 
subtleties specific for the single-stage procedure including the fact that 49% had to 
undergo only one operation and (a-)symmetry of a bilateral reconstruction. Since panel 
scores on symmetry differed significantly between the groups it would be interesting 
to have a patient reported outcome on symmetry as well. Further, the group consisted 
of women who underwent bilateral RRM and of women with a unilateral risk-reducing 
and unilateral therapeutic mastectomy. The latter subgroup may be at greater risk for an 
asymmetric outcome. A subgroup analysis, however, in the 115 women who underwent 
bilateral RRM showed results similar to the overall group (data not shown).
In conclusion, the single-stage intent of a direct-to-implant BR did not prevent surgi-
cal reinterventions in a majority of patients. Long-term aesthetic panel outcome was 
poor to reasonable in both groups and significantly lower in the reoperated group. 
However, long-term patient satisfaction and QoL were good and did not differ between 
the groups, suggesting reoperations after direct-to-implant BR do not affect long-term 
patient satisfaction and QoL. Prospective follow-up studies are urgently needed that as-
sess long-term patient satisfaction and aesthetic outcome of modern direct-to implant 
BR compared with expander/implant BR.
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SuMMARy
This thesis focuses on breast surgery in BRCA1/2 gene mutation carriers. We studied a 
broad variety of subjects ranging from molecular and prognostic tumor characteristics 
in breast cancer, to safety, aesthetics and patient reported outcomes of prophylactic 
breast surgery.
In Chapter 2 we review the literature on safety of prophylactic mastectomy in BRCA1/2 
gene mutation carriers. To allow for immediate breast reconstruction after bilateral 
mastectomy the skin envelope is left in situ with or without the nipple-areola complex 
(NAC). Any residual breast tissue with the skin flap of with the NAC represents a remain-
ing breast cancer risk after prophylactic surgery. Anatomical studies on prophylactic 
mastectomy find residual breast glandular tissue behind the skin flap or the spared 
NAC in up to 60% mastectomies. The associated remaining breast cancer risk seems 
low. However, when pooling all reviewed data on BRCA1/2 gene mutation carriers, over 
time approximately 1 in 140 will develop a primary breast cancer after risk-reducing 
mastectomy.
Chapter 3 studies the diminishing effect of risk-reducing salpingo-oophorectomy 
(RRSO) on the incidence of post-RRSO breast cancers in BRCA1/2 gene mutation carriers. 
The hypothesis is that breast cancers developing after RRSO have a less aggressive char-
acter compared to breast cancers that develop before RRSO. From a cohort of BRCA1/2 
gene mutation carriers with screen detected breast cancers, women who developed 
their first breast cancer < 12 months after RRSO were age-matched with women with 
breast cancer before RRSO. Breast cancers that developed after RRSO indeed had a 
lower mitotic count (12 versus 22 mitotic counts/2mm2) and were smaller at detection 
(11 vs. 17 mm diameter). Median tumor volume doubling times were assessed on serial 
mammographies or MRIs and were non-significantly longer after RRSO (124 days vs. 93 
days). These data suggest a less aggressive biological phenotype of breast cancers that 
develop after RRSO, which after being confirmed in larger series in the future may have 
consequences for the intensity of breast cancer screening after RRSO. The inhibiting 
mechanism of estrogen depletion on mainly estrogen receptor negative tumors, as 
typically found in BRCA1 gene mutation carriers remains unclear.
Chapter 4 continues to focus on tumor characteristics. Due to intensive breast cancer 
screening protocols, most BRCA1/2-associated breast cancers are detected in an early 
stage - e.g. small and lymph node negative – poorly differentiated and in case of a BRCA1 
gene mutation triple-negative. The use of histologic characteristics for risk stratification 
is therefore limited, as are targeted therapy options in the triple-negative subgroup. In 
a Rotterdam cohort of 138 BRCA1 and 37 BRCA2 gene mutation carriers (breast cancer 
diagnosis 1982-2008) several histologic breast cancer characteristics that have earlier 
been investigated in sporadic breast cancers were evaluated in relation to recurrence-
free survival (RFS), corrected for established prognostic factors. Tumor-associated 
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inflammation was the strongest independent favorable factor (HR 0.18 for moderate/
marked vs. absent/mild; 95%CI 0.05-0.61). Other prognostic factors for RFS were tumor 
size (HR 2.47 for >2 cm vs. ≤2 cm; 95%CI 1.10-5.57) and intra-tumor necrosis (HR 2.60 for 
presence vs. absence; 95%CI 1.12-6.05). Nodal status and differentiation grade were not 
significantly related to RFS.
Since BRCA1/2 gene mutation carriers have high risks of developing breast cancer, 
contralateral breast cancer as well as ovarian cancer, over time multiple tumors may 
be prevalent in one patient with or without concurrent metastases. Metastatic pat-
terns may be atypical. However, knowing the tumor origins and clonal relationships 
between different tumors has consequences for therapy and prognosis and is therefore 
important. In Chapter 5 we evaluate the value of molecular analysis in the form of Next 
Generation Sequencing (NGS) in a cohort of 42 female BRCA1/2 gene mutation carri-
ers who have multiple tumor localizations. In 4 of the 42 patients tumor origins could 
not conclusively be determined with tumor morphology and immunohistochemistry 
alone (cases) and therefore targeted NGS was performed. Another 10 patients with 
conclusive histopathology outcomes served as controls. In all 4 cases, the intra-patient 
clonal relationships between the tumor localizations could be unequivocally identified 
by molecular analysis. In all controls, molecular outcomes unequivocally matched the 
conventional histopathological results. Therefore we conclude that in case of inconclu-
sive conventional histology results molecular analyses using NGS can reliably determine 
clonal relationships between tumors.
Following the results of Chapter 4, Chapter 6 assesses the value of another potential 
prognostic marker in BRCA1/2-associated breast cancers. Nuclear β-catenin expres-
sion as a marker of Wnt activity has been studied in various cancers, and it is most 
significantly expressed in colorectal cancers. In sporadic breast cancer, the role of the 
Wnt/β-catenin pathway is thought to vary depending on the molecular subtype, be-
ing a prognostic factor especially in basal-like breast cancer, which suggests a role in 
BRCA-associated tumorigenesis. The Rotterdam cohort as described in Chapter 4 was 
extended to 2014. Since paraffin blocks of tumor material were needed for β-catenin 
stainings only 120 BRCA1/2 gene mutation carriers were analyzed. When corrected for 
established prognostic markers, the only significant prognostic factor associated with 
RFS was strongly positive membrane-associated β-catenin expression (HR 0.19; 95%CI 
0.05-0.73). Nuclear β-catenin expression was found in 38% of breast cancers, suggesting 
a potential role of Wnt activity in BRCA1/2-associated breast cancers. However in most 
cases nuclear β-catenin staining was confined to one or two nucleuses per tumor slide, 
and of no prognostic influence. Membranous β-catenin is also involved in cell-cell adhe-
sion. The loss of membranous β-catenin expression may lead to epithelial-mesenchymal 
transition of cancer cells and therefore is probably not merely a marker of Wnt activity. 
Further, nuclear and membranous β-catenin expressions were not clearly (inversely) 
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correlated in this study. The prognostic value of membranous β-catenin expression has 
to be further elucidated and it would be useful to identify target genes as markers of 
Wnt activity.
Chapter 7 describes an anatomical study on the numbers of terminal duct lobular 
units (TDLUs) - being a quantification of the amount of breast glandular tissue - remain-
ing with skin flap and the NAC after nipple-sparing mastectomy (NSM). In conventional 
mastectomies the NAC and an adjacent skin island were dissected as if it were an NSM 
and sectioned perpendicularly to the skin. Slides were scanned and slide surface ar-
eas (cm2) were measured using Photoshop. TDLUs were counted microscopically and 
reported as numbers of TDLUs per cm2 slide surface area. In total 105 NACs and skin 
islands of 90 women were analyzed pairwise. Sixty-four NACs (61%) vs. 25 skin islands 
(24%) contained ≥1 TDLUs. TDLU density was higher in NACs as compared to skin islands. 
Independent risk factors for presence of TDLUs in the NAC were younger age and parity 
(versus nulliparity). The finding of higher TDLU density behind the NAC as compared to 
the skin flap suggests that sparing the NAC in prophylactic NSM in high-risk patients 
possibly may increase postoperative breast cancer risk as compared to prophylactic SSM.
A frequently used scale to assess body image after cancer surgery is the Body Image 
Scale (BIS). In 2000 the BIS was developed and validated in breast cancer patients by 
Hopwood and colleagues. It assesses affective, behavioral and cognitive changes that 
may result from a cancer treatment. Because of its conciseness it may be broadly ap-
plied in clinical practice. In Chapter 8 we describe the validation of the Dutch translated 
version of the BIS, which was performed in 150 patients who underwent mastectomy 
and 150 after breast conserving treatment. Psychometric evaluation of the Dutch BIS 
showed consistent results that were comparable to those of the original version.
In Chapter 9, the Dutch translated BIS was concurrently used for assessment of body 
image after prophylactic mastectomy. Studies in breast cancer populations have shown 
that patient satisfaction after prophylactic NSM is higher as compared with SSM. In 
succession to Chapter 7 considering the possible extra risk of residual TDLUs with the 
spared NAC, the question raised whether, according to women who choose prophylactic 
mastectomy, NSM is superior to SSM followed by reconstruction of the NAC using lo-
cal skin flaps and intradermal tattooing. We administered the Breast-Q Reconstruction 
questionnaire and the Dutch BIS to 25 patients who underwent prophylactic SSM and 
20 patients after prophylactic NSM. Additionally we developed a questionnaire that 
specifically focused on satisfaction with the spared or reconstructed NAC, including NAC 
sensitivity and the role of the NAC and the reconstructed breast in sexuality. One open-
ended question was added to further explore patient’s motivations for choosing either 
NSM or SSM, their opinion on the breast reconstruction, the spared or reconstructed 
NAC and about changes in sexuality. Univariably, Breast-Q scores were favorable in the 
SSM group for ‘satisfaction with breasts’ and ‘satisfaction with outcome’. However, when 
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corrected for follow-up BIS and Breast-Q scores did not differ significantly between SSM 
and NSM. Also satisfaction with the reconstructed NAC was similar to satisfaction with 
the spared NAC. The sensitivity of the spared NAC was tested using monofilaments and 
compared to a healthy, non-operated control group, and was significantly lower after 
NSM. The results from this study suggest that SSM with NAC reconstruction is a bal-
anced alternative to NSM. Motivations of women to choose either operation varied and 
therefore should be explored when choosing prophylactic NSM or SSM.
From 1994-2006 women in the Erasmus MC Cancer Center who underwent bilateral 
mastectomy for high breast cancer risk (bilateral prophylactic or unilateral therapeu-
tic, unilateral prophylactic) followed by direct-to-implant breast reconstruction were 
photographed during follow-up. For the study described in Chapter 10 we asked these 
patients to complete a survey on re-operations and complications, and to complete the 
Breast-Q Reconstruction questionnaire, to assess long-term patient satisfaction with 
direct-to-implant reconstruction. A panel consisting of reconstructive surgeons ana-
lyzed the patient photographs for aesthetic outcome. Although the direct-to-implant 
reconstruction is a single-stage reconstruction, half of the patients had undergone 
additional surgery over the years for complications of aesthetic dissatisfactory results. 
The aesthetic outcome as scored by the panel was only poor to reasonable in the overall 
group, and significantly lower in the group who underwent reoperations. Breast-Q 
scores on ‘satisfaction with breasts’ and ‘satisfaction with overall outcome’ were compa-
rable to scores reported in the literature after a two-stage implant reconstruction with 
tissue expansion, and not significantly lower in the group who underwent reoperations. 
This suggests that reoperations do not significantly impact patient satisfaction on the 
long-term. Whether direct-to-implant breast reconstruction is a viable alternative for 
two-stage implant reconstruction after previous tissue expanding is unknown, but does 
not seem likely based on the aesthetic outcome scores in this study.
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SAMEnvATTInG
Dit proefschrift gaat over mammachirurgie in BRCA1/2-genmutatiedraagsters. De 
onderwerpen die aan bod komen variëren van moleculaire en prognostische tumorkara-
kteristieken in BRCA-geassocieerde borstkanker tot veiligheid, cosmetische resultaten 
en patient reported outcomes van preventieve mammachirurgie.
Hoofdstuk 2 bevat een review van literatuur over veiligheid van de preventieve 
ablatio bij BRCA1/2-genmutatiedraagsters. Wanneer na een mastectomie een directe 
reconstructie volgt wordt de huid in situ gelaten, waarbij ook de tepel-areola gespaard 
kan worden. Er is een kans dat borstklierweefsel achterblijft met de huid en met de 
gespaarde tepel-areola, wat mogelijk een risico vormt op het ontwikkelen van mam-
macarcinoom na de preventieve ablatio. Anatomische studies vonden resterend 
borstklierweefsel na 60% van de profylactische mastectomieën. Uit studies blijkt dat 
hierin slechts zeer incidenteel nog een mammacarcinoom ontstaat, maar na bundelen 
van de data blijkt het toch te gaan om 1 op de 140 vrouwen die een mammacarcinoom 
ontwikkelen na preventieve ablatio.
In hoofdstuk 3 bestuderen we het verlagende effect van de risico-reducerende 
salpingo-ovariëctomie (RRSO) op de incidentie van mammacarcinomen die ontstaan 
na RRSO bij BRCA1/2-genmutatiedraagsters. De hypothese is dat mammacarcinomen 
die na RRSO ontstaan minder agressieve tumorkenmerken hebben dan de mam-
macarcinomen die ontstaan bij vrouwen die (nog) geen RRSO hebben ondergaan. Uit 
een cohort van BRCA1/2-genmutatiedraagsters selecteerden we alle vrouwen die hun 
eerste mammacarcinoom kregen tenminste 12 maanden na RRSO en vergeleken hen 
met op leeftijd (ten tijden van mammacarcinoom) gematchte vrouwen die hun eerste 
mammacarcinoom voor RRSO kregen. Borstkankers die ontstonden na RRSO hadden 
inderdaad een lagere mitotische index (12 versus 22 mitosen/2mm2) en waren kleiner 
op het moment van diagnose (11 versus 17 mm diameter). De tumorverdubbelingstijd 
werd gemeten op mammografieën en MRI’s, en was (niet-significant) langer na RRSO 
(124 dagen vs. 93 dagen). Deze data suggereren dat mammacarcinoom dat ontstaat 
na RRSO een minder agressief fenotype heeft dan mammacarcinoom zonder RRSO. 
Uiteindelijk kan deze bevinding consequenties hebben voor de frequentie van borst-
kankerscreening bij BRCA1/2-genmutatiedraagsters die een RRSO hebben ondergaan. 
Het is echter nog onduidelijk hoe oestrogeenverlaging een vertragende invloed kan 
hebben op de ontwikkeling van oestrogeenreceptor-negatieve tumoren zoals bij 
BRCA1-genmutatiedraagsters vaak worden aangetroffen.
Ook in hoofdstuk 4 staan tumorkarakteristieken centraal. Dankzij intensieve screen-
ingsprotocollen bij vrouwen met een BRCA1/2-genmutatie worden veel BRCA1/2-mam-
macarcinomen in een vroeg stadium gediagnosticeerd. Hierdoor is er meestal sprake 
van een kleine, hooggradige tumor zonder lymfekliermetastasen en – passend bij 
BRCA1-genmutaties – vaak een triple-negatieve status voor oestrogeen-, progesteron- 
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en Her2-receptoren. De toegevoegde waarde van gebruikelijke histologische tumorken-
merken voor risicostratificatie is daarom beperkt, net als de opties voor doelgerichte 
therapieën. Van een cohort van BRCA1/2-genmutatiedraagsters met een mammacarci-
noom gediagnosticeerd tussen 1982 en 2008 reviseerden we de tumoren. Verschillende 
histologische tumorkenmerken die in eerdere studies bij sporadisch mammacarcinoom 
van potentieel prognostische waarde leken, correleerden we met de ziektevrije overlev-
ing, gecorrigeerd voor bekende prognostische markers. Tumor-geassocieerde inflam-
matie was de sterkste onafhankelijke prognostische marker in deze serie (hazard ratio; 
HR 0.18 voor matig tot sterk aanwezige versus milde of afwezige tumor-geassocieerde 
inflammatie; 95% confidence interval; CI 0.05-0.61). Andere onafhankelijke factoren van 
invloed op de prognose waren tumorgrootte (HR 2.47 voor > 2 cm versus ≤2 cm; 95%CI 
1.10-5.57) en intra-tumor necrose (HR 2.60 voor necrose versus geen necrose; 95%CI 
1.12-6.05). Lymfeklierstatus en differentiatiegraad waren geen van beide significant 
gecorreleerd met ziektevrije overleving.
Omdat BRCA1/2-genmutatiedraagsters naast een hoog risico op mammacarcinoom 
en contralateraal mammacarcinoom ook een hoog risico op het ontwikkelen van ovari-
umcarcinoom hebben, kunnen in de loop van de tijd verschillende tumoren voorkomen 
in een patiënt, met daarbij eventueel metastasen op afstand. Hierbij is het op basis 
van klinische en histopathologische kenmerken niet altijd mogelijk goed onderscheid 
te maken tussen de verschillende tumoren en origines van de metastasen. In hoofd-
stuk 5 onderzoeken we de waarde van clonaliteitsanalyse middels Next Generation 
Sequencing (NGS) in een cohort van 42 BRCA1/2-genmutatiedraagsters met meerdere 
tumorlokalisaties. Twee pathologen reviseerden het beschikbare tumormateriaal van 
deze patiënten en deden op indicatie extra immunohistochemische analyses. Bij 4 van 
de 42 patiënten konden de tumor-origines niet met zekerheid bepaald worden en was 
NGS geïndiceerd (cases). Bij nog eens 10 patiënten met een zekere histopathologische 
uitslag werd ook NGS uitgevoerd (controles). In alle cases kon de clonaliteit van de ver-
schillende tumoren met zekerheid worden aangetoond of uitgesloten. In alle controles 
kwamen de uitkomsten van de clonaliteitsanalyse overeen met de histopathologische 
uitkomsten bevestigd middels NGS. Daarom concluderen we dat bij een inconclusieve 
histopathologie-uitslag NGS een zinvolle bijdrage kan leveren om met zekerheid de 
clonale relaties tussen verschillende tumoren vast te stellen.
Als vervolg op de resultaten van hoofdstuk 4, bekijken we in hoofdstuk 6 opnieuw de 
waarde van een potentiële prognostische marker in het BRCA1/2-geassocieerde mam-
macarcinoom. Nucleaire β-catenine aankleuring als marker van Wnt-activiteit werd al 
in meerdere soorten kanker bestudeerd en is het meest duidelijk aanwezig in colorec-
taal carcinoom. In sporadisch mammacarcinoom hangt de rol van de Wnt/β-catenine 
pathway mogelijk deels af van het moleculaire subtype van het mammacarcinoom. 
Mogelijk speelt de Wnt/β-catenine pathway een rol in basal-like mammacarcinoom en 
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daarom mogelijk in BRCA-geassocieerde tumorgenese. Het Rotterdamse cohort zoals 
beschreven in hoofdstuk 4 werd voor deze studie uitgebreid naar 2014. Omdat voor 
de β-catenine kleuringen paraffineblokjes van tumoren nodig waren konden in deze 
studie maar 120 BRCA1/2-genmutatiedraagsters geanalyseerd worden. Gecorrigeerd 
voor bekende prognostische markers was de enige onafhankelijke prognostische 
factor die geassocieerd was met ziektevrije overleving sterk positieve expressie van 
membraangeassocieerde β-catenine (HR 0.19; 95%CI 0.05-0.73). Nucleaire β-catenine 
expressie werd gezien in 38% van de tumoren, wat een mogelijke rol van Wnt activ-
iteit in BRCA1/2-mammacarcinoom suggereert. In de meeste tumoren was nucleaire 
β-catenine aankleuring echter slechts zichtbaar in een paar celkernen per tumor. Nu-
cleaire expressie van β-catenine was dan ook niet van prognostische waarde. Membra-
neuze β-catenine speelt ook een rol in cel-cel adhesie. Het verlies van β-catenine op de 
celmembraan kan een teken zijn van epithelial-mesenchymal transition van tumorcellen 
en is daarom waarschijnlijk niet alleen maar een marker van Wnt-activatie. Bovendien 
waren nucleaire en membraneuze β-catenine expressie niet omgekeerd evenredig met 
elkaar gecorreleerd. De prognostische waarde van membraneuze β-catenine expressie 
behoeft meer onderzoek terwijl het nuttig zou zijn om target genen te identificeren als 
specifieke markers van Wnt activiteit.
Hoofdstuk 7 beschrijft een anatomische studie naar de hoeveelheid terminal duct 
lobular units (TDLU’s) die een kwantificatie zijn van de hoeveelheid borstklierweefsel 
dat achterblijft met de huid en de tepel-areola na tepelsparende mastectomie. In con-
ventionele en in huidsparende mastectomieën werden tepel-areola en een daarnaast 
gelegen huideiland geprepareerd alsof het een sparende mastectomie betrof, en 
daarna uitgenomen en loodrecht op de huid gelamelleerd voor histologisch onderzoek. 
De coupes van borst en huideiland werden ingescand en de oppervlaktes van de coupes 
(cm2) werden opgemeten met behulp van Photoshopâ. De TDLU’s werden geteld onder 
de microscoop en gedocumenteerd als hoeveelheid TDLU’s/cm2 coupe-oppervlakte. In 
totaal werden 105 tepel-areola’s en huideilanden gepaard geanalyseerd. Vierenzestig 
tepel-areola’s (61%) en 25 huideilanden (24%) bevatten TDLU’s. Vergeleken met de 
huideilanden was de TDLU-dichtheid (/cm2) hoger in tepel-areola’s. Onafhankelijke 
risicofactoren voor het vinden van TDLU’s in een tepel-areola waren een jongere leeftijd 
en pariteit (versus nullipariteit). Een hogere TDLU-dichtheid achter de tepel-areola 
vergeleken met de huid suggereert dat het sparen van de tepel-areola bij een preven-
tieve mastectomie het postoperatieve risico op het krijgen van borstkanker verhoogt 
ten opzichte van het risico na een huidsparende mastectomie.
Om de body image van een patiënt te beoordelen na een operatie voor kanker wordt 
vaak de Body Image Scale (BIS) gebruikt. De BIS is ontwikkeld in 2000 in het Verenigd 
Koninkrijk door Hopwood en beoordeelt affectieve, gedragsmatige en cognitieve ve-
randeringen die kunnen resulteren na een behandeling voor kanker. Omdat het een 
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korte vragenlijst is, is het een aantrekkelijke vragenlijst voor gebruik in de kliniek. In 
hoofdstuk 8 beschrijven we het validatieproces van de Nederlandse vertaling van de 
BIS. De validatie werd uitgevoerd in 150 vrouwen na mammasparende therapie en 150 
vrouwen na mastectomie in verband met borstkanker. Psychometrische evaluatie van 
de Nederlandse BIS toonde consistente uitkomsten die vergelijkbaar waren met de 
oorspronkelijke versie van de BIS.
In hoofdstuk 9 gebruiken we de BIS vervolgens om body image uit te vragen na een 
profylactische mastectomie. Studies bij borstkankerpatiënten laten zien dat patiënt-
tevredenheid na een tepelsparende mastectomie mogelijk hoger is dan na een huid-
sparende mastectomie. Als vervolg op hoofdstuk 7 vragen we ons af of, gezien het ad-
ditionele risico wat er mogelijk gelopen wordt door het behoud van de tepel-areola, een 
preventieve tepelsparende ablatio inderdaad superieur is aan een huidsparende ablatio, 
gevolgd door een reconstructie van de tepel-areola met behulp van een lokaal huidflapje 
en intradermale tatoeage. We gaven de Breast-Q Reconstructie vragenlijst en de Neder-
landse BIS aan 25 patiënten die een preventieve tepelsparende ablatio ondergingen en 
aan 20 patiënten na een preventieve huidsparende ablatio. Daarnaast ontwikkelden we 
een vragenlijst om specifiek de tevredenheid met de gespaarde of gereconstrueerde 
tepel, de sensibiliteit van de tepel-areola en de rol van de tepel-areola bij de seksu-
aliteit uit te vragen. Hieraan was een open vraag toegevoegd om de motivatie van de 
patiënt te achterhalen om voor een tepelsparende danwel een huidsparende ingreep 
te kiezen. Univariaat waren de Breast-Q scores beter in de huidsparende mastectomie 
groep dan in de tepelsparende mastectomiegroep voor de onderdelen ‘tevredenheid 
met borsten’ en ‘tevredenheid met gehele resultaat’. Echter, gecorrigeerd voor follow-up 
verschilden de BIS en Breast-Q scores niet significant van elkaar. Ook de tevredenheid 
met de tepelreconstructie was niet significant verschillend van de tevredenheid met 
de gespaarde tepel-areola. De sensibiliteit van de gespaarde tepel-areola werd getest 
met monofilamenten en vergeleken met een niet-geopereerde controlegroep, en was 
significant lager na tepelsparende ablatio. De resultaten uit deze studie laten zien dat 
een preventieve huidsparende mastectomie gevolgd door tepelreconstructie een goed 
alternatief is voor een preventieve tepelsparende mastectomie. Het is daarom belan-
grijk om de motivaties en voorkeuren van vrouwen die een preventieve tepelsparende 
danwel huidsparende mastectomie overwegen goed uit te vragen.
Tussen 1994 en 2006 werden vrouwen die in het Erasmus MC Kankerinstituut een 
bilaterale mastectomie ondergingen gevolgd door een directe, 1-etappe, implan-
taatreconstructie in verband met een hoog borstkankerrisico (bilateraal preventief of 
unilateraal therapeutisch en unilateraal preventief ) gefotografeerd tijdens de follow-up. 
Voor de studie beschreven in hoofdstuk 10 vroegen wij deze vrouwen om een vra-
genlijst over re-operaties en complicaties in te vullen die gedurende de jaren daarna 
hadden plaatsgevonden. Wij vroegen hen de Breast-Q Reconstructie vragenlijst in 
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te vullen voor evaluatie van de lange-termijn patiënttevredenheid met de directe 
implantaatreconstructie. Een panel van vijf plastisch chirurgen beoordeelde de foto’s 
op cosmetisch resultaat. Ondanks het feit dat het in principe om een 1-etappe recon-
structie ging bleek de helft van de patiënten een of meerdere re-operaties te hebben 
ondergaan in verband met complicaties of ontevredenheid over het cosmetisch 
resultaat. Het cosmetische resultaten werd als slecht tot redelijk beoordeeld door het 
panel in de hele groep, maar was significant slechter in de gere-opereerde groep. De 
Breast-Q scores ten aanzien van ‘tevredenheid met borsten’ en ‘tevredenheid met hele 
resultaat’ waren vergelijkbaar met de scores die in de literatuur beschreven zijn na een 
2-etappe reconstructie middels tissue-expander gevolgd door implantaatreconstructie, 
en niet significant lager in de gere-opereerde groep. Deze resultaten suggereren dat 
re-operaties niet de lange-termijn tevredenheid van de patiënt beïnvloeden. Of een 
1-etappe directe implantaatreconstructie een waardig alternatief is voor een 2-etappe 
reconstructie met tissue-expander gevolgd door implantaat is onbekend, maar lijkt op 
basis van deze gegevens onwaarschijnlijk.
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IS RISk-REduCInG MASTECTOMy IndICATEd In All fEMAlE BRCA1/2 GEnE 
MuTATIOn CARRIERS?
For ethical reasons, no randomized controlled trials exist that compare the efficacy of 
breast cancer screening versus risk-reducing mastectomy (RRM) in BRCA1/2 gene muta-
tion carriers. Alternatively, Kurian et al developed a Monte Carlo model with input of 
cancer risks and survival data as a simulation of various risk-reducing options to esti-
mate their efficacies on mortality 1. According to this model, women with a BRCA1 gene 
mutation who do not undergo breast cancer screening or risk-reducing surgery (e.g. 
risk-reducing salpingo-oophorectomy; RRSO or RRM) have a 53% survival by the time 
they reach the age of 70. BRCA2 gene mutation carriers have a 71% survival. To compare; 
survival probability in the general US population is 84% at 70 years. The most effective 
risk-reducing combination strategy for BRCA1 gene mutation carriers was RRM at age 
25 combined with RRSO at 40 years, yielding a survival gain of 26% resulting in 79% 
survival at 70 yrs. The same strategy seemed the most effective in BRCA2 gene mutation 
carriers yielding a survival gain of 12%, resulting in 83% survival at 70 years. According 
to the model, breast cancer screening until their 40th year followed by RRM combined 
with RRSO at 40 years reduced the survival gain by 2% (from 79% to 77%) in BRCA1 
and by 1% (83% to 82%) in BRCA2 gene mutation carriers. When RRM was eliminated 
completely, a breast cancer-screening schedule (yearly mammography and MRI from 
25-69 years) combined with RRSO at 40 years, decreased the survival probability at 70 
years with another 3% in BRCA1 gene mutation carriers to 74% and with 3% to 80% in 
BRCA2 gene mutation carriers. These model-derived survival rates do show a survival 
benefit of RRM in BRCA1/2 gene mutation carriers when compared with intensive breast 
cancer screening, albeit very small. The survival advantage of RRM of 3% for both BRCA1 
and BRCA2 gene mutation carriers decreases even more when RRM is performed at the 
age of 40 instead of 25 years 1.
As compared with breast cancer screening, up to date no clinical studies have been 
able to reproduce this survival benefit of RRM in BRCA1/2 gene mutation carriers. 
Heemskerk-Gerritsen et al. studied a large prospective database of a non-randomized 
series (the MRISC study population) with women who at inclusion had both breasts and 
no history of breast cancer 2. Breast cancer incidence was, logically, higher in the screen-
ing group. However, breast cancer-specific survival was only non-significantly lower in 
the RRM group compared with the screening group (HR 0.29; 95% CI 0.03-2.61). Ingham 
et al. found a clear overall mortality reduction of RRSO compared with no risk-reducing 
surgery (HR 0.22; 95%CI 0.08-0.61), but found no survival benefit of RRM (HR 0.25; 95% CI 
0.03-1.81) 3. Another large multicenter cohort study of 2,482 female BRCA1/2 gene muta-
tion carriers (257 underwent RRM and 992 underwent RRSO) shows a survival benefit 
of RRSO on overall survival and even on breast cancer specific survival (HR 0.44; 95%CI 
0.26-0.76). The impact of RRM on survival was not studied 4. Overall, there is plenty of 
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evidence that RRM reduces breast cancer risk in BRCA1/2 gene mutation carriers, but no 
clinical study has convincingly established an actual survival benefit 3-7.
Two notes are of importance concerning the efficacy of breast cancer screening. 
First, sensitivity and efficacy of breast cancer screening have spectacularly increased by 
adding MRI to screening protocols 8, 9. MRI is probably essential to reach survival rates 
of women who choose breast cancer screening that are comparable to women who 
choose RRM. A recent study showed survival benefit of MRI added to mammography-
only breast cancer screening in BRCA1/2 gene mutation carriers 10.
Second, without subsequent RRSO, RRM and breast cancer screening both are much 
less effective, especially in BRCA1 gene mutation carriers, as is shown by the model of 
Kurian et al 1. Following RRSO at the age of 40, overall survival in breast cancer-screened 
BRCA1 and BRCA2 gene mutation carriers rises by 15% and 5%, respectively. In BRCA1 
gene mutation carriers RRSO should be performed at 40 years; when performed at 50 
years RRSO only yields about half the survival benefit 1.
Almost as important as the discussion about the impact of breast cancer screening and 
RRM on breast cancer survival, is the question whether we will be able to better guide 
BRCA1/2 gene mutation carriers while choosing either RRM or screening. Breast cancer 
screening allows one to keep ones own breasts, while breast surgery and its complica-
tions can be postponed or even avoided at all. Downsides are the recurrent, frequent 
outpatient clinic visits, burdensome radiological examinations and biopsies and anxiety 
towards to examination results. However, a study from 2004 (n= 334) showed that qual-
ity of life did not further decrease after starting breast cancer screening, and was even 
better as compared with the general population 11. As an alternative, RRM minimizes 
breast cancer risk and, after a satisfying aesthetic result of the reconstruction is obtained, 
it minimizes hospital visits too. On the other side, the surgery may feel very mutilating, 
may compromise sexual functioning (in up to 70%) and body image as also described 
in Chapter 9 12, 13. In Chapter 10 we show that surgical complications may delay and 
even compromise the final aesthetic result and enlarge the psychological burden, which 
also has been reported by others 14. Complications – major and minor – of the surgery 
and the reconstruction occur in up to 50% and surgical reinterventions are eventually 
needed also in about half of the patients (Chapters 9 and 10) 12. The impact on quality of 
life, body image and sexual functioning of a – after all previously healthy – BRCA1/2 gene 
mutation carrier of both screening and RRM should be further investigated. Certain 
types of personalities may help to benefit more from RRM or breast cancer screening 
in terms of quality of life. It would be of interest to assess personality traits of women 
who choose RRM versus those who choose breast cancer screening and correlate them 
to quality of life results. Regarding cancer surveillance programs, risk factors that have 
been associated with a negative impact on quality of life during cancer surveillance 
are female gender, a personal history of cancer, having a first degree relative who was 
General discussion and future perspectives
213
diagnosed with cancer and/or died from it, a high perceived risk of developing cancer, 
negative illness perceptions, a passive or pessimistic coping style and having little social 
support 15. Even more, possibly women who exhibit predominant cancer anxiety may 
benefit more from a cognitive behavioral intervention with concurrent breast cancer 
screening, whether or not followed by a delayed RRM, than from RRM alone 16, 17. Assess-
ment of possibly subclinical psychological disorders is common in the intake of newly 
diagnosed BRCA1/2 gene mutation carriers but tools that can predict quality of life after 
RRM or the start of breast cancer screening are lacking 15.
Finally, in choosing screening versus RRM it would be also helpful to be able to more 
precisely predict the exact breast cancer risk of the individual patient. As mentioned 
before, reported breast cancer risks of BRCA1/2 gene mutation carriers vary strongly. 
This is due to the type and the exact location of the mutation, but also may be subject 
to unrecognized environmental factors that influence genotype-phenotype translation 
18. More insight in these potential risk modifiers would help to better counsel women to-
wards RRM or breast cancer screening. Using data on risk-reduction and survival benefit 
in combination with a patient’s personalized risk estimate, medical history, personality 
traits, coping style and personal preferences a decision model could be developed.
dOES RISk-REduCInG SAlPInGO-OOPHORECTOMy dECREASE bREAST 
CAnCER InCIdEnCE?
As compared with cancer screening, the only surgical risk-reducing option that has been 
proved to reduce mortality in BRCA1/2 gene mutation carriers is risk-reducing salpingo-
oophorectomy (RRSO). This is partly due to the limited role of gynaecological screening, 
which does not contribute to the early detection of ovarian cancer 19, 20. Ovarian cancer-
related mortality is reduced by RRSO, but the effects of RRSO on breast cancer incidence 
and breast cancer related mortality are still subject of discussion. In daily practice it 
is common to communicate a breast cancer risk reduction of about 50% after RRSO. 
These risk reduction rates are derived from large clinical studies 4, 21-23. Unfortunately, 
again due to ethical considerations, these studies were not randomized and therefore 
subject to various types of bias. Recently, risk reduction of RRSO was analyzed in a large 
Dutch cohort. Included were female BRCA1/2 gene mutation carriers without a history 
of a previous cancer or of risk reducing surgery 24. The previously mentioned studies 
were replicated in the Dutch cohort copying their methods and not adjusting for bias, 
yielding hazard ratios of about 0.5 that were comparable to the results of the replicated 
studies. Additionally, analyses were repeated while adjusting for several types of bias: 
the cumulative breast cancer incidence did not differ between the RRSO-group and the 
non-RRSO group. The authors therefore concluded that the risk-reducing effect of RRSO 
found in previous studies was most likely attributable to various forms of bias, and that 
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the true breast cancer risk reduction of RRSO is probably much smaller than commonly 
thought. In Chapter 3, we studied characteristics of breast cancers that originated after 
RRSO. The finding of fewer mitotic counts suggested a less aggressive biological pheno-
type of breast cancers that develop after RRSO 25. The biological mechanism of estrogen 
depletion as accomplished with RRSO on the development of frequently estrogen-
receptor negative breast cancers still has not been clarified. Future studies may be able 
to elucidate the effect of RRSO on breast cancer development.
IS nIPPlE-SPARInG MASTECTOMy (nSM) SuPERIOR TO SkIn-SPARInG 
MASTECTOMy (SSM)?
To minimize the residual breast cancer risk after prophylactic nipple-sparing mastec-
tomy (NSM), as much breast glandular tissue as possible should be removed behind 
the nipple-areola complex (NAC) and skin. Anatomically, the NAC is the center of the 
breast gland, while the peripheral skin-flap is divided from the breast glandular tissue 
by subcutaneous fat. According to this concept, the risk of residual breast tissue behind 
the NAC should be higher. In a pathological study using mastectomy specimen (Chapter 
7) we have established that after NSM indeed more terminal duct lobular units (TDLUs) 
are left in situ behind the NAC as compared to the skin 26. However, the true impact of 
microscopic amounts of residual breast tissue on breast cancer risk is difficult to esti-
mate. Further, (microscopic amounts of ) breast glandular tissue may be left elsewhere, 
for example in the axilla 27, 28. In Chapter 2, studies on residual breast glandular tissue and 
concurrent breast cancer risk after prophylactic mastectomy are reviewed 29.
More importantly, it is necessary to balance any remaining oncological risk versus 
the desired aesthetic outcome. It has been reported that NSM leads to a more natural 
and thus more desirable aesthetic outcome and possibly increases patient satisfaction. 
However, studies that report higher patient satisfaction after NSM as compared with 
SSM have been conducted in breast cancer populations 30-32. Likely, women undergoing 
mastectomy for prophylaxis because of a BRCA1/2 gene mutation cannot be compared 
to a (sporadic) breast cancer population in terms of pre-operative expectations and 
postoperative patient satisfaction 33, 34. Obviously, especially in this population due to 
the prophylactic character of the mastectomy and the young age at the time of the sur-
gery a natural aesthetic outcome should be pursued. On the other hand, many BRCA1/2 
gene mutation carriers who were interviewed for the studies on patient satisfaction and 
quality of life after prophylactic surgery (Chapters 9 and 10) remarked that they felt that 
aesthetic outcome was clearly secondary to the oncologic risk reduction. Some wrote 
that the high breast cancer rates in their family in combination with their own high breast 
cancer risk made them feel unattached to their breasts. Others were very content with 
the natural look of their NAC preservation after NSM. Unfortunately, these are just single 
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observations. It would be informative to gain more insight for example by a prospective 
study that preoperatively assesses motivations that determine the type of surgery and 
breast reconstruction of choice. Lastly, current techniques of NAC reconstruction consist 
of a small skin flap and specialized tattoo techniques. When performed well, the recon-
structed NAC can hardly be distinguished from the native NAC. SSM followed by NAC 
reconstruction may even have a superior aesthetic outcome compared with NSM since 
NAC reconstruction routinely is delayed until the final postoperative breast reconstruc-
tion shape is achieved. Then, the position and shape of the NAC is adjusted. In Chapter 9, 
we show that women were equally satisfied with a reconstructed NAC as compared with 
a spared NAC. There were no differences in Breast-Q scores and Body Image Scale (BIS) 
scores after reconstruction, when adjusted for follow-up. Unadjusted Breast-Q scores 
were even slightly in favor of the SSM group for ‘satisfaction with breasts’ (66.2 vs. 56.6; 
P=0.06) and ‘satisfaction with outcome’ (76.1 vs. 61.5; P=0.09) 12.
IS IT ACHIEvAblE TO fuRTHER PERSOnAlIzE MEdICAl TREATMEnT Of 
BRCA1/2-ASSOCIATEd bREAST CAnCER PATIEnTS?
Breast cancers in BRCA1 and BRCA2 gene mutation carriers are marked by some distinct 
tumor characteristics as compared with sporadic breast cancers. BRCA1-associated 
breast cancers are triple-negative (with negative status for estrogen receptor; ER, pro-
gesterone receptor; PR and HER2) in about 70%, and frequently have a medullary-like 
morphology. BRCA2-associated breast cancers more frequently are ER positive. Both 
BRCA1/2-associated breast cancers typically are of high grade and have a young age 
of onset 35. Alike in all forms of cancer, the concept of personalized medicine is gaining 
interest in this subgroup of breast cancers, especially for BRCA1-associated breast cancer 
since a triple-negative status is common and regular targeted therapies are not appli-
cable most of the time. According to the current guidelines, many BRCA1/2-associated 
breast cancer patients are candidates for adjuvant chemotherapy albeit having small 
tumors (node-negative Tis or T1 in 75%), due to their young age and a Bloom Richardson 
grade 3 2, 36. In sporadic breast cancer patients, several tests – for example Oncotype DX® 
and Mammaprint® - help identify patients at high recurrence risk who may benefit from 
adjuvant chemotherapy 37. However, these tests are mainly used for ER positive breast 
cancer and have not been validated for use in the BRCA1/2 gene mutation subgroup. In 
the present thesis, we present two studies that investigate potential prognostic markers 
(Chapter 4 and 6). Despite some promising and hypothesis-generating results, we could 
not draw firm conclusions from our results 38. This is mainly due to the relatively small 
numbers of BRCA1/2-associated breast cancers, in combination with high breast cancer 
survival rates, in BRCA1/2 gene mutation carriers alike in sporadic breast cancer patients. 
Of course, this is not a local limitation. To be able to identify prognostic markers and 
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potential therapeutic targets in BRCA1/2-associated breast cancer it is mandatory to ex-
tend study populations to nationwide and even international cohorts, comparable with 
already existing genetic and epidemiologic databases. This way, large series of breast 
cancer material can be analyzed by pathologists or biologists and linked to clinical data 
in order to identify novel markers that have impact on breast cancer survival.
SHOuld nExT GEnERATIOn SEquEnCInG (nGS) bE APPlIEd MORE 
bROAdly In dAIly ClInICAl PRACTICE?
Lately, next generation sequencing (NGS) enables us to perform sequencing of previ-
ously selected genes or parts of genes that are known - when mutated - to be pathogenic 
or of other clinical consequence in certain types of cancer. NGS is a cheaper and less 
time-consuming technique than whole-genome sequencing and we showed in Chapter 
5 that in certain cases NGS can be of clinical consequence 39. Further, molecular charac-
teristics of breast cancers help to increasingly personalize breast cancer treatment (for 
example gene expression profiles such as Oncotype DX® and Mammaprint® in sporadic 
breast cancer). In regular breast cancer workup, to perform such a relatively quick, non-
invasive test that provides a great amount of information is tempting. However, as long 
as it is not possible to translate the genetic information found to a clinical outcome, NGS 
should be reserved for selected clinical and research purposes with a clear hypothesis 
that can be answered using NGS. Collecting genetic information in a more haphazard 
manner may lead to random associations of unclear clinical significance.
SHOuld wE ExTEnT TESTInG fOR GERM lInE BRCA1/2 GEnE MuTATIOnS TO 
IMPROvE SuRvIvAl In BRCA1/2 GEnE MuTATIOn CARRIERS?
In the Netherlands, genetic analyses for BRCA1/2 gene mutations and for other breast 
cancer susceptibility genes are currently reserved for women and their families who 
develop breast cancer at a very young age, who develop triple negative breast cancer at 
young age and with prevalence of (multiple) breast and ovarian cancers in patients and/
or families 40. Previously to being tested, women who visit the clinical genetic practice 
are being informed of the consequences of being tested, and of the diagnosis of a germ 
line BRCA1/2 gene mutation.
As we know that, as compared to no intervention, breast cancer screening or RRM, and 
RRSO improve survival in BRCA1/2 gene mutation carriers even after a first breast cancer 
1, 41, it is tempting to extent screening of BRCA1/2 mutations to the sporadic breast cancer 
population. It is plausible that NGS will gradually be more routinely used for diagnostic 
purposes and risk stratification and therefore molecular information of the tumor will be-
come more readily available. This makes it possible to more routinely screen for BRCA1 and 
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BRCA2 gene mutations in breast cancers. A mutation in the BRCA1 or BRCA2 gene found 
in the tumor may be a somatic as well as germ line mutation. To confirm the presence of a 
germ line mutation the analyses only has to be repeated in healthy tissue.
The downside of screening for BRCA1/2 gene mutations is that probably not all 
BRCA1/2 gene mutations are equally pathogenic, while the participants of the studies 
that demonstrated survival benefit of risk-reducing surgery and breast cancer screening 
were selected for BRCA1/2 testing due to high familial breast- and/or ovarian cancer risks 
1, 9, 41. Routine diagnosis of BRCA1/2 mutations of unknown significance for an underlying 
breast- and ovarian cancer risk may lead to overdiagnosis and therefore overtreatment 
of patients and their families. The focus of research should therefore lie on the treatabil-
ity of BRCA1/2-associated breast cancer and on identifying targets that can be used for 
risk stratification, instead of trying to identify as many BRCA1/2 gene mutation carriers 
as possible.
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